  
 
 
 Group Chair 
Peter C. Adamson, M.D. 
adamson@email.chop.edu  
 
Group Statistician Todd Alonzo, Ph.D. 
talonzo@childrensoncology 
group.org 
 
Group Vice Chair 
Susan Blaney, M.D. 
smblaney@txch.org   
 
Chief Operating Officer 
Elizabeth O‚ÄôConnor, M.P.H. econnor@childrensoncology 
group.org  
 
Executive Director of  
Administration Deborah L. Crabtree, M.S. 
crabtreed@email.chop.edu 
 
Group Chair‚Äôs Office 
The Children's Hospital 
of Philadelphia  
3501 Civic Center Blvd CTRB 10060 
Philadelphia, PA 19104 
 
P 215 590 6359 
F 215 590 7544 
 
Group Operations Center 222 E. Huntington Drive 
Suite 100 
Monrovia, CA 91016 
 
P 626 447 0064 
F 626 445 4334 
 
Statistics & Data Center Headquarters 
222 E. Huntington Drive Suite 100 Monrovia, CA 91016 
 
P 626 447 0064 F 626 445 4334 
 
Gainesville Office 6011 NW 1
st Place 
Gainesville, FL 32607 
 
P 352 273 0556 F 352 392 8162 
 
  
 
  
A National Cancer Institute- 
supported member group  
of the National Clinical  Trials Network  
 
  
 
June 1, 2018 
 
 
Martha Kruhm, MS, RAC 
Head, Protocol and Information Office  
Operations and Informatics Branch 
Cancer Therapy Evaluation Program Division of Cancer Treatment and Diagnosis National Cancer Institute Executive Plaza North Room 730 Bethesda, MD 20892 
 
  Dear Ms. Kruhm,  
The Study Committee for ACNS1022 , A Phase II Randomized Trial of 
Lenalidomide (NSC # 703813, IND #) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pi locytic Astrocytomas and Optic Pathway 
Gliomas , has provided Amendment #6 for CTEP review. 
 
The submission of this amendment is in response to an RRA from Dr. Howard 
Streicher (streicherh@ctep.nci.nih.gov). Revisions to the protocol are detailed in the summary of changes below.  The ACNS1022 Study Committee looks forward to approval of this amendment. Please contact me with any questions or concerns. 
 
Sincerely,  Nina Butingan, MBS, Protocol Coordinator (for) Katherine Warren, MD, ACNS1022 Study Chair 
Peter Adamson, MD, Children‚Äôs Oncology Group Chair 
     
 
    
  
 
ii 
 
SUMMARY OF CHANGES: PROTOCOL DOCUMENT 
In accordance with the above discussion, the following specific revisions have been made to the 
protocol. Additions are in boldfaced  font and deletions in strikethrough font. 
 
# Section Page(s) Change 
1. General  The amendment number has been updated. 
2. General  The version date has been updated. 
3. General  The Study Chair‚Äôs phone number has been updated. 
4. Table of 
Contents  2-4 The Table of Contents has been updated. 
5. 6.1 30-37 The drug monograph for lenalidomide has been updated. 
6. 11.0 51-55 Changes have been made to the section based on CTCAE version 
5.0. 
 
 
 
    ACNS1022  
 
1 
 
 
Activated: March 19, 2012 Version Date: 6/1/2018 
Closed: January 18, 2017 Amendment #: 6 
 
 
CHILDREN'S ONCOLOGY GROUP 
  
ACNS1022 
 
A Phase II Randomized Trial of Lenalidomide (N SC # 703813, IND #) in Pediatric Patients 
with Recurrent, Refractory or Progressive  Juvenile Pilocytic Astrocytomas and Optic 
Pathway Gliomas 
 
NCI Supplied Agent: Lenalidomide (IND# , NSC# 703813)  
 
A Groupwide Phase II Study  
 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , AND SHOULD NOT BE COPIED , REDISTRIBUTED OR USED FOR ANY 
OTHER PURPOSE .  MEDICAL AND SCIENTIFIC INFORMATION CONTAINED WITHIN THIS PROTOCOL IS NOT INCLUDED TO 
AUTHORIZE OR FACILITATE THE PRACTICE OF MEDICINE BY ANY PERSON OR ENTITY .  RESEARCH  MEANS A 
SYSTEMATIC INVESTIGATION , INCLUDING RESEARCH DEVELOPMENT , TESTING AND EVALUATION , DESIGNED TO 
DEVELOP OR CONTRIBUTE TO GENERALIZABLE KNOWLEDGE .  THIS PROTOCOL IS THE RESEARCH PLAN DEVELOPED 
BY THE CHILDREN ‚ÄôS ONCOLOGY GROUP TO INVESTIGATE A PARTICULAR STUDY QUESTION OR SET OF STUDY 
QUESTIONS AND SHOULD NOT  BE USED TO DIRECT THE PRACTICE OF MEDICINE BY ANY PERSON OR TO PROVIDE 
INDIVIDUALIZED MEDICAL CARE , TREATMENT , OR ADVICE TO ANY PATIENT OR STUDY SUBJECT .  THE PROCEDURES IN 
THIS PROTOCOL ARE INTENDED ONLY FOR USE BY CLINICAL ONCOLOGISTS IN CAREFULLY STRUCTURED SETTINGS , 
AND MAY NOT PROVE TO BE MORE EFFECTIVE THAN STANDARD TREATMENT .  ANY PERSON WHO REQUIRES MEDICAL 
CARE IS URGED TO CONSULT WITH HIS OR HER PERSONAL PHYSICIAN OR TREATING PHYSIC IAN OR VISIT THE NEAREST 
LOCAL HOSPITAL OR HEALTHCARE INSTITUTION . 
 
 
STUDY CHAIR 
 
Katherine Warren, MD 
National Cancer Institute  Pediatric Oncology Branch 
10 Center Drive, Bldg 10 CRC, Room 1-5750 
Bethesda, MD 20892-1102 
Phone: (240) 760-6202 Fax: (301) 480-2308 E-mail: warrenk@mail.nih.gov 
   
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022  
 
Version Date: 6/1/2018  Page 2 
 
 
TABLE OF CONTENTS 
SECTION PAGE 
TABLE OF CONTENTS 2  
STUDY COMMITTEE 5  
ABSTRACT 7 
EXPERIMENTAL DESIGN SCHEMA 8  
1.0 GOALS AND OBJECTIVES (SCIENTIFIC AIMS) 9  
1.1 Primary Objective 9  
1.2 Secondary Objectives 9  
2.0 BACKGROUND 9  
2.1 Introduction/Rationale for Development 9  
2.2 Angiogenesis in Childhood CNS Tumors 10  
2.3 Thalidomide 11  
2.4 Lenalidomide (CC-5013) 11  
2.5 Rationale for Pharmacokinetic Studies 14  
2.6 Rationale for Imaging Studies 14  
3.0 STUDY ENROLLMENT PROCEDURES AND PATIENT ELIGIBILITY 14  
3.1 Study Enrollment 14  
3.2 Patient Eligibility Criteria 18  
4.0 TREATMENT PROGRAM 23  
4.1 Overview of Treatment Plan 23  
4.2 Concomitant therapy restrictions 24  
4.3 Lenalidomide Administration 25  
5.0 DOSE MODIFICATIONS FOR TOXICITIES 29  
5.1 Non-Hematologic Toxicities 29  
5.2 Hematologic Toxicities 29  
6.0 DRUG INFORMATION 30  
6.1 LENALIDOMIDE (RevlimidTM, CC-5013, CDC-501) NSC# 703813, IND # 
(05/15/18) 30  
7.0 EVALUATIONS/MATERIAL AND DATA TO BE ACCESSIONED 40  
7.1 Required Clinical, Laboratory and Disease Evaluations 40  
7.2 Follow-up 41  
8.0 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY 
CRITERIA 41  
8.1 Criteria for Removal fr om Protocol Therapy 41  
8.2 Off Study Criteria 41  
9.0 STATISTICAL CONSIDERATIONS 42  
9.1 Sample Size and Study Duration 42  
9.2 Study Design 42  
9.3 Methods of Analysis 42  
9.4 Analysis of Efficacy 43  
9.5 Monitoring for Efficacy 43  
9.6 Monitoring for Toxicity 44  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022  
 
Version Date: 6/1/2018  Page 3 
 
 
9.7 Interim Monitoring of Toxic Death 44  
9.8 Analysis of Toxicity 45  
9.9 Analysis of Lenalidomide Pharmacokinetic Parameters 45  
9.10  Analysis of Standard MR Sequences 45  
9.11  Effect of the Stratification on Response Rate 45  
9.12  Gender and Minority Accrual Estimates 46  
10.0  EVALUATION CRITERIA 46  
10.1  Common Terminology Criteria fo r Adverse Events (CTCAE) 46  
10.2  Methodology to Determine Tumor Measurement 46  
10.3  Selection of Target and Non-Target Lesions 49  
10.4  Response Criteria for Target Lesions 49  
10.5  Response Criteria for Non-target Lesions 50  
10.6  Retrospective Response Review 50  
11.0  ADVERSE EVENT REPORTING REQUIREMENTS 50  
11.1  Purpose 50  
11.2  Expedited Reporting Requirements ‚Äì Se rious Adverse Events (SAEs) 50  
11.3  Specific Examples for Expedited Reporting 51  
11.3.5  Pregnancy, Pregnancy Loss, and Death Neonatal 52  
11.4  Reporting Requirements for Specialized AEs 53  
11.5  Exceptions to Expedited Reporting 53  
11.6  Reporting Requirements - Inv estigator Responsibility 54  
11.7  General Instructions for Exped ited Reporting via CTEP-AERS 54  
11.8  Reporting Table for Late Phase 2 and Phase 3 Studies 55  
11.9  Protocol Specific Additional Instru ctions and Reporting Exceptions 56  
11.10  Routine Reporting of Adverse Events 57  
12.0  STUDY REPORTING AND MONITORING 58  
12.1  CDUS 58  
12.2  Data and Safety Monitoring Committee 58  
12.3  CRADA/CTA 58  
13.0  SPECIAL STUDIES SPECIMEN REQUIREMENTS 60  
13.1  Steady State Pharmacokinetic Study 60  
14.0  IMAGING STUDIES REQUIRED AND GUIDELINES FOR OBTAINING 61  
14.1  Timing of MRIs 61  
14.2  MRI Guidelines for Brain/Spine Tumors 61  
14.3  Tumor Response Assessment 62  
14.4  Retrospective Central Review 62  
APPENDIX I:  SITE COUNSELOR IDENTIFICATION FORM 63  
APPENDIX II: LENALIDOMIDE RISKS OF FETAL EXPOSURE, PREGNANCY  
TESTING GUIDELINES AND ACCEPTABLE BIRTH CONTROL METHODS 65  
APPENDIX III A: LENALIDOMIDE EDUCATION AND COUNSELING GUIDANCE 
DOCUMENT FOR FEMALE SUBJECTS 70  
APPENDIX III B: LENALIDOMIDE EDUCATION AND COUNSELING GUIDANCE 
DOCUMENT FOR MALE SUBJECTS 74  
APPENDIX IV: LENALIDOMIDE PATIENT CARD FOR PEDIATRIC PATIENTS 76  
APPENDIX V:    LENALIDOMIDE INFORMATION SHEET 77  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022  
 
Version Date: 6/1/2018  Page 4 
 
 
APPENDIX VI: PATIENT DIARY FOR LENALIDOMIDE CAPSULE  
ADMINISTRATION 79  
APPENDIX VII: ACNS1022 PHARMACOKINETIC STUDY FORM: STEADY STATE 
SAMPLES 80  
APPENDIX VIII:  YOUTH INFORMATION SHEETS 81  
APPENDIX IX:  REGIMEN A LENALIDOMIDE DOSING TABLES 83  
APPENDIX X:  CTEP AND CTSU REGISTRATION PROCEDURES 84  
REFERENCES 86  
 
 
 
    
 
    
 
     
 
    
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022  
 
Version Date: 6/1/2018  Page 5 
 
 
STUDY COMMITTEE 
STUDY CHAIR STUDY COMMITTEE MEMBERS 
Katherine E. Warren, MD Jason R. Fan gusaro, MD 
Pediatric Hematolo gy/Oncolo gy Pediatric Hematolo gy/Oncolo gy 
National Cancer Institute Childrens Memorial Hospital 
Pediatric Oncolo gy Branch 2300 Children's Plaza 
Bldg 10 CRC, Room 1-5750 Chica go IL 60614 
10 Center Drive Phone: (773) 880-3660 
Bethesda MD 20892-1102 Fax: (773) 880-3223 Phone: (240) 760-6202 E-mail:  
jfangusaro @childrensmemorial.or g 
Fax: (301) 480-2308  
E-mail: warrenk @mail.nih. gov Karen M. Gauvain, MD 
 Pediatrics Hematolo gy/Oncolo gy 
STUDY VICE CHAIR Cardinal Glen non Children's Medical Center 
Daniel Charles Bowers, MD 1465 S. Grand Blvd Hematolo
gy/Oncolo gy St. Louis MO 63104 
Universit y of Texas Southwestern Medical Center Phone: (314) 577-5638 
5323 Harr y Hines Boulevard MC 9063 Fax: (314) 268-4081 
Dallas TX 75390-9063 E-mail: k gauvain @slu.edu 
Phone: (214) 648-3896  
Fax: (214) 648-3122 Soumen Khatua, MD FAAP 
E-mail:  daniel.bowers @utsouthwestern.edu Pediatrics Hematolo gy/Oncolo gy 
 MD Anderson Cancer Center STUDY STATISTICIAN Children‚Äôs Cancer Hospital 
Mark Krailo, Ph.D. 1515 Holcombe Blvd, Unit 87 
Statistics Houston, TX 77030 Children's Oncolo
gy Group - Operations Center Phone: (713) 792-6620 x3280  
222 E. Huntin gton Drive, Suite 100 Fax: (713) 792-0608 
Monrovia, CA 91016 E-mail: skhatua@mdanderson.org       
Phone: (626) 241-1520  
Fax: (626) 445-4334 AeRan g Kim, MD 
E-mail: mkrailo @childrensoncolo gygroup.or g Hematolo gy/Oncolo gy 
 Children's National Medical Center 
STUDY COMMITTEE MEMBERS Center fo r Cancer and Blood Disorders 
Esther Adeba yo-Olo jo, PhD, RPh 111  Michi gan Avenue, N.W. 
Pharmac y Washin gton DC 20010 
New York Universit y Langone Medical Center Phone: (202) 476-4744 
560 First Avenue, Rm HN300 Fax: (202) 476-5685 
New York NY 10016 E-mail:  aekim @cnmc.or g 
Phone: (212) 263-6936  Fax: (212) 263-8939 Kell
y Anne Laschin ger, MSN 
E-mail:  adebae01 @nyumc.or g Nursin g 
 Rainbow Babies and Childrens Hospital Charles G. Eberhart, MD PhD Pediatric Oncolo
gy 
Patholo gy 11100 Euclid Ave 
Johns Hopkins Universit y RB&C 6054 
720 Rutland Ave - Ross 55 8 Cleveland OH 44106 
Neuropatholo gy Phone: (216) 844-3345 x43919 
Baltimore MD 21205 Fax: (216) 844-5431 
Phone: (410) 502-5185 E-mail:  Kell y.Laschin ger@UHhospitals.or g 
Fax: (410) 955-9777  E-mail:  ceberha
@jhmi.edu  
  
 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022  
 
Version Date: 6/1/2018  Page 6 
 
 
STUDY COMMITTEE MEMBERS PROTOCOL COORDINATOR 
 
Gilbert Vezina, MD  
Chris Williams-Hu ghes 
Diagnostic Ima ging Children's Oncolo gy Group - Operations Center 
Children's National Medical Center 222 E. Huntin gton Drive, Suite 100 
The Geor ge Washin gton Universit y Monrovia, CA 91016 
School Medicine and Health Sciences Phone: (660) 553-5049 
111 Michi gan Ave NW Fax: (626) 445-4334 
Washin gton, DC 20010-2970 E-mail:  chrismwhu ghes@att.net 
Phone:  (202) 476-3651  
Fax:  (202) 476-3644 Stephanie Badour 
E-mail:  gvezina @cnmc.or g Clinical Research Associate 
 British Columbia children‚Äôs hospital 
RESEARCH COORDINATOR 4480 Oak Street, Room B315 Austin Hamm
 Vancouver, BC V6H 3V4 
Children's Oncolo gy Group - Operations Center  Canada 
222 Huntin gton Dr.,Suite 100 Phone:   (604) 875-2345 x 5975 
Monrovia, CA  91016 Fax:   (604) 875-2911 
Phone: (626) 241-1501 E-mail:  sbadour @cw.bc.ca 
Fax: (626) 445-4334  E-mail:  ahamm
@childrensoncolo gygroup.or g  
  
    
  
 AGENT NSC# AND IND#‚Äôs  
 Lenalidomide NSC#703813  IND# 
  
  
 
 
SEE SECTION 13  FOR SPECIMEN SHIPPING ADDRESSES 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 7 
 
 
 
The Children's Oncology Group has received a Certificat e of Confidentiality from the federal government, 
which will help us protect the privacy of our resear ch subjects.  The Certificate protects against the 
involuntary release of information about your subjects collected during the course of our covered studies.  
The researchers involved in the studies cannot be forced to disclose the identity or any information collected 
in the study in any legal proceedings at the federal, st ate, or local level, regardless of whether they are 
criminal, administrative, or legislative proceedings.  Ho wever, the subject or the researcher may choose to 
voluntarily disclose the protected information under cer tain circumstances.  For example, if the subject or 
his/her guardian requests the release of information in writing, the Certificate does not protect against that 
voluntary disclosure.  Furthermore, federal agencies  may review our records under limited circumstances, 
such as a DHHS request for inform ation for an audit or program evaluation or an FDA request under the 
Food, Drug and Cosmetics Act. 
The Certificate of Confidentiality will not protect ag ainst mandatory disclosure by the researchers of 
information on suspected child abu se, reportable communicable diseases, and/or possible threat of harm to 
self or others 
 
 
ABSTRACT 
 
Given the poor outcome of patients with recurrent or  refractory gliomas and the limited activity of most 
cytotoxic agents, new agents with nove l mechanisms of action are needed. Inhibition of angiogenesis offers 
a new approach based upon the dependence of tumor grow th on angiogenesis. Lenalidomide is an oral agent 
with both antiangiogenic and immunomodulatory activity that is well-tol erated in adults and children, and 
appears to have some activity in childhood CNS tumors. 
 
This study is a randomized comparis on of response rate am ong patients with recurrent, refractory or 
progressive juvenile pilocytic astrocytomas and optic pathway gliomas who are treated with lenalidomide. 
Lenalidomide will be given either as a low dose (20 mg/m2/dose) or high dose (115 mg/m2/dose) regimen 
PO for 21 days of each 28 day cycle. Treatment will co ntinue for a maximum of 26 cycles in the absence 
of disease progression or unacceptable side effects. Re sponse will be evaluated prior to every other cycle 
for the first 13 cycles and prior to every third cy cle for cycles 14-26. Correlation of steady state 
pharmacokinetic levels with patient  outcome will be performed.   
    
THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY ,SEE PAGE 1FOR USAGE POLICY ACNS1022
Version Date: 6/1/2018 Page 8
EXPERIMENTAL DESIGN SCHEMA
Note: Each cycle is 28 days
PD = Progressive DiseaseSD = Stable DiseasePR = Partial Response
CR = Complete ResponsePDPD
SD,PR,CRStudy Entry
and Randomization
Off Protocol 
Therapy
Cycles 14-26 of Lenalidomide
115 mg/m2/day PO on Days 1-21
Response Evaluation
prior to
Cycles 16, 19, 22, 25 
and after Cycle 26Off Protocol 
TherapyRegimen B
Cycles 1-13 of Lenalidomide
115 mg/m2/day PO on Days 1-21
Response Evaluation
prior to
Cycles 3, 5, 7, 9, 11 and 13
Response Evaluation
prior to
Cycles 16, 19, 22, 25 
and after Cycle 26PD
PD
Regimen A
Cycles 1-13 of Lenalidomide
20 mg/m2/day PO on Days 1-21
Response Evaluation
prior to
Cycles 3, 5, 7, 9, 11 and 13
Cycles 14-26 of Lenalidomide
20 mg/m2/day PO on Days 1-21SD,PR,CR
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 9 
 
 
1.0 GOALS AND OBJECTIVES (SCIENTIFIC AIMS) 
1.1 Primary Objective 
To determine the objective response rate of child ren with recurrent, refractory or progressive 
juvenile pilocytic astrocytomas and optic pa thway gliomas who are treated with Regimen A 
low-dose (20 mg/m
2/dose)  or Regimen B high-dose (115 mg/m2/dose) lenalidomide. 
 
1.2 Secondary Objectives 
 
1.2.1 
To estimate the event-free survival (EFS) (b ased on standard two-dimensional tumor 
measurements, determined by each institution)  of children with recurrent, refractory or 
progressive juvenile pilocytic astrocytomas a nd optic pathway gliomas who are treated with 
lenalidomide.  
1.2.2 
To compare response categories and EFS across the 3 MR sequences (T2-weighted, 
FLAIR, T1-weighted post-contrast).   1.2.3 
To correlate steady state pharmacokinetics of  lenalidomide (1 sample obtained between 
Days 5-21) with objective response and EFS.  1.2.4 To evaluate toxicities of long term
 lenalidomide use. 
 
 
2.0 BACKGROUND 
2.1 Introduction/Rationale for Development 
Brain tumors are the most common solid tumors  of childhood, with an annual incidence of 
33 per 1,000,000 children. Low-grade gliomas are the most common, representing 1/3 of 
all childhood primary CNS tumors. While tr eatment of these lesions is somewhat 
controversial, the general consensus is that these lesions are best treated with surgical 
resection if this can be performed without significant sequelae. Frequently, complete 
resection is not feasible without significant  morbidity. Five- and ten-year progression-free 
survival rates for children with incomplete  resections are 50% and 38%, respectively.1, 2  
Radiation therapy and chemotherapy are utilized in the setting of incomplete resection, but 
radiation may be associated with significant side  effects. In addition, in a recent analysis, 
adults with low-grade gliomas who receive d postoperative radia tion therapy had an 
improved 5 year progression-free survival (PFS), but overall survival (OS) was not significantly different.
3 In pediatric patients, particularly those younger than 10 years and 
those with neurofibromatosis type I (NF1), chem otherapy is frequently utilized in an effort 
to postpone radiation therapy and its accompanying neurotoxic effects. 
 
Low-grade gliomas are a histologically he terogeneous group of tumors. Significant 
interobserver variability has been documen ted for pathologic diagnosis and grading.4,5 This 
is further complicated by the fact that some tumors are diagnosed by biopsy alone, which 
may not be representative of the entire tumor. The course of the disease in patients with 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 10 
 
 
low-grade gliomas can be unpredictable. Wh ile some patients are symptomatic, some 
lesions, particularly those associated with NF1, represent incidental findings and the 
disease may be indolent.  
 The major goals for treating unresectable lesions are therefore prevention of tumor 
progression and ablation of associated symp toms, while minimizing side effects of 
treatment. Radiation therapy has been shown to have efficacy, but is associated with cognitive deficits, cerebrovascular sequel ae, endocrinologic dysfunction and second 
malignancies. Many low-grade gliomas are ch emosensitive tumors and chemotherapeutic 
regimens have been used to delay or avoid radiation therapy. Chem otherapeutic regimens 
that have resulted in objective responses an d increased PFS for patients with low-grade 
gliomas include vincristine and carboplatin, a nd the combination procarbazine, lomustine, 
vincristine dibromodulci tol and 6-thioguanine.
6,7 In a study of children with newly 
diagnosed low-grade gliomas with evidence of progression, 56% had an objective response 
to vincristine/carboplatin and PFS was 68 ¬± 7% at 3 yrs.8 In children with recurrent low-
grade gliomas, 52 ¬± 10% of assessable patie nts had an objective response to this 
chemotherapy regimen.6 However, these chemotherapeutic  regimens are associated with 
significant toxicities, including allergic reactions to carboplatin. 
  
Temozolomide and weekly vinblastine are alte rnative chemotherapeutic regimens. In the 
COG Phase II study of temozolomide given on a 5-day every 28 day schedule to children 
with recurrent CNS tumors (A09701), 1/21 patients with low-grade glioma had an 
objective response.9 Despite this low objective response  rate, 41% of patients remained on 
study for 12 courses with no evidence of progress ion. In a second study of children with 
progressive or recurrent low-grade gliomas treat ed with temozolomide on a 5/28 day cycle, 
11% of patients with optic pathway/pilocytic astrocytomas had a partial response and 38% 
had stable disease.10 Although it appears to have modest activity, temozolomide is 
associated with hematologic toxicity and a pot ential risk of second malignancy. In A09701, 
25% of patients had Grade 3 or 4 thrombocyt openia and 19% had Grade 3 or 4 neutropenia 
during cycle 1. 
 
Weekly vinblastine has also been studied in the recurrent setting. In a Phase II study of 
weekly vinblastine in children with recurr ent or refractory low-grade gliomas, 57% 
completed 52 weeks of chemotherapy.11 Objective responses occu rred in 40% of patients. 
Patients in this study were eligible at the tim e of first recurrence, and disease progression 
was defined radiographically by either GLPHQVLRQDO¬ï  25% increase) or 3-dimensional 
¬ï 40% increase) criteria, confirmed at 8 week s. More than 50% of these patients required 
a dose reduction for toxicity. It is importan t to note that these Phase II studies were 
performed in a heterogeneous group of patients with sma ll numbers, different eligibility 
requirements and different definitions of pr ogression. Toxicity was fairly significant. 
 
Juvenile pilocytic astrocytomas are the most  common low-grade glioma in the pediatric 
age group12,28, but, historically, low-grade gliomas have been consolidated into one 
diagnostic category for the purposes of clin ical trials.  Biological data on low-grade 
astroctytomas has recently emerged,  challenging this concept.   
 
2.2 Angiogenesis in Childhood CNS Tumors 
Angiogenesis plays a role in tumor growth, in cluding tumors of the CNS. Brain tumors 
have demonstrated intense neovascular ization and produce potent angiogenic 
mediators.13,14 Several types of childhood CNS tumors, including low-grade astrocytic, 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 11 
 
 
high-grade astrocytic, and embryonal tumors exhibit significant angiogenic activity.15 Over 
the last decade, several of the mechanisms involved in tumor-induced angiogenesis have 
been elucidated. The most direct of these me chanisms is the secretion of cytokines with 
angiogenic properties by the tumor cells. Examples of such cytokines include acidic and 
basic fibroblastic growth factor ( D,E-FGF), angiogenin, vascular endothelial growth factor 
(VEGF), and tumor necrosis factor alpha (TNF- D).16-17 Alternately, tumor cells can release 
angiogenic peptides through the production of  proteases and the subsequent breakdown of 
the extracellular matrix where so me cytokines are stored (i.e. EFGF). Angiogenesis can 
also be induced indirectly through the recr uitment of inflammatory cells (particularly 
macrophages) and their subsequent releas e of angiogenic cytokines (i.e. TNF- D, EFGF).18 
 
2.3 Thalidomide 
Thalidomide is a drug with a broad spectr um of activity, including anti-angiogenic 
properties. It inhibits growth factor-mediate d neovascularization, is a known inhibitor of 
TNF-D, and has demonstrated inhibition of tumor growth in solid tumor models. 
Thalidomide costimulates T cells in vitro , inducing cytokine production (including IL-2 
and IFN-J) and cytotoxic responses.19 In clinical trials of this agent in adults with recurrent 
high-grade gliomas, some anti-tumor activity  was observed (4/36 objective radiographic 
responses in one study, with 12/36 stable disease  (SD) for minimum of 2 months), although 
the overall response rate was low.20,21 
 
2.4 Lenalidomide (CC-5013) 
Lenalidomide is a potent analog of thalidomid e and is classified as  an immunomodulatory 
agent. Like thalidomide, it exerts a broad spectrum of pharmacologic and immunologic 
effects. Lenalidomide has been shown to be mo re potent than thalidomide in stimulating 
proliferation of T cells following primary induction by T-cell receptor (TCR) activation, 
and more potent than thalidomide in augmenting production of IL-2 and IFN- J following 
TCR activation of PBMC (IL-2) or T-cells (IFN- J). Lenalidomide also exhibits dose-
dependent inhibition of LPS-stimulated pr oduction of the pro-inflammatory cytokines 
TNF-D, IL-1E, and IL-6 by PBMC, and increased production of the anti-inflammatory 
cytokine IL-10 by LPS-stimulated PBMC. Lena lidomide up-regulates caspase 8 and down-
modulates leukocyte adhesion molecules. In contrast to thalidomide, lenalidomide 
stimulates activity of NK cells and induces G1  growth arrest of tumor cells. Lenalidomide 
exhibits significant antiangiogenic properties.  It inhibits vascularization by inhibiting 
endothelial cell migration, rather than endothelia l cell proliferation, and is an inhibitor of 
EFGF, VEGF, and TNF- D. (Investigator Brochure) 
  
Lenalidomide has been studied for use in pa tients with multiple myeloma, MDS, solid 
tumors and congestive heart failure. In Phase I clinical trials of lenalidomide in patients 
with multiple myeloma treated for 28 days at doses of 5 mg-50 mg per day, neutropenia 
and thrombocytopenia were the most common toxicities.22 Grade 4 neutropenia was 
observed in 1 patient at dose level 5 mg, 1 pa tient at dose level 25 mg; grade 3 neutropenia 
was observed in 2 patients at dose level 10 mg, 2 patients at dose level 25 mg and 4 patients 
at dose level 50 mg. Grade 3 thrombocytopenia was observed in 1 patient at each of the 
dose levels (5 mg, 10 mg, 25 mg, 50 mg). In an  adult study of patients with solid tumors, 
16 patients with various solid tumors were en rolled at doses ranging  from 5 mg/day ‚Äì150 
mg/day for six weeks. 24,30 The majority of patients trea ted above 25 mg/day developed 
dose-limiting neutropenia or thrombocytopenia.  Additional adverse events considered 
possibly, probably or definitely related to le nalidomide were mild to moderate in severity 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 12 
 
 
and included rash, paresthesias, peripheral  neuropathy, leg or hand cramps, taste 
disturbance, dry mouth, fever, nausea, vom iting, achiness, myalgias, generalized pains, 
bone pain, headache, itchy eye, constipation,  bloating, cough, aphasia, tinnitus, 
pharyngitis, epistaxis, lightheadedness, shortn ess of breath, depression, night sweats, 
insomnia, dry skin, sinus congestion, urinar y frequency, elevated SGOT, hyperuricemia, 
hyperglycemia, and elevated creatinine.   In a Phase I study of lenalidomide administered  daily to adults with refractory metastatic 
cancer (median age 66 yrs), an episode of thrombosis (dose-limiting) and Grade III 
hypotension was observed at a dose of 20 mg/day.
23 Other toxicities (nausea, vomiting, 
diarrhea, rash, dizziness, peripheral neuropat hy, fatigue, bone marrow suppression) were 
mild. In a second study of lenalidomide in adul ts with solid tumors (primarily melanoma 
and renal cell carcinoma), daily doses of 5- 150 mg/day were well tolerated. Grade 4 
neutropenia was observed in 2 patients receiving > 50 mg/day.24 In a Phase I study in adults 
with recurrent high-grade gliomas, lenalidomid e at doses of 40 mg/day x 21 days was well 
tolerated and no MTD was define d. This dose of 40 mg daily was predetermined to be the 
maximum dose to be tested in the adult glioma  population based on some, but not all, prior 
3KDVH,DGXOWVWXGLHVZKLFKGHPR QVWUDWHGP\HORVXSSUHVVLRQDWGR VHV¬ï  50 mg/day. 
  
A Phase I study of lenalidomide was recently  performed within the COG in pediatric 
patients with relapsed or refractory so lid tumors or myelodysplastic syndrome. 
(ADVL0319) The primary objectives were to determine the maximum tolerated dose and 
recommended Phase II dose for children with  refractory solid tumors and describe the 
toxicities in this population. Doses up to 70 mg/m2/day x 21 days followed by a 7-day rest 
were evaluated. Although 6 episodes of dose -limiting toxicity (DLT) were observed, they 
were sporadic and not clearly associated  with dose. These DLTs included Grade 3 
hypercalcemia, Grade 3 hypophosphatemia, Gr ade 3 hypokalemia, Grade 4 neutropenia, 
Grade 3 somnolence, and Grade 3 urticaria and occurred at doses ranging from 15 mg/m2 
to 55 mg/m2. 29 No MTD was reached. The majority of pa tients on this study did not receive 
more than one course of therapy. 
  A Phase I trial of lenalidomide in pediatric patient s with recurrent, refractory or progressive 
CNS tumors performed within  the Pediatric Brain Tumor Consortium (PBTC-018) has 
recently closed to accrual.
25 Fifty-one patients were enrolled; 44 patients are evaluable for 
toxicity and response. Patients were  treated at doses of 15-116 mg/m2/day for 21 days 
followed by a 7 day rest period (one course is 21 days of therapy + 7 day break). A 
maximum tolerated dose has not been reached . The agent has been well tolerated. Two 
DLTs were reported with an unclear associa tion with lenalidomide. One patient treated at 
the 20 mg/m2/day dose level had cardiac dose limiting toxicity with a presumed myocardial 
infarct and elevated troponin. This patient ha d multiple risk factors for thromboembolism. 
One patient at dose level 68 mg/m2/day had dose-limiting fati gue but had concurrent 
disease progression. Twenty-three patients, repr esenting all dose levels, received 6 or more 
courses of treatment and 9 patients have received 12 or more courses to date. 
 On this study (PBTC-018), myelosuppression wa s the primary toxicity and occurred 
sporadically. No patient had Grad e 4 myelosuppression during Course 1. 
0\HORVXSSUHVVLRQIRUSDWLHQWVWUHDWHGIRU¬ïF\FOHVZDVDOVRV SRUDGLFDQGQRWFOHDUO\
associated with dose, although data at the high er dose levels shows a possible trend toward 
moUHIUHTXHQWHSLVRGHVRI*UDGHV DQGP\HORVXSSUHVVLRQDWGRVH OHYHOV¬ïPJP
2/day. 
Other common toxicities include fatigue (30% ), gastrointestinal symptoms including 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 13 
 
 
nausea (10%), emesis (4%), diarrhea (16%), an d constipation (8%), as well as rash (14%) 
and muscle cramping (10%). It is also uncl ear if responses were dose-related. Objective 
responses (two partial responses, diagnoses JPA, OPG) were reported at doses of ¬ï
mg/m2/day. Of note, nine patients with recurrent, refractory or progressive optic pathway 
gliomas enrolled on study have received 8, 12+, 24, 24, 12, 13, 11 and 11+ cycles of therapy to date. Dose levels for these patients ranged from 15-116 mg/m
2/day. Of 12 patients with 
-3$KDYHUHFHLYHG¬ï  6 courses to date at doses ranging from 68-116 mg/m2/day. Other 
patients with low-grade gliomas, including thir d ventricular astrocytomas (2 patients) and 
ganglioglioma (1 patient) have received 22, 24 and 12 courses, respectively. No patient 
with glioblastoma (n=4) received more than one course of therapy. Results from pharmacokinetic analysis show a linear re lationship between lenalidomide dose and C
max 
and AUC 24 hrs.  
 
Early phase clinical trials of noncytotoxic (eg,  antiangiogenic) agents in patients with brain 
tumors are complicated by several issues. Co nventional endpoints in phase I trials are 
defined by predetermined toxicity criteria in  order to define a maximum tolerated dose 
(MTD), or, more recently, by biologic endpoints in order to define a biologically effective 
dose. Standard phase I studies are designed to  best identify acute, rather than long-term 
toxicities. Antiangiogenic agents frequently have  little acute toxicity and may need to be 
administered chronically. They may be e ffective at doses well below the MTD and 
therefore dose escalations to the MTD may be unnecessary. However, defining a biologically effective dose is difficult as ther e is a lack of validated biological surrogate 
markers. Although objective responses were ob served in the Pediatric Phase I trial at the 
higher dose levels and preliminary PK data s uggests increasing exposure with increasing 
dose, it is unclear if response to this agen t is dose related. We will therefore estimate 
activity in two cohorts, with patients receiving Regimen A low-dose (20 mg/m
2/day) or 
Regimen B high-dose (115 mg/m2/day) lenalidomide. 
 Efficacy of an agent in patients with brain tumo rs is historically defined in phase II trials 
by measuring response of the tumor based upon two-dimensional measurements using 
post-contrast MRI scans. These endpoints are neither ideal, nor applicable, when 
evaluating cytostatic agents, such as antiangi ogenic agents, in patients with CNS tumors, 
especially with tumors such as low grade gliomas, that have variable and sometimes 
heterogeneous enhancing patterns and frequen tly contain cystic areas. Time-dependent 
endpoints, such as time to tumor progression, may be more appropriate for this group of 
agents in this patient population. However, th is can be complicated by the erratic growth 
patterns of low-grade gliomas. The majority of  clinical studies estimating activity report 
objective response rate as the primary objectiv e. We will therefore evaluate both objective 
response rate and event-free survival in this study.  
In summary, lenalidomide is a well-tolerated , novel agent that appears to have some 
activity in childhood CNS tumors. Although it has immunomodulatory, anti-inflammatory 
and antiangiogenic activity, its exact antitumor mechanism is unclear. It is unclear if a 
dose-response relationship exists or if the pr imary toxicity (myelosuppression) is dose-
related. Long-term toxicities have not been fully evaluated. Given its apparent activity 
profile in children with low-grade gliomas enrolled on the pediatric Phase I study (PBTC-
018), we are proposing a Phase II trial of lenali domide in a subset of this population. Initial 
dosing will be 20 mg/m
2/day on Regimen A and 115 mg/m2/day on Regimen B, which is 
the maximum dose evaluated in the PBTC- 018 Phase I study. Two dose reductions will be 
allowed as long as the patient is deriving clin ical benefit. Response as defined in this trial 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 14 
 
 
will include the objective response rate and long term stable disease; EFS will also be 
determined and compared to the objective response rate. It is  expected that a number of 
these patients will remain on therapy for an extended period of time and therefore the long-
term hematologic tolerability of  this agent will be evaluated. 
 
2.5 Rationale for Pharmacokinetic Studies 
In order to obtain more information regard ing a potential dose-response relationship and 
to further determine if myelosuppression is dos e-related, pharmacokinetic studies will be 
performed in all patients in this study. Stead y state PK levels of lenalidomide will be 
performed prior to administering the daily dose any day between Days 5-21 on Cycle 1 and 
again between Days 5-21 on any cycle followi ng a dose reduction. Correlation of steady 
state levels and best response at the patient dose will be performed. A single blood sample 
(2 ml in a heparinized tube) will be collected at up to three time-points and pharmacokinetic 
analyses will be performed using HPLC.   
 
2.6 Rationale for Imaging Studies 
To date, there are no reliable biologic surr ogate markers established in humans for the 
effect of lenalidomide in children with CNS tumo rs. It is unclear if objective response in 
patients with low grade gliomas correlates w ith progression-free survival. In this study, 
standard COG MRI sequences, including T2-weighted, FLAIR, and T1-weighted post 
contrast, will be retrospectively reviewed to  compare response categories with event-free 
survival.  
  
3.0 STUDY ENROLLMENT PROCEDURES AND PATIENT ELIGIBILITY 
3.1 Study Enrollment 
3.1.1 Patient Registration 
Prior to enrollment on this study, patient s must be assigned a COG patient ID 
number. This number is obtained via the eRDE system once authorization for the 
release of protected health information (PHI) has been obtained. The COG patient ID number is used to identify the patient in  all future interactions with COG. If you 
have problems with the registration,  please refer to the online help.   
 
A Biopathology Center (BPC) number will be assigned as part of the registration 
process. Each patient will be assigned only one BPC number per COG Patient ID. 
For additional information about the labe ling of specimens please refer to the 
Pathology and/or Biology Guidelines in this protocol.  
 
Please see Appendix X  for detailed CTEP Registration  Procedures for Investigators 
and Associates, and CTSU Registration Proc edures including: how to download site 
registration documents; requirements for site registration, submission of regulatory documents and how to check you r site‚Äôs registration status. 
 
3.1.2  IRB Approval 
Sites must obtain IRB/REB approval fo r this protocol and submit IRB/REB 
approval and supporting documentation to th e Cancer Trials Support Unit (CTSU) 
Regulatory Office before they can be appr oved to enroll patients. Allow 3 business 
days for processing. The submission must  include a fax coversheet (or optional 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 15 
 
 
CTSU IRB Transmittal Sheet) and the IR B approval document(s). The CTSU IRB 
Certification Form may be submitted in lie u of the signed IRB approval letter. All 
CTSU forms can be located  on the CTSU web page (https://www.ctsu.org). Any 
other regulatory documents needed for ac cess to the study enro llment screens will 
be listed for the study on the CTSU Member‚Äôs Website under the RSS Tab.   IRB/REB approval documents may be faxed (1-215-569-0206), E-mailed 
(CTSURegulatory@ctsu.coccg.org) or mailed  to the CTSU Regulatory office.  
 
When a site has a pending patient enrollmen t within the next 24 hours, this is 
considered a ‚ÄúTime of Need‚Äù registration . For Time of Need registrations, in 
addition to marking your submissions as ‚ÄòURGENT‚Äô and faxing the regulatory 
documents, call the CTSU Regulatory He lpdesk at: 1-866-651-CTSU. For general 
(non-regulatory) questions call the CTSU General Helpdesk at: 1-888-823-5923.  
 Study centers can check the status of th eir registration packets by querying the 
Regulatory Support System (RSS) site re gistration status page of the CTSU 
members‚Äô web site by entering credential s at https://www.ctsu.org. For sites under 
the CIRB initiative, IRB data will automatically load to RSS. 
 
Note: Sites participating on the NCI CIRB initiative and accepting CIRB approval for the study are not required to submit separate IRB approval documentation to the CTSU Regulatory Office for initial, continuing or amendment review.  This information will be pr ovided to the CTSU Regulatory 
Office from the CIRB at the time the site‚Äôs  Signatory Institution accepts the CIRB 
approval. The Signatory site may be co ntacted by the CTSU Regulatory Office or 
asked to complete information verifying th e participating institutions on the study. 
Other site registration requirements (i.e ., laboratory certifications, protocol-
specific training certifications, or modality  credentialing) must be submitted to the 
CTSU Regulatory Office or compliance co mmunicated per protocol instructions. 
 
3.1.3  Reservation Requirements  
CRAs/Site Investigators should refer to th e COG website to determine if the study 
is currently open for accrual. If the study is active, a reservation can be made 
by following the steps below : 
1) Log in to https://www.ctsu.org and enter your CTEP IAM user name and 
password to access the CTSU members ar ea.  Then, click on the following 
link: https://www.ctsu.org/OPEN_SYSTEM/. 
2) Then, click on ‚ÄòConnect to OPEN‚Äô link, and finally on ‚ÄòCreate New 
Registration‚Äô link. 
3) After entering your Institution CTEP ID and protocol number, click on the 
‚ÄòSlot Availability Information‚Äô link  to see how many reservations are 
available for that study. 
4) If one or more is available, select  step 0 under registration step and 
complete the remaining questi ons to obtain a reservation. 
  
Prior to obtaining informed consent for the clinical trial and enrolling a patient, a 
reservation must be made following the steps above. Reservations may be obtained 
24 hours a day through the OPEN system.  
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 16 
 
 
3.1.4 Study Enrollment  
Patient enrollment will be facilitated us ing the Oncology Patient Enrollment 
Network (OPEN). OPEN is a web-based registration system available on a 24/7 
basis. To access OPEN, the site user must have an active CTEP-IAM account 
(check at < https://eapps-ctep.nci.nih.gov/ia m/index.jsp >) and a 'Registrar' role on 
either the lead protocol organization (L PO) or participating organization roster. 
 All site staff will use OPEN to enroll patients to this study. It is integrated with the 
CTSU Enterprise System for regulatory and roster data and, upon enrollment, 
initializes the patient position in the Ra ve database. OPEN can be accessed at 
https://open.ctsu.org or from the OPEN tab on the CTSU members‚Äô side of the 
website at https://www.ctsu.org .  
 
Prior to accessing OPEN, site staff and the results from the rapid central pathology 
screening review have confirmed the patient is eligible. 
x All eligibility criteria have been met w ithin the protocol stated timeframes. 
x All patients have signed an appr opriate consent form and HIPAA 
authorization form (if applicable).  Note: The OPEN system will provide the site with a printable confirmation of 
registration and treatment in formation. Please print th is confirmation for your 
records.  Further instructional information is pr ovided on the CTSU members' web site 
OPEN tab or within the OPEN URL (http s://open.ctsu.org). For any additional 
questions contact the CTSU Help Desk at 1-888-823-5923 or 
ctsucontact@westat.com. 
 
3.1.5 Timing 
Female patients of childbearing potenti al must have negative serum or urine 
pregnancy test (sensitivity of at least 25  mIU/mL) results performed within 10-14 
days and again within 24 hours prior to th e anticipated start of protocol therapy. 
(Refer to Appendix II  for definition of female chil dren of childbearing potential 
[FCCBP]) Also see Exclusion Criteria in Section 3.2.9.3  regarding the requirement 
for female patients of childbearing potential  to commit to comp lete abstinence or 
to be on two forms of effective birth control prior to, during, and following 
protocol therapy.  
 
Patients must be enrolled before treatment begins. The date protocol therapy is projected to start must be no later than five (5)  calendar days after the date of study 
enrollment. Patients who are started on protocol  therapy on this Phase II study 
prior to study enrollment will be considered ineligible .  
 
3.1.5.1 Required Counseling FDA requires that each clinical trials site  have two counselors (Investigators are 
not eligible) trained by Celgene thr ough the Celgene Pregnancy Prevention 
Counselor Program-Pediatric (CPPCP-PED). The CPPCP-PED is available on the 
internet for each person who has complete d the site counselor identification form 
(Appendix I) and registered with Celgen e prior to completing the CPPCP-PED. 
Each patient/guardian must be counseled  prior to dispensing lenalidomide and 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 17 
 
 
documentation is kept in the patient‚Äôs reco rds. Both the training certificates and 
the completed Lenalidomide Education a nd Counseling Guidance Documents are 
auditable documents and must be produc ed upon request. Counselors who wish to 
counsel patients for different protocols at the same site or for the same protocol at different silts should indicate this on the site counselor form. Please not that 
counselor training for pediatric patients is  separate from training for adult patients. 
Counselors who previously obtained CPPC P certificates must complete pediatric 
version. CPPCP-PED, in order to coun sel patients in NCI-sponsored pediatric 
studies. 
 Examples of healthcare professionals that may be trained counselors include nurses, pharmacists and physicians. Inve stigators may not serve as designated, 
trained counselors for the purpose of this study. Trained counselors must complete 
training using the online program provided  free by Celgene. After the training is 
complete, the counselors must generate a training certificate and provide it to the 
CTSU for documentation. Sites may not order lenalidomide until documentation for two trained counselors is provided to the appropriate office as instructed in the email from Celgene. Because it may take up to 7 days for training, it is suggested that 
counselors be identified at the onset of the protocol and receive training as soon as 
possible after IRB protocol approval.  Following completion of training, the designated counselors will be responsible for counseling subjects prior to a ny treatment or the dispensing of lenalidomide to ensure 
that the subject has complied with all requ irements including use of birth control and 
pregnancy testing and that the subject understands the risks associated with 
lenalidomide.  Information pertinent to the risks of lenalidomide that should be used as part of training can be found in the document entitled ‚ÄúLenalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods‚Äù 
(Appendix II ).    All investigators should be familiar with this document and the risks 
associated with lenalidomide.  Counseling must be documented by the completion of 
a Lenalidomide Education and Counseling Guidance Document ( Appendix III ).  No 
drug will be dispensed until counseling and co mpletion of this document occurs.  A 
copy of this document must be maintained in the patient‚Äôs medical record. Counseling 
includes verification with the patient that required pregnancy testing was performed and results were negative. Pregnancy test results should be documented on the 
Lenalidomide Patient Card for Pediatric Patients ( Appendix IV ).  
A Lenalidomide Information Sheet ( Appendix V ) will be supplied with each 
medication dispense. 
 Please Note: The counseling requirements fo r investigational use of lenalidomide 
are separate from the RevAssist program re quirements in the United States and the 
RevAid
SM program in Canada.  Participation in these two programs is not required, 
nor sufficient for use of the i nvestigational lenalidomide product. 
 All clinical and laboratory studies to determine eligibility must be performed 
within 7 days prior to enrollment unless  otherwise indicated in the eligibility 
section below. 
 
3.1.6 Randomization 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 18 
 
 
Randomization will take place at the time a patient is entered On Study via eRDE. Patients will be assigned to receive on e of two lenalidomide doses with equal 
probability: 20 mg/m
2/day (Regimen A ‚Äì lo w dose) or 115 mg/m2/day (Regimen 
B ‚Äì high dose).  Patients will be stratified according to the number of prior 
regimens (2 or less regimens ve rsus greater than 2 regimens). 
 
3.2 Patient Eligibility Criteria 
Important note: The eligibility criteria lis ted below are interpreted literally and 
cannot be waived (per COG policy posted 5/11 /01). All clinical and laboratory data 
required for determining eligibility of a patien t enrolled on this trial must be available 
in the patient's medical/research record wh ich will serve as the source document for 
verification at the time of audit.  
 
See Section 7.1  for required studies to be obtained prior to starting protocol therapy. 
 
 
INCLUSION CRITERIA 
3.2.1 Age 
Patients must be less than 22 years of age at the time of enrollment.  
 
3.2.2 Body Surface Area (BSA) 
3DWLHQWVPXVWKDYHD%6$¬ïP2 at the time of study enrollment. 
 
3.2.3 Diagnosis  
Patients must have a pilocytic astrocytom a or optic pathway glioma that has 
relapsed, progressed or become refractory  to conventional therapy. Patients with 
neurofibromatosis (NF-1) are eligible. 
 
3.2.3.1 
Patients must have histologic verification of malignancy. Histologic confirmation 
for patients with optic pathway g liomas will not be required.  
 3.2.3.2 
Patients must have measurable residual  disease, defined as tumor that is 
measurable in two perpendicular diameters on MRI.  For a lesion to be considered 
measurable, it must be at least twice the slice thickness on MRI (i.e visible on more 
than one slice). 
 
3.2.3.3 Brain and Spine MRI 
To document the degree of residual tumor, the following must be obtained (see 
Section 14.0  for complete details): 
 
3.2.3.3.1 All patients must have a brain MRI with and without contrast (gadolinium) within 1 week prior to study enrollme nt. For patients on steroids, baseline 
MRI scans must be performed after at least 1 week at a stable or decreasing 
dose of steroids. 
 3.2.3.3.2 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 19 
 
 
All patients with a history of spinal or leptomeningeal disease, and those 
patients with symptoms suspicious of spinal disease, must have a spine 
MRI with and without contrast (ga dolinium) performed within 2 weeks 
prior to study enrollment. 
 
3.2.4 Performance Level  
Patients must have a /DQVN\RU.DUQRIVN\SHUIRUPDQFHVWDWXVVFRUHRI¬ï 60%. Use 
Karnofsky for patients > 16 years of age and Lansky for patients d 16 years of age. 
See https://members.children soncologygroup.org/prot/reference_materials.asp under 
Standard Sections for Protocols. 
 
3.2.5 Prior Therapy 
 
3.2.5.1 Patients must have been treated with at least one prior treatment regimen that  
included carboplatin. Patients who have rece ived prior radiation therapy for this 
tumor are eligible. 
 
3.2.5.2 Patients must have recovered (to CTC v.4.0 ¬îGrade 1 unless indicated below) 
from the acute toxic effects of all prior chemotherapy, immunotherapy, or 
radiotherapy prior to entering this study, with the exception of alopecia, weight 
changes and Grade I or II lymphopenia. 
a. Myelosuppressive chemotherapy: Must not have received within 3 weeks 
of entry onto this study (6 weeks if  prior nitrosourea or mitomycin-C). 
b. Biologic (anti-neoplastic agent): At l east 7 days after the last dose of a 
biologic agent.  For agents that  have known adverse events occurring 
beyond 7 days after administration, this period must be extended beyond 
the time during which adverse ev ents are known to occur.   
c. Immunotherapy: At least 42 days afte r the completion of any type of 
immunotherapy, e.g. tumor vaccines. 
d. Monoclonal antibodies: At least 3 half-l ives of the antibody after the last 
dose of a monoclonal antibody. (See table on DVL homepage listing 
monoclonal antibody half-lives.) 
e. Radiation therapy (RT): Patients must have had their last fraction of 
craniospinal RT 
¬ï6 months prior to study entry and their last fraction of focal RT ¬ïZHHNV
prior to study entry. If the lesion used for on-study criteria is in the 
radiation field, there must be eviden ce of tumor progression after radiation 
therapy was completed. 
f. S tudy specific limitations on prior therapy: 
1) Patients who have received thalid omide are eligible if all acute 
thalidomide-related toxicity has resolved. 
2) Patients must not have received lenalidomide previously. 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 20 
 
 
3.2.6 Concomitant Medications Restrictions 
(Please see Section 4.2  for the concomitant therapy re strictions for patients during 
treatment.) 
 
a. Growth factor(s): Must not have received within 2 weeks of entry 
onto this study. 
b. Steroids: Patients who are receiving corticosteroids must be on a 
stable or decreasing dose for at l east 1 week prior to baseline MRI.  
 
3.2.7 Organ Function Requirements 
 
3.2.7.1 Adequate Bone Marrow Function Defined As: 
- Peripheral absolute neutrophil count (ANC) t 1000/PL  
- Platelet count t 100,000/PL (transfusion independent) 
- Hemoglobin t 8.0 g/dL (may receive RBC transfusions) 
 
3.2.7.2 Adequate Renal Function Defined As: 
- Creatinine clearance or radioisotope GFR t 70 mL/min/1.73 m2 or 
- A serum creatinine based on  age/gender as follows: 
 
Age 
 Maximum Serum 
Creatinine (m g/dL) 
 Male Female 
1 month to < 6 months 0.4 0.4 
6 months to < 1 year 0.5 0.5 
1 to < 2 years 0.6 0.6 
2 to < 6 years 0.8 0.8 
6 to < 10 years 1 1 
10 to < 13 years 1.2 1.2 
13 to < 16 years 1.5 1.4 
¬ï\HDUV 1.7 1.4 
The threshold creatinine values in this  Table were derived from the Schwartz 
formula for estimating GFR (Schwartz et  al. J. Peds, 106:522, 1985) utilizing 
child length and stature data published by the CDC. 
 
3.2.7.3 Adequate Liver Function Defined As: 
- Total bilirubin d 1.5 x upper limit of normal (ULN) for age, and 
-  SGPT (ALT) d 110 U/L.  For the purpose of this study, the ULN 
for SGPT is 45 U/L. 
- Serum albumin ¬ïJG/ . 
 3.2.7.4 Adequate Pulmona ry Function Defined As: 
- No evidence of dyspnea at rest and a pulse oximetry > 94% if there 
is clinical indication for determination. 
 
3.2.8 Patients must be able to swallow intact capsules. 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 21 
 
 
EXCLUSION CRITERIA 
 
3.2.9 Pregnancy and Breast Feeding  
 
3.2.9.1 Female patients who are pregnant are not eligible due to risks of fetal and 
teratogenic adverse events as seen in an imal studies of lenalidomide. Lenalidomide 
is structurally related to thalidomide,  which is known to cause severe life-
threatening birth defects in humans. 
 3.2.9.2 Lactating females are not eligible unless th ey have agreed not to breastfeed their 
infants while receiving protocol therapy a nd for 28 days after the last dose of 
lenalidomide. 
 3.2.9.3 
Female patients of childbearing potential are not eligible unless they commit to 
complete abstinence or have been on 2 met hods of birth control, including 1 highly 
effective method and 1 additional method at the same time (unless committing to 
complete abstinence of heterosexual intercou rse) at least 28 days (4 weeks) prior 
to study enrollment. Sexually active fema les must also agree to remain on 2 
methods of birth control, during treatmen t (including during dose interruptions), 
and continuing for at least 28 days afte r the completion of protocol therapy. 
Examples of methods of contraception are as follows: 
x Highly effective methods (must use at least 1): 
¬É Intrauterine device (IUD) 
¬É Hormonal (prescription birth control pills, injections, 
implants) 
¬É Tubal ligation 
¬É Partner‚Äôs vasectomy 
 
x Additional effective methods: 
¬É Male condom 
¬É Diaphragm 
¬É Cervical cap 
 
The two methods of birth control requirem ent applies to all sexually active females 
unless they have undergone a hysterectomy or bilateral oophorectomy. 
 
3.2.9.4 Female patients of childbearing potential (including those who commit to complete 
abstinence) are not eligible unless they  agree to ongoing pregnancy testing (see 
Section 4.1  for details) and counseling every 28  days about pregnancy precautions 
and risks of fetal exposure. 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 22 
 
 
3.2.9.5 Male patients of child fathering potential ar e not eligible unless they have agreed 
to use latex condoms during intercourse with a woman of childbearing potential 
while receiving treatment and for 28 days thereafter. 
 
3.2.10 Pre-existing conditions 
 
3.2.10.1 
Patients with a history of thromboembolism unrelated to a central line, or patients 
with a known predisposition syndrome for thromboembolism are not eligible. 
 3.2.10.2 Patients who have an uncontrolled or untreated infection are not eligible. 
 
3.2.10.3 Patients with known overt cardiac disease,  including but not limited to a history of 
myocardial infarction, severe or unstable angina, clinically significant peripheral 
vascular disease, Grade 2 or greater heart failure, or serious and inadequately 
controlled cardiac arrhythmia are not eligible. 
 3.2.10.4 
Patients with a significant systemic illness that is not well-controlled in the opinion 
of the treating physician are not eligible. 
 
REGULATORY 
 
3.2.11 
All patients and/or their parents or legal gu ardians must sign a written informed consent. 
 3.2.12 All institutional, FDA, and NCI requirements for human studies must be met. 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 23 
 
 
 
4.0 TREATMENT PROGRAM 
Timing of protocol therapy administration, response assessment studies, and surgical interventions are 
based on schedules derived from the experimental design or on established standards of care. Minor 
unavoidable departures (up to 72 hours) from protocol directed therapy and/or disease evaluations (and 
up to 1 week for surgery) for valid clinical, patient and family logistical, or facility, procedure and/or 
anesthesia scheduling issues are acceptable per C OG administrative Policy 5.14  (except where explicitly 
prohibited within the protocol). 
 
4.1 Overview of Treatment Plan 
Upon enrollment, patients will be randomized  to receive one of two treatments with 
lenalidomide; Regimen A (low dose) versus Re gimen B (high dose). Please note there is a 
requirement for contraception for female patients of childbearing potential, such that they 
must commit to complete abstinence or agr ee to use two forms of effective contraception 
beginning at least 28 days prior to the first dose of lenalidomide and continuing until 28 
days after the last dose of lenalidomide. (See Section 3.2.9.4  and Appendix II ). The primary 
study endpoint is objective response. Therapy may continue for a maximum of 26 cycles, 
in the absence of disease progression (see Section 10.4  for definition) if off protocol criteria 
have not yet been satisfied (see Section 8.1 ). 
 
Each cycle of therapy will last 28 days. Lena lidomide will be administered daily for the 
first 21 days of each cycle followed by a 7 day rest period. The lenalidomide dose for 
Regimen A will be 20 mg/m2/day by mouth daily and the dose for Regimen B will be 115 
mg/m2/day by mouth daily. The dose will be rounde d to within 10% of the prescribed dose 
for convenience of capsule size. The calcul ated dose should be rounded in a manner to 
minimize the daily number of capsules.   
 Patients or their guardians will keep a diar y to document the intake of each dose of 
lenalidomide and potential side effects (see Appendix VI ). Please instruct patient/parents 
to record each dose on the diary immediately rather than waiting until a later time. Errors 
on the diary should be crossed out and initialed.  The patient diary should be reviewed with 
the patient and family at the completion of  each treatment cycle, and drug should be 
accounted for at this time.  
 
Brain MRI will be performed at b aseline (within 1 week prior to VWXG\HQUROOPHQWDQG¬ï
week on a stable or decreasing dose of ster oids for those patients receiving steroids) and 
prior to each odd-numbered cycle (ie, prior to cy cles 3, 5, 7, 9, 11, and 13) for the first 13 
cycles.  During cycles 14-26, imaging will be performed prior to every third cycle (ie, prior 
to cycles 16, 19, 22, and 25), after cy cle 26, and as clinically indicated. See Section 14.0  
for imaging requirements. Patients with spine disease will also have spine MRI performed 
at the same timepoints after enrollment, (ie, pr ior to cycles 3, 5, 7, 9, 11, and 13) for the 
first 13 cycles.  During cycles 14-26, imagi ng will be performed prior to every third cycle 
(ie, prior to cycles 16, 19, 22, and 25), after cycle 26, and as clinically indicated.   
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 24 
 
 
Pharmacokinetic Study 
For all patients, a blood sample must be obt ained prior to the daily dose between Day 5-21 
of cycle 1 at the time of routine safety lab m onitoring. In the event of a dose reduction, a 
blood sample must also be obtained between Day 5-21 of the first cycle following each 
dose reduction. Please see Section 13.1  for details on pharmaco kinetic sample collection 
and shipping. 
 Required Pregnancy Testing During Study Participation 
Pregnancy tests with a minimum sensitivity of  25 mIU/mL must be performed for female 
patients of childbearing potential, including those who commit to comp lete abstinence. If 
menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28 
days and then every 14 days while on study, wh en the patient is taken off protocol therapy, 
and at Days 14 and 28 following the last dose of lenalidomide. All other female patients of 
childbearing potential must have pregnancy te sts weekly for the first 28 days of study 
participation and then every 28 days while on study, at the time the patient is taken off 
protocol therapy, and at Day 28 following the last dose of lenalidomid e. If pregnancy or a 
positive pregnancy test does occur during pr otocol therapy, lenalidomide must be 
immediately discontinued. Pregna ncy testing and counseling must  be performed if a patient 
misses her period, if her pregnancy test is pos itive, or if her menstrua l bleeding is abnormal.  
Lenalidomide treatment must be disc ontinued during this evaluation.  
 Pregnancies and suspected pregnancies (incl uding in the partner of a male study patient 
during study participation) must be reported as an adverse event. See Section 11.0  for 
adverse event expedited reporti ng guidelines for pregnancies and suspected pregnancies. 
 
Required Patient Education and Counseling 
Counseling about pregnancy pr ecautions and the potential risks of fetal exposure will be 
conducted every 28 days, on Day 1 of each cycle. See Section 3.1.5.1  for counselor training 
requirements. Counseling must be completed pr ior to each dispensing of lenalidomide, and 
the counseling of each subject must be docum ented using the Lenali domide Education and 
Counseling Guidance Document ( Appendix III ).   
 
See Section 7.1  for required observations prior to starting protocol therapy. 
 
4.2 Concomitant therapy restrictions 
 
4.2.1 Concurrent cancer therapy, including chemothe rapy, radiation therapy, immunotherapy, or 
biologic therapy may NOT be administered to patients while on this study. The use of 
alternative or complementary therapies is discouraged.  4.2.2 Radiotherapy is not permitted.  
4.2.3 
Filgrastim (G-CSF) may be used at the trea ting physician‚Äôs discretion in patients with 
severe neutropenia (i.e. ANC <500 »ù/) to enhance neutrophil recovery when clinically 
indicated (for culture proven bacteremia or invasive fungal infections). Prophylactic or 
routine use of filgrastim in clinically well patients awaiting count recovery is not 
recommended. 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 25 
 
 
 4.2.4 
Corticosteroid therapy is permissible only for the treatment of increased intracranial 
pressure or physiologic replacement. The lowe st dose consistent with good medical 
management should be used. Corticosteroids s hould NOT be used as an antiemetic due to 
their effect on the blood brain barrier. Patients on  steroids who require an increase in steroid 
dose for worsening neurologic symptoms s hould have an MRI performed within 72 hours 
to rule out tumor progression. 
 
 4.2.5 Appropriate antibiotics, blood products, antie metics, fluids, electr olytes and general 
supportive care are to be used as n ecessary. Antiemetics should not be given 
prophylactically for cycle 1.  
 
4.2.6 Anticonvulsants may be administered as clinic ally indicated.  However, it is unclear what 
effect, if any, lenalidomide has on antic onvulsant pharmacokinetics.  It is strongly 
recommended that anticonvulsant le vels be checked at least weekly during the first course 
of therapy. 
 4.2.7 Drugs known to be pro-thrombotic (i.e. eryt hropoietic stimulating agents) should be 
avoided.  
For COG Supportive Care Guidelines see:  
https://members.children soncologygroup.org/prot/re ference_materials.asp  under Standard 
Sections for Protocols. 
 
4.3 Lenalidomide Administration 
The lenalidomide cycle will be repeated every 28 days. Each cycle will be comprised of 
lenalidomide orally once daily for 21 days fo llowed by 7 days without lenalidomide. 
Lenalidomide should be taken at  approximately the same time each day.  One cycle of 
lenalidomide is described below. Lenalinomide is distributed by the NCI DTCD. Do 
not use commercially available drug.  
 Begin Cycle 1 on Day 1 if ANC ¬ï»ù/ , SODWHOHWFRXQW¬ï»ù/WUDQVIXVLRQ
independent), and upon the following: 
x confirmation of negative serum or urine pr egnancy test (sensitivity of at least 25 
mIU/mL) in female patients of childbearing potential, 
x confirmation of the use of 2 forms of eff ective birth control for female patients of 
childbearing potential OR confirmation of  commitment to complete abstinence, 
and 
x completion and documentation of required lenalidomide education and counseling 
(all patients) 
 Dose calculations should be based on actual BSA and adjusted as necessary prior to 
each cycle. There is no maximum dosing. 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 26 
 
 
Lenalidomide: PO once daily  
Days: 1 through 21. 
Dose:  Regimen A (Low Dose):  20 mg/m2/dose (See Appendix X  for Dosing Tables) 
Regimen B (High Dose): 115 mg/m2/dose 
 
Note: The calculated dose shoul d be rounded to within 10% of the prescribed dose for 
convenience of capsule size. The calculated dose should be rounded in a manner to 
minimize the daily number of capsules.  The dose should be given without food when 
possible, although this is not mandatory. If a patient vomits a dose within 10 minutes of 
administration and the capsules are clearly visi ble, the dose may be repeated. The capsules 
should be swallowed whole a nd not opened or chewed.  
 
See Section 5.0  for Dose Modifications based on Toxicities.  
 
The therapy delivery maps (TDMs) for this cycle are on the next two pages. See Section 4.3.1  
for the Regimen A (Low Dose: 20 mg/m2/dose) therapy delivery map and Section 4.3.2  for 
the Regimen B (High Dose: 115 mg/m2/dose) therapy delivery map.  
 
Following completion of the first cycle, the lena lidomide cycle is repeated for up to a total 
of 26 cycles, as tolerated and in the absence of disease progression (see Section 10.4  for 
Response Evaluation). If disease progression occu rs, the patient will be taken off protocol 
therapy.  
 Susbequent lenalidomide cycles should begin on Day 29 or when $1&¬ï»ù/ , platelet 
count ¬ï»ù/WUDQVIXVLRQLQGHSHQGHQW whichever occurs later, AND once the 
following criteria have been met: 
x confirmation of negative serum or urine pr egnancy test (sensitivity of at least 25 
mIU/mL), 
x confirmation of the use of 2 effective method s of  birth control for female patients 
of childbearing potential OR confirmation of commitment to complete abstinence, 
x completion and documentation of required lenalidomide educat ion and counseling 
(all patients). 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 27 
 
 
 
4.3.1 Lenalidomide Cycle ‚Äì Regi men A (Low Dose: 20 mg/m2) 
Four consecutive weeks (28 days) will constitute  one cycle (Lenalidomide daily x 21 days 
followed by 7 day rest). This therapy delivery map relates to all cycles of  Regimen A. Use a copy 
of this page once for each cycle. (Please note cycle number below.)  ________________________ 
Patient name or initials 
____________________________ 
DOB 
Criteria to start this cycle $1&¬ï ,»ù/DQGSODWHOHW FRXQW¬ï»ù/  (transfusion independent), confirmatio n of negative pregnancy test and the 
use of 2 methods of effective birth control for female patients of childbearing potential or commitment to complete abstinence,  completion and 
documentation of required c ounseling. Details are in Section 4.0  (Treatment Overview). The Thera py Delivery Map for this cycle is on 1 page.  
DRUG ROUTE DOSAGE DAYS IMPO RTANT NOTES OBSERVATIONS 
Lenalidomide 
NSC#703813 PO 20 
mg/m2/dose 1-21 See admin guidelines in 
Section 4.3 . (See 
Appendix IX for Dosing 
Tables) a. History, PE (Ht, Wt, VS), Performance Status 
b. CBC (differential, platelets) 
c. Urinalysis 
d. Electrolytes (inc BUN, Calcium, PO 4, Magnesium)  
e. Creatinine; Total protein;  Albumin, ALT, AST, bilirubi 
f. Pregnancy test (female pts of childbearing potential only) 
g. Brain MRI with an d without gadolinium 
h. Spine MRI with and without gadolinium 
i. Pharmacokinetic study (see Section 13.0 ) 
j. Required Education and Counseling; Confirmation of birth 
control/abstinence  
OBTAIN OTHER STUDIES AS REQUIRED FOR GOOD 
PATIENT CARE 
Please Enter Cycle #: _____ Ht _________cm  Wt _________kg  BSA _________m2 
 
Date 
Due Date 
Given Day Lenalidomide 
____ mg Studies Comments (Include any held doses, or 
dose modifications ) 
   Enter calculated dose above and actual dose administered below   
  1 ____ mg a, b@, c, d, e, f*, g#, h^, j  
  2 ____ mg   
  3 ____mg   
  4 ____mg   
  5 ____ mg i$  
  6 ____ mg   
  7 ____ mg   
  8 ____mg b, d, f*  
  9 ____mg   
  10 ____mg   
  11 ____ mg   
  12 ____ mg   
  13 ____ mg   
  14 ____mg   
  15 ____mg b, d, f*  
  16 ____ mg   
  17 ____ mg   
  18 ____ mg   
  19 ____mg   
  20 ____mg   
  21 ____mg b, d, f*  
  29 Start next cycle on Day 29 or when blood count parame ters are met (whichever occ urs later). For end of therapy 
observations, see Section 7.1 . 
@ Obtain weekly. If patien t develops hematologic toxicity as defined in Section 5.2 , CBCs should be checked every 3 to 4 days until recovery to Grade 3. 
*Obtain within 24 hours prior to starting each  cycle and weekly during cy cle 1. If menstrual cycles are known to be irregular, pregnancy testing must occur every 14 
days beginning with Day 1 of Cycle 2.  If a patient misses her period or menstrual bleeding becomes irregular, hold lenalidomid e and perform pregnancy testing and 
counseling immediately.Only for fema les of childbearing potential.  
#Obtain prior to each odd-numbered cycle of th erapy (ie, prior to cycles 3, 5, 7, 9,  11 and 13) for the first 13 cycles. During  cycles 14-26, obtain every third cycle 
(ie, prior to cycles 16, 19, 22 and 25), after cycle 26 and as clinically indicated.  
^ Obtain at same time points as  brain MRI, for patients with kn own or suspected spinal disease. 
$ For PK study, obtain 2 mL blood in heparinized tube (green top)  any day between Days 5-21 of Cycle 1 and any day between Days  5-21 of the first cycle 
following a dose reduction at the time of safety lab monitoring. See Section 13.0  
See Section 5.0  for Dose Modifications for Toxicities. For COG Supportive Care  Guidelines see: 
https://members.childrensoncologygroup.org/prot/reference_materials.asp .   
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 28 
 
 
4.3.2 Lenalidomide Cycle ‚Äì Regimen B (High Dose: 115 mg/m2) 
Four consecutive weeks (28 days) will constitute one cycle (Lenalidomide daily x 21 
days followed by 7 day rest). This therapy delivery map relates to all cycles of Regimen 
B. Use a copy of this page once for each cycle. (Please note cycle number below.)  ____________________________ 
Patient name or initials 
____________________________ 
DOB 
Criteria to start this cycle $1&¬ï»ù/DQGSODWHOHWF RXQW¬ï»ù/WUDQVIXVLRQL QGHSHQGHQWFRQILUPDWLRQRIQHJDWLYHSUHJQDQF\WHVW  and the 
use of 2 methods of effective birth control for female patients of childbearing potential or commitment to complete abstinence,  completion and 
documentation of required c ounseling. Details are in Section 4.0  (Treatment Overview). The Thera py Delivery Map for this cycle is on 1 page.  
DRUG ROUTE DOSAGE DAYS IMPO RTANT NOTES OBSERVATIONS 
Lenalidomide 
NSC#703813 
 PO 115  
mg/m2/dose 1-21 See admin guidelines 
in Section 4.3 . a. History, PE (Ht, Wt, VS ), Performance Status 
b. CBC (differential, platelets) 
c. Urinalysis 
d. Electrolytes (inc BUN, Calcium, PO 4, Magnesium)  
e. Creatinine; Total protein; Albumin, ALT, AST, bilirubin 
f. Pregnancy test (female pts of childbearing potential only) 
g. Brain MRI with an d without gadolinium 
h. Spine MRI with and without gadolinium 
i.  Pharmacokinetic study (see Section 13.0 ) 
j.  Required Education and Counseling; Confirmation of birth 
control/abstinence  
OBTAIN OTHER STUDIES AS REQUIRED FOR 
GOOD PATIENT CARE 
Please Enter Cycle #: _____ Ht _________cm  Wt _________kg  BSA _________m2 
 
Date 
Due Date 
Given Day Lenalidomide 
____ mg Studies Comments (Include any held doses, or 
dose modifications ) 
   Enter calculated dose above and actual dose administered below   
  1 ____ mg a, b@, c, d, e, f*, g#, h^, j  
  2 ____ mg   
  3 ____mg   
  4 ____mg   
  5 ____ mg i$  
  6 ____ mg   
  7 ____ mg   
  8 ____mg b, d, f*  
  9 ____mg   
  10 ____mg   
  11 ____ mg   
  12 ____ mg   
  13 ____ mg   
  14 ____mg   
  15 ____mg b, d, f*  
  16 ____ mg   
  17 ____ mg   
  18 ____ mg   
  19 ____mg   
  20 ____mg   
  21 ____mg b, d, f*  
  29 Start next cycle on Day 29 or when blood count paramete rs are met (whichever occurs later). For end of therapy 
observations, see Section 7.1 . 
@ Obtai n weekly. If patient develops hem atologic toxicity as defined in Section 5.2 , CBCs should be checked every 3 to 4 days until recovery to grade 3. 
*Obtain within 24 hours prior to starting each  cycle and weekly during cycle 1. If me nstrual cycles are known to be irregular, pregnancy testing must occur every 
14 days beginning with Day 1 of Cycle 2.  If a patient misses her period or me nstrual bleeding becomes irregular, hold lenalido mide and perform pregnancy testing 
and counseling immediately. Only for females of childbearing potential.  
#Obtain prior to each odd-numbered cycle of therapy (ie, prior to  cycles 3, 5, 7, 9, 11 and 13) for the first 13 cycles. During  cycles 14-26, obtain every third cycle 
(ie, prior to cycles 16, 19 , 22 and 25), after cycle 26 an d as clinically indicated.  
^ Obtain at same time points as brain MRI, for patien ts with known or suspected spinal disease. 
$ For PK study, obtain 2 mL blood in heparinized tube (green to p) any day between Days 5-21 of  Cycle 1 and any day between Days  5-21 of the first cycle 
following a dose reduction at the time of safety lab monitoring. See Section 13.0 . 
See Section 5.0  for Dose Modifications for Toxicities. For COG Supportive Care  Guidelines see: 
https://members.childrensoncologygroup.org/prot/reference_materials.asp . 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 29 
 
 
5.0 DOSE MODIFICATIONS FOR TOXICITIES 
Lenalidomide dose reductions will not be re-escalat ed, even if there is minimal or no toxicity with 
the subsequent reduction in dose. Patients who ex perience significant toxicity (as listed in Sections 
5.1 and 5.2) will have the dose reduced by 25% on subsequent cycles.  Two dose reductions are 
allowed, as long as there is no evidence of disease progression (see Section 10.0 ). Each dose 
reduction will be a reduction of 25% of the starting dose; therefore the first dose reduction will be 
to 75% of the starting dose (either to 15 mg/m2/dose for patients on Regimen A or to 86 mg/m2/dose 
for patients on Regimen B), and a second reduction w ill be to 50% of the starting dose (either to 
10 mg/m2/dose for patients on Regimen A or to 58 mg/m2/dose for patients on Regimen B).  See 
Appendix IX  for Regimen A dosing tables. Patients who again experience dose modifying toxicity 
after two dose reductions will be  taken off protocol therapy.  
 
If a dose reduction occurs, a blood sample fo r pharmacokinetic study sh ould be drawn during the 
cycle subsequent to the reduction. See Section 13.0  for details of pharmacokinetic sample 
collection. 
 
5.1 Non-Hematologic Toxicities  
The dose of lenalidomide will be reduced for any of the following toxicities at least 
possibly attributed to lenalidomide: 
‚Ä¢ Any Grade 4 non-hematological toxicity  ‚Ä¢ Any Grade 3 non-hematological toxicity with the specific exclusion of:  
 - Grade 3 nausea and vomiting controlled by antiemetics    - Grade 3 fever or infection  
- Grade 3 hypophosphatemia, hypokalemia,  hypocalcemia or hypomagnesemia 
responsive to oral supplementation. 
‚Ä¢ Any Grade 2 non-hematologic toxicity that persists for > 3 days and is considered 
sufficiently medically significant or suffi ciently intolerable by patients that it 
requires treatment interruption  ‚Ä¢ Any other adverse event attributed to  lenalidomide that requires treatment 
interruption for > 3 days or which re curs upon drug rechallenge and requires 
treatment interruption. 
‚Ä¢ Non-hematological toxicity that causes a delay of t 14 days between treatment 
cycles. 
  
Patients who experience non-hematologic toxi city should have a ppropriate laboratory 
testing at least twice week ly (3-4 days apart) until the toxicity has resolved. 
 Lenalidomide will be held for any patient e xperiencing any Grade hemorrhagic or bullous 
skin rash until a specific evaluation to exclude  toxic epidermal necrolysis (TEN) has been 
performed.  Any patient with evidence of  TEN or Stevens-Johnson syndrome will not be 
retreated with lenalidomide. 
 If the patient experiences a thromboembo lic event unrelated to a central line, 
lenalidomide will be discontinued and the pa tient will be taken off protocol therapy. 
 
5.2 Hematologic Toxicities   
The dose of lenalidomide will be reduced for any of the following toxicities: 
‚Ä¢ Grade 4 decreased neutrophil count (neutropenia) > 3 days duration 
‚Ä¢ Grade 4 decreased platelet  count (thrombocytopenia)  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 30 
 
 
¬á¬ïSODWHOHWWUDQVIXVLRQVSHUF ycle for platelet counts < »ù L  
¬á¬ï14 day delay in starting subsequent  cycles due to low ANC (< 1,000 »ù/ or low 
platelet count (< 100,000/ »ùL.  
‚Ä¢ ,I$1&»ù/  and platelets <100,000 »ù/ during the 21 day dosing period, the 
lenalodomide should be held until recove ry. Counting of cycle days should 
continue uninterrupted. 
Patients who experience hematologic toxicity should have appropriate laboratory testing at 
least twice weekly (3-4 days apart) unti l the toxicity has resolved (i.e. ANC > 10 »ù/  and 
platelets >100,000/ »ùL) . 
 
 
 
6.0 DRUG INFORMATION 
6.1 LENALIDOMIDE (RevlimidTM, CC-5013, CDC-501) NSC# 703813, IND # (05/15/18) 
 
Source and Pharmacology:  Lenalidomide is a thalidomide analogue with the chemical 
name 3-(4‚Äô-amino-1,3-dihydro-1-oxo-2 H-isoindol-2-yl) -2,6-piperidinedione. The 
molecular weight of lenalidomide is 259.25.  
Lenalidomide is an immunomodulatory agent with  a mechanism of action that remains to 
be fully characterized. Lenalidomide inhibits proliferation of certain hematopoietic tumor 
cells (including MM plasma tumor cells and those with deletions of chromosome 5), 
enhances T cell- and natural killer (NK) cel l-mediated immunity and increases the number 
of NK T cells, inhibits angiogenesis by bloc king the migration and adhesion of endothelial 
cells and the formation of microvessels, a ugments fetal hemoglobi n production by CD34+ 
hematopoietic stem cells, and inhibits secre tion of proinflammatory cytokines (eg, TNF- ƒÆ 
and IL-6) from monocytes. Lenalidomide also i nhibited the expression of cycoloxygenase-
2 (COX-2) but not COX-1 in vitro . 
 Following oral administration, lenalidomide is rapidly absorbed with maximum plasma 
concentrations occurring between 0.5 and 1.5 hours postdose. Co-administration with food 
does not alter the extent of lenalidomide absorption (area under the concentration time 
curve, AUC) but does reduce the maximal plasma concentration (C
max) by 36%. The Cmax 
and AUC increase proportionally (linearly) with increases in dose and multiple dosing (up 
to 100 mg twice daily) does not cause a signi ficant drug accumulation. In plasma, the 
relative exposures of the S- and R- enantio mers of lenalidomide are approximately 55% 
and 45%, respectively. 
 Lenalidomide binding to plasma proteins is low with mean plasma protein binding around 
30% (22.7% and 29.2% in multiple myeloma pati ents and healthy volunteers, respectively). 
Lenalidomide is neither metabolized by nor i nhibited or induced by the cytochrome P450 
pathway. In healthy volunteers, lenalidomid e undergoes limited metabolism and the parent 
compound is the predominant circulating co mponent. Approximately 65% to 85% of 
lenalidomide is eliminated unchanged in the urine. The half-life of elimination is 
approximately 3 hours at the clinically releva nt doses and steady-state levels are achieved 
within 4 days. Pharmacokinetic analyses in pa tients with impaired renal function indicate 
that as renal function decreases, the total dr ug clearance decreases proportionally resulting 
in an increase in AUC. The half-life of le nalidomide increased from  approximately 3.5 
hours in subjects with creatinine clearance > 50 mL/min to more than 9 hours in subjects 
with creatinine clearance < 50 mL/min; theref ore, patients with inadequate renal function 
are ineligible for this study. 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 31 
 
 
 With regards to potential drug interactions , the periodic monitoring of digoxin plasma 
levels is recommended due to increased Cm ax with concomitant administration of 
lenalidomide. Patients taking concomitant ther apies such as erythropoietin stimulating 
agents or estrogen containing therapies may have an increased risk of venous 
thromboembolic events. Therefore, erythropoie tic agents should not be used while patients 
are receiving lenalidomide on this trial. Ot her agents that may increase the risk of 
thrombosis, such as estrogen containing therapie s, should be used with caution in patients 
receiving lenalidomide. 
 
Toxicity:  
Comprehensive Adverse Events and Potential Risks list (CAEPR)  for 
Lenalidomide (CC-5013, NSC 703813) 
 
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single 
list of reported and/or potential adverse events  (AE) associated with an agent using a 
uniform presentation of events by body syste m. In addition to the comprehensive list, a 
subset, the Specific Protocol Exceptions to  Expedited Reporting (SPEER), appears in a 
separate column and is identified with bold a nd italicized text. This subset of AEs (SPEER) 
is a list of events that are prot ocol specific exceptions to expedited reporting to NCI (except 
as noted below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting 
Requirements'  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pd
f  for further clarification. Frequency is provided based on 4081 patients. Below is the 
CAEPR for Lenalidomide (CC-5013). 
 
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses 
next to the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple 
investigational agents and has an AE listed on different SPEERs, use the lower of the 
grades to determine if expedited reporting is required. 
 
Version 2.7, March 14, 20181 
 
 Adverse Events with Possible  
 Relationship to Lenalidomide (CC-5013) 
 (CTCAE 5.0 Term) 
[n= 4081]  
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likel y (>20% ) Less Likel y (<=20% ) Rare but Serious (<3%)   
BLOOD AND LYMPHATIC SYSTEM DISORDERS   
Anemia    Anemia (Gr 3)  
 Blood and lymphatic system 
disorders - Other 
(pancytopenia)    
 Febrile neutropenia    
 Hemolysis    
CARDIAC DISORDERS   
  Atrial fibrillation   
  Heart failure   
  Myocardial infarction2   
EAR AND LABYRINTH DISORDERS   
 Vertigo    
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 32 
 
 
 
 Adverse Events with Possible  
 Relationship to Lenalidomide (CC-5013) 
 (CTCAE 5.0 Term) 
[n= 4081]  
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likel y (>20% ) Less Likel y (<=20% ) Rare but Serious (<3%)   
ENDOCRINE DISORDERS   
  Hyperthyroidism   
 Hypothyroidism   Hypothyroidism (Gr 3)  
EYE DISORDERS   
 Blurred vision    
 Cataract    
GASTROINTESTINAL DISORDERS   
 Abdominal pain    
Constipation    Constipation (Gr 3)  
Diarrhea    Diarrhea (Gr 3)  
 Dry mouth    
 Dyspepsia    
 Nausea   Nausea (Gr 3)  
 Vomiting   Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINI STRATION SITE CONDITIONS   
 Chills   Chills (Gr 2)  
 Edema limbs   Edema limbs (Gr 3)  
Fatigue    Fatigue (Gr 3)  
 Fever   Fever (Gr 3)  
 Generalized edema    
 Non-cardiac chest pain    
 Pain    
HEPATOBILIARY DISORDERS   
  Hepatic failure   
  Hepatobiliary disorders - Other 
(cholestasis)   
IMMUNE SYSTEM DISORDERS   
  Allergic reaction   
  Anaphylaxis   
  Immune system disorders - Other 
(angioedema)   
  Immune system disorders - Other 
(graft vs. host disease)3   
INFECTIONS AND INFESTATIONS   
 Infection4   Infection4 (Gr 3)  
INJURY, POISONING AND PR OCEDURAL COMPLICATIONS   
 Bruising    
 Fall    
INVESTIGATIONS   
 Alanine aminotransferase 
increased    
 Alkaline phosphatase 
increased    
 Aspartate aminotransferase 
increased    
 Blood bilirubin increased    
 GGT increased    
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 33 
 
 
 
 Adverse Events with Possible  
 Relationship to Lenalidomide (CC-5013) 
 (CTCAE 5.0 Term) 
[n= 4081]  
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likel y (>20% ) Less Likel y (<=20% ) Rare but Serious (<3%)   
 Investigations - Other (C-
Reactive protein increased)    
  Lipase increased   
 Lymphocyte count decreased   Lymphocyte count decreased (Gr 4)  
Neutrophil count 
decreased    Neutrophil count decreased (Gr 4)  
Platelet count decreased    Platelet count decreased (Gr 4)  
 Weight loss   Weight loss (Gr 2)  
 White blood cell decreased   White blood cell decreased (Gr 4)  
METABOLISM AND NUTRITION DISORDERS   
 Anorexia   Anorexia (Gr 3)  
 Dehydration    
 Hyperglycemia    
 Hyperuricemia    
 Hypocalcemia    
 Hypokalemia    
 Hypomagnesemia    
 Hyponatremia    
 Hypophosphatemia    
 Iron overload    
  Tumor lysis syndrome   
MUSCULOSKELETAL AND CONN ECTIVE TISSUE DISORDERS   
 Arthralgia    
 Back pain    
 Bone pain    
 Generalized muscle 
weakness    
 Muscle cramp   Muscle cramp (Gr 2)  
 Pain in extremity    
  Rhabdomyolysis5   
 Myalgia   Myalgia (Gr 2)  
NEOPLASMS BENIGN, MALIGNANT AN D UNSPECIFIED (INCL CYSTS AND 
POLYPS )   
  Leukemia secondary to oncology 
chemotherapy6   
  Myelodysplastic syndrome6   
  Neoplasms benign, malignant 
and unspecified (incl cysts and 
polyps) - Other (tumor flare)7   
  Neoplasms benign, malignant 
and unspecified (incl cysts and 
polyps) - Other (second primary 
malignancies)   
  Treatment related secondary 
malignancy6   
NERVOUS SYSTEM DISORDERS   
 Dizziness    
 Depressed level of 
consciousness    
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 34 
 
 
 
 Adverse Events with Possible  
 Relationship to Lenalidomide (CC-5013) 
 (CTCAE 5.0 Term) 
[n= 4081]  
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likel y (>20% ) Less Likel y (<=20% ) Rare but Serious (<3%)   
 Dysesthesia    
 Dysgeusia    
 Headache    
 Paresthesia    
 Peripheral motor neuropathy    
 Peripheral sensory 
neuropathy    
  Stroke2   
 Syncope    
 Tremor    
PSYCHIATRIC DISORDERS   
 Depression    
 Insomnia   Insomnia (Gr 2)  
 Psychiatric disorders - Other 
(mood altered)    
RENAL AND URINARY DISORDERS   
  Acute kidney injury   
RESPIRATORY, THORACIC AN D MEDIASTINAL DISORDERS   
 Cough   Cough (Gr 2)  
 Dyspnea   Dyspnea (Gr 3)  
 Epistaxis    
  Pneumonitis   
SKIN AND SUBCUTANEOUS TISSUE DISORDERS   
 Dry skin    
  Erythema multiforme   
 Hyperhidrosis   Hyperhidrosis (Gr 2)  
 Pruritus   Pruritus (Gr 2)  
 Rash maculo-papular   Rash maculo-papular (Gr 3)  
  Skin and subcutaneous tissue 
disorders - Other (drug reaction 
with eosinophilia and systemic 
symptoms [DRESS])   
 Skin and subcutaneous tissue 
disorders - Other (pyroderma 
gangrenosum)    
  Stevens-Johnson syndrome   
  Toxic epidermal necrolysis   
SURGICAL AND MEDICAL PROCEDURES   
  Surgical and medical procedures 
- Other (impaired stem cell 
mobilization)8   
VASCULAR DISORDERS   
 Hematoma    
 Hypertension    
 Hypotension    
 Peripheral ischemia    
 Thromboembolic event9   Thromboembolic event9 (Gr 3)  
 Vasculitis    
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 35 
 
 
 
1This table will be updated as the toxicity profil e of the agent is revised.  Updates will be 
distributed to all Principal Investigators at th e time of revision. The current version can be 
obtained by contacting PIO@CTEP.NCI.NIH.GOV.  Your name, the name of the investigator, the 
protocol and the agent should be included in the e-mail. 
 
2Myocardial infarction and cerebrovascular accide nt (stroke) have been observed in multiple 
myeloma patients treated with lenalidomde and dexamethasone. 
 
3Graft vs. host disease has been observed in subjects who have received lenalidomide in the 
setting of allo-transplantation. 
 
4Infection includes all 75 sites of infection u nder the INFECTIONS A ND INFESTATIONS SOC. 
 
5The rare adverse event of rhabdomyolysis has b een observed with lenalidomide. The reports of 
rhabdomyolysis were confounded by concurrent us e of statins and dexamethasone, concurrent 
viral and bacterial infections, trauma, and serot onin syndrome. Statins, infections, trauma, and 
serotonin syndrome are known risk factors for rhabdomyolysis. 
 
6There has been an increased frequency of second ary malignancies (including ALL, AML, and 
MDS) in multiple myeloma patients being treated with melphalan, prednisone, and lenalidomide 
post bone marrow transplant. 
 
7Serious tumor flare reactions have been observed in patients with chronic lymphocytic leukemia 
(CLL) and lymphoma. 
 
8A decrease in the number of stem cells (CD34+ ce lls) collected from patients treated with >4 
cycles of lenalidomide has been reported. 
 
9Significantly increased risk of deep vein thro mbosis (DVT), pulmonary embolism (PE), and 
arterial thrombosis has been observed in patients with multiple myeloma receiving lenalidomide 
with dexamethasone. 
 
10Gastrointestinal hemorrhage includes: Anal hemorrhage, Cecal hemorrhage, Colonic 
hemorrhage, Duodenal hemorrhage, Esophageal he morrhage, Esophageal varices hemorrhage, 
Gastric hemorrhage, Hemorrhoidal hemorrhage, Ileal hemorrhage, Intra-abdominal hemorrhage, 
Jejunal hemorrhage, Lower gastrointestinal he morrhage, Oral hemorrhage, Pancreatic 
hemorrhage, Rectal hemorrhage, Retroperitonea l hemorrhage, and Upper gastrointestinal 
hemorrhage under the GASTROINTESTINAL DISORDERS SOC. 
 
11Gastrointestinal obstruction includes:  Colonic obstruction, Duodenal obstruction, Esophageal 
obstruction, Ileal obstruction, Jejunal obstruction,  Obstruction gastric, Rectal obstruction, and 
Small intestinal obstruction under the GASTROINTESTINAL DISORDERS SOC. 
 
12Osteonecrosis of the jaw has been seen with in creased frequency when lenalidomide is used in 
combination with bevacizumab, docetaxel (Tax otere¬Æ), prednisone, and zolendronic acid 
(Zometa¬Æ). 
 
 
NOTE :  While not observed in human subjects, lenalidomide, a thalidomide analogue, caused 
limb abnormalities in a developmental monkey study similar to birth defects caused by 
thalidomide in humans. If lenalidomide is used duri ng pregnancy, it may cause birth defects or 
embryo-fetal death. Pregnancy mu st be excluded before start of treatment. Prevent pregnancy 
during treatment by the use of two reliable methods of contraception. 
 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 36 
 
 
Adverse events reported on lenalidomide (CC-5013) trials, but for which there is insufficient 
evidence to suggest that there was a reasonabl e possibility that lenalidomide (CC-5013) 
caused the adverse event:  
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Blood and lymphatic system disorders - 
Other (monocytosis); Disseminated intravascular coagulation; Eosinophilia CARDIAC DISORDERS  - Atrial flutter; Atrioventricular bl ock first degree; Cardiac arrest; Cardiac 
disorders - Other (cardiovascular edema); Cardiac disorders - Other (ECG abnormalities); Chest 
pain - cardiac; Left ventricular systolic dysfunctio n; Palpitations; Pericard itis; Sinus bradycardia; 
Sinus tachycardia; Supraventricular ta chycardia; Ventricular tachycardia 
EAR AND LABYRINTH DISORDERS  - Tinnitus 
ENDOCRINE DISORDERS  - Cushingoid 
EYE DISORDERS  - Dry eye; Flashing lights; Retinopathy 
GASTROINTESTINAL DISORDERS  - Abdominal distension; Anal mucositis; Ascites; Colonic 
perforation; Dysphagia; Flatulence; Gastroesophageal  reflux disease; Gastrointestinal disorders - 
Other (Crohn's disease aggravated); Gastroin testinal disorders - Other (diverticulitis); 
Gastrointestinal disorders - Other (pal e feces); Gastrointestinal hemorrhage
10; Gastrointestinal 
obstruction11; Ileus; Mucositis oral; Pancreatitis; Rectal mucositis; Small intestinal mucositis 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Malaise; Multi-organ 
failure HEPATOBILIARY DISORDERS  - Cholecystitis 
INFECTIONS AND INFESTATIONS  - Conjunctivitis; Infections  and infestations - Other 
(opportunistic infection associated with >=Grade 2 Lymphopenia); Myelitis INJURY, POISONING AND PR OCEDURAL COMPLICATIONS  - Fracture; Hip fracture; Vascular 
access complication 
INVESTIGATIONS  - Activated partial thromboplastin time  prolonged; Cholesterol high; Creatinine 
increased; Electrocardiogram QT corrected interv al prolonged; INR increased; Investigations - 
Other (hemochromatosis) 
METABOLISM AND NUTRITION DISORDERS  - Acidosis; Hypercalcemia; Hyperkalemia; 
Hypoglycemia
 
MUSCULOSKELETAL AND CONN ECTIVE TISSUE DISORDERS  - Arthritis; Chest wall pain; 
Joint effusion; Muscle weakness lower limb; Neck pain; Osteonecrosis of jaw12 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  - 
Tumor pain NERVOUS SYSTEM DISORDERS  - Ataxia; Cognitive disturbance; Dysphasia; Edema cerebral; 
Encephalopathy; Intracranial hemorrhage; Ischemia cerebrovascular; Leukoencephalopathy
; 
Memory impairment; Nervous system disorders - Ot her (hyporeflexia); Spinal cord compression;  
Seizure; Somnolence; Transient ischemic attacks 
PSYCHIATRIC DISORDERS  - Agitation; Anxiety;  Confusion; Psychosis 
RENAL AND URINARY DISORDERS  - Urinary frequency; Urinary incontinence; Urinary tract 
pain 
REPRODUCTIVE SYSTEM AND BREAST DISORDERS  - Reproductive system and breast 
disorders - Other (hypogonadism); Vaginal hemorrhage 
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS  - Adult respiratory distress 
syndrome; Allergic rhinitis; Atelectasis; Br onchopulmonary hemorrhage; Hypoxia; Laryngeal 
mucositis; Pharyngeal mucositis; Pleural effusi on; Pulmonary hypertension;  Respiratory failure; 
Tracheal mucositis; Voice alteration 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  - Alopecia; Nail loss; Photosensitivity; Rash 
acneiform; Skin and subcutaneous tissue disord ers - Other (Sweet‚Äôs Syndrome); Urticaria 
VASCULAR DISORDERS  - Hot flashes; Phlebitis; Vascular  disorders - Other (hemorrhage NOS) 
 
 
Note : Lenalidomide (CC-5013) in combination with other agents could cause an exacerbation of 
any adverse event currently known to be caused by the other agent, or the combination may result in events never previously associated with either agent. 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 37 
 
 
 
Effect in Pregnancy and Lactation: 
Lenalidomide is Pregnancy category X . It can cause fetal harm when administered to a 
pregnant woman and is contraindicated in women who are or may become pregnant. There are no adequate and well-controlled studies in pregnant women. However, in an embryofetal developmental toxicity study in monkeys, teratogenicity, including 
thalidomide-like limb defects occurred in offs pring when pregnant monkeys received oral 
lenalidomide during organogenesis at doses approximately 0.17 times the adult maximum 
recommended human dose (MRHD) of 25 mg, b ased on BSA. Similar studies in pregnant 
rabbits and rats at 20 times and 200 times the MRHD respectively, produced embryolethality in rabbits and no adverse repr oductive effects in rats. In another study, 
pregnant rats received lenalidomide from or ganogenesis through lactation; some delay in 
sexual maturation occurred in male offspring. As with thalidomide, the rat model may not 
adequately address the full spectrum of po tential human embryofetal developmental 
effects for lenalidomide.  
The requirements of this study and the requirem ents to receive the co mmercially available 
supply are slightly different.  For the purpose of  this study, female of childbearing potential 
(FCBP) is a sexually mature (at least Tanner 2) female who: 1) has achieved menarche or 
breast development in Tanner Stage 2 or great er, and 2) has not un dergone a hysterectomy 
or bilateral oophorectomy and must use effectiv e means of contraception for 28 days before 
therapy, during lenalidomide therapy and dos e interruptions, and for 28 days following 
discontinuation of lenalidomide therapy or  continually abstain from reproductive 
heterosexual intercourse.  Venous thromboemb olism (VTE) has been seen in patients with 
multiple myeloma receiving lenalidomide pl us dexamethasone and patients with 
myelodysplastic syndrome receiving lenalidomid e monotherapy (to a lesser extent).  
Because oral contraceptives may also place the patient at risk of VTE, physicians should 
discuss this increased risk and the risk/b enefit of contraceptive methods with patients 
receiving lenalidomide. 
Male patients must agree to completely abst ain from sexual contact with women who are 
pregnant or are able to become pregnant or use a latex condom every time he engages in 
sexual contact with women who are pregna nt or who may become pregnant.   
 
If a pregnancy occurs during treatment, the dr ug must be immediately discontinued and the 
suspected fetal exposure should be reporte d to CTEP via CTEP-AERS. Refer to Section 
11.9. 
 
It is not known whether lenalidomide is ex creted in human milk. Since many drugs are 
excreted in human milk and because of the pote ntial for adverse reactions in nursing infants 
from lenalidomide, a decision should be ma de whether to discontinue nursing or to 
discontinue the drug, taking into considera tion the importance of the drug to the mother.  
 Formulation and Stability: Lenalidomide is available in 2.5 mg, 5 mg, an d 25 mg capsules for oral administration for 
the purpose of this study. Lenalidomide 10 mg capsules will not be used in this study. 
 Each capsule contains lenalidomide as the active ingredient and the following inactive 
ingredients: lactose anhydrous, microcryst alline cellulose, croscarmellose sodium, and 
magnesium stearate. The capsules are supplied in tamper-evident, child-resistant, opaque, 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 38 
 
 
high density polyethylene (HDPE) bottles) with  polypropylene caps.  Each bottle contains 
100 capsules. Lenalidomide should be stored at  25¬∞C (77¬∞F); excursions permitted to 15-
30¬∞C (59-86¬∞F).  
 Guidelines for Administration: See Treatment and Dose Modification sections of the 
protocol. Each subject must receive counseling regard ing the use and risks of lenalidomide by a 
healthcare professional who has received sp ecific training by Celgene.  Additional 
information about the training of these h ealthcare professionals can be found in Section 
3.1.5.1  and Appendix I .  The counseling of each subject  must be documented using the 
Lenalidomide Education and Coun seling Guidance Document ( Appendix III ).  Once 
documentation has been confirmed, a phar macist may dispense the investigational 
lenalidomide to the patient.  Pharmacists may on ly dispense up to a 28-day supply at one 
time (1 cycle, or a 21-day supply for th e purpose of this study).  A Lenalidomide 
information sheet ( Appendix V ) must be provided each and every time the medication is 
dispensed.  Prescriptions may not be mailed to the patient.   
 
Lenalidomide capsules should not be opened or crushed. If lenalidomide powder contacts 
the skin, it must be washed immediatel y and thoroughly with soap and water. If 
lenalidomide contacts mucous membran es, flush thoroughly with water.  
 
Lenalidomide s hould be taken  by mouth with a full glass of water and without food at 
approximately the same time each day for 21 consecutive days. If nausea occurs after 
taking the dose, administer with food as this may decrease nausea.  If a dose is forgotten 
but remembered within 8 hours, the missed dose should be taken/given immediately. If 
more than 8 hours have passed since the time th e dose was due, that day‚Äôs dose should be 
skipped.  If a dose is vomited within 10 minut es of taking the dose and the capsules are 
visible in the emesis, the dose should be re peated and the patient‚Äôs provider should be 
notified.  
 
Procedures for the proper handling and dispos al of hazardous/antic ancer drugs should be 
considered.  
 
Supplier:   Supplied by Celgene and distributed by the NCI DTCD. Do not use 
commercially available drug.  
 
Agent Ordering 
NCI supplied agent may be requested by the Pr incipal Investigator (or their authorized 
designee) at each participating institution.  Pharmaceutical Management Branch (PMB) 
policy requires that agent be shipped directly to the institution where the patient is to be 
treated.  PMB does not permit the transfer of  agents between institutions (unless prior 
approval from PMB is obtained.)  The CTEP assi gned protocol number must be used for 
ordering all CTEP supplied investigational agen ts.  The responsible investigator at each 
participating institution must be register ed with CTEP, DCTD through an annual 
submission of FDA form 1572 (Statement of Investigator), Curriculum Vitae, 
Supplemental Investigator Data Form (IDF), and Financial Disclosure Form (FDF).  If 
there are several participating investigat ors at one institution, CTEP supplied 
investigational agents for the study should be ordered under the name of one lead 
investigator at that institution. One additi onal dose of lenalidomid e may be ordered and 
dispensed so it is readily available in the event the patient vomits the capsules. 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 39 
 
 
Active CTEP-registered investigators and inve stigator-designated shipping designees and 
ordering designees must submit agent requ ests through the PMB Online Agent Order 
Processing (OAOP) application < https://ea pps-ctep.nci.nih.gov/ OAOP/pages/login.jspx 
>.  Access to OAOP requires the establis hment of a CTEP Identity and Access 
Management (IAM) account < https://eapps-cte p.nci.nih.gov/iam/ > and the maintenance 
of an ‚Äúactive‚Äù account status and a ‚Äúcurrent‚Äù pa ssword.   For questions about drug orders, 
transfers, returns, or accountability, call ( 240) 276-6575 Monday through Friday between 
8:30 am and 4:30 pm (ET) or email PMBAfterHours@mail.nih.gov anytime. 
 
Agent Accountability  
Agent Inventory Records ‚Äì The investigator , or a responsible party designated by the 
investigator, must maintain a careful record of the inventory and disposition of all agents 
received from DCTD using the NCI Drug Accoun tability Record Form (DARF).  (See the 
CTEP home page at 
http://ctep.cancer.gov/protocolDevel opment/default.htm#agents_drugs for the 
Procedures for Drug Accountability and Storage and 
http://ctep.cancer.gov/forms/default.htm to obtain a copy of the DARF and Clinical Drug 
Request form.) 
 
Agent Returns 
Investigators/Designees must return unused DCTD supplied investigational agent to the 
NCI clinical repository as soon as possible when: the agent is no longer required because 
the study is completed or discontinued and the agent cannot be transferred to another 
DCTD sponsored protocol; the ag ent is outdated or the agent is damaged or unfit for use. 
Regulations require that all agents received from the DCTD, NCI be returned to the DCTD, 
NCI for accountability and disposition. Return  only unused vials/bottles. Do NOT return 
opened or partially used vials/bottles unle ss specifically requested otherwise in the 
protocol. See the CTEP web site for Policy and Guidelines for Investigational agent 
Returns at: http://ctep.cancer.gov/protocol Development/default.htm#agents_drugs. The 
appropriate forms may be obtained at: http://ctep.cancer.gov/forms/default.htm. 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 40 
 
 
7.0 EVALUATIONS/MATERIAL AND DATA TO BE ACCESSIONED 
Timing of protocol therapy administration, response a ssessment studies, and surgical interventions are 
based on schedules derived from the experimental de sign or on established standards of care. Minor 
unavoidable departures (up to 72 hours) from protocol directed therapy and/or disease evaluations (and 
up to 1 week for surgery) for valid clinical, patient  and family logistical, or  facility, procedure and/or 
anesthesia scheduling issues are acceptable per C OG administrative Policy 5.14  (except where explicitly 
prohibited within the protocol). 
 
7.1 Required Clinical, Laboratory and Disease Evaluations  
All baseline studies must be performed prior to starting protocol therapy unless otherwise 
indicated below.  Obtain other studies prior to start of subsequent cycles and as 
otherwise indicated.   
STUDIES TO BE OBTAINED Baseline Prior to 
Each 
Cycle During 
Each 
Cycle When Patient 
is Removed 
from Protocol 
Therap y 
Histor y X X   
Physical Exam (Ht, Wt, VS) X X  X 
Performance Status X X  X 
CBC (differential, platelets) X X Weekl yA X 
Urinal ysis X X  X 
Electrolytes (including BUN, Calcium, PO 4, 
Magnesium)  X X Weekly X 
Creatinine X X   
Total protein, AST, ALT, albumin, bilirubin X X  X 
Pregnancy test (serum or urine, with 
sensitivity of 25 mIU/mL)  (for females of 
childbearin g potential) XB XB WeeklyC XD 
Confirmation of use of 2 effective methods 
of  birth control OR confirmation of 
complete abstinence (for  female patients of 
childbearin g potential) X X   
Education and Counselin g (all patients)E   X  X 
Brain MRI with and without gadolinium X F XG  X 
Spine MRI with and without gadoliniumF,H X XG  X 
Pharmacokinetic studies (see Section 13.0 )   XI  
A If patient develops hematologic toxicity as defined in Section 5.2 , CBCs should be checked every 
3 to 4 days until recovery.  
B Obtain 2 weeks prior to study enrollment and again within 24 hours prior to Day 1 of each cycle. 
C Obtain weekly during cycle 1. Females with irregular menstruation must have a pregnancy test 
every 14 days while receiving prot ocol therapy (including breaks in  treatment). Pregnancy test is 
also required if patient misses her period or has unusual menstrual bleeding. 
D Pregnancy testing must also occur at Day 28 (and at Day 14 if female has irregular menstruation) 
after lenalidomide discontinuation). 
E The Lenalidomide Education and Counseling Document ( Appendix III ) must be completed and 
signed by a trained counselor at the site prior to each dispensing of lenalidomide. 
F Obtain brain MRI within 1 week prior to st udy enrollment. Spine MRI (if necessary) may be 
obtained within 2 weeks prior to enrollment. 
G Obtain prior to each odd-numbered cycle of therapy (ie, prior to cycles 3, 5, 7, 9, 11 and 13) for 
the first 13 cycles. During cycles 14-26, imaging will be performed every third cycle (ie, prior to 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 41 
 
 
16, 19, 22 and 25), after cycle 26,  and as clinically indicated. See Section 14.0  for imaging 
requirements. 
H Obtain in patients with a history of spinal or leptomeningeal disease, or those patients with 
symptoms suspicious of spinal disease. Obtain spine MRI at same time points as brain MRI. 
I PK blood sample must be obtained prior to the daily dose between Day 5-21 of cycle 1 at the time 
of routine safety lab monitoring. In the event of a dose reduction, a blood sample must also be obtained between Day 5-21 of the cycle following the dose reduction. 
This table only includes ev aluations necessary to answer  the primary and secondary 
aims. Obtain other studies as indi cated for good clinical care.  
 
7.2 Follow-up  
See COG Late Effects Guidelines for r ecommended post treatment follow-up:  
http://www.survivorshipguidelines.org/  Note:  Follow-up data are expected to be su bmitted per the Case Report Forms (CRFs) 
schedule. This includes required pregnancy tes ting for all female patients of childbearing 
potential on Day 28 following the last dose of lenalidomide. Patients with irregular 
menstrual cycles must have pregnancy tes ting completed on Day 14 and Day 28 following 
the last dose of lenalidomide.  
  
8.0 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY 
CRITERIA 
 
8.1 Criteria for Removal from Protocol Therapy 
a) Progressive disease (see definition in Section 10.0 ). 
b) Significant toxicity at least possibly attr ibuted to lenalidomide despite two dose 
reductions (as stated in  Section 5.0 ). 
c) Refusal of further protocol therapy by patient/parent/guardian. 
d) Completion of 26 cycles of protocol therapy. 
e) Physician determines it is in  patient‚Äôs best interest. 
f) Development of a second malignancy. 
g) Patient becomes pregnant while on study. 
h) Refusal to cooperate with required birth co ntrol methods or to commit to complete  
 abstinence. 
i) Development of a thromboembolism, unrelated to central line. 
j) Evidence of toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome. 
 
Patients who are off protocol therapy are to be followed until they meet the criteria for Off Study (see below). Follow-up data will be required unless consent was withdrawn. 
 
8.2 Off Study Criteria 
a) Death. 
b) Lost to follow-up. 
c) Patient enrollment onto another COG study with tumor therapeutic intent. 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 42 
 
 
d) Withdrawal of consent for a ny further data submission. 
e) The fifth anniversary of the date the patient was enrolled on this study. 
 
 
9.0 STATISTICAL CONSIDERATIONS 
 
9.1 Sample Size and Study Duration 
Approximately 45 patients per year less than 10 years of age with progressive/recurrent 
and high-risk LGA were enrolled on COG-A9952, Chemotherapy for Progressive Low 
Grade Astrocytoma in Children Less Than Ten Years Old . About half of these children (22 
patients) would be expected to progress and would be eligible for the current study.  
 
The total accrual of newly diagnosed LGA patients on CCG-9891/POG-9130, Treatment 
of Newly Diagnosed Low Grade Astrocytomas , was 713 over a period of 5 years. About 
40% of these patients were older than 10 ye ars of age and 20% progressed within 6 years 
of diagnosis. This corresponds to about 11 patients per year older than 10 years with 
progressive LGA. Adding to this those wh o will be entered because of symptomatic, 
incomplete resections, we would expect approximately 20 pati ents per year older than 10 
years of age.   Adding together patients who are younger than and those older than 10 years of age (22 + 
20 = 42), and taking into account patients  who may opt for other treatments and the 
eligibility criteria of at least 1 prior therapy including carboplatin, we expect a total of 30 
patients with recurrent or progressive low-grade glioma per year.  This study will enroll only patients with pilocytic astrocytoma and progressive optic 
pathway gliomas.  Based on prior COG enrollm ent, we estimate 70% of low grade glioma 
patients to be in this subset (30*0.7=21/yr).  The total accrual target for this study is 74 
patients enrolled in 3.5 years. Considering that  some patients enrolled may be found to be 
ineligible, the maximum number of patients e xpected to be accrued is 80 patients.   
 
9.2 Study Design 
This is a randomized study to estimate the response rate of children with recurrent or 
progressive pilocytic astrocytoma and optic pathway gliomas who are treated with lenalidomide assigned to either Regimen A low dose (20 mg/m
2/dose) or Regimen B high 
dose (115 mg/m2/dose). 
 
9.3 Methods of Analysis 
9.3.1 Endpoints 
 
9.3.1.1 Primary Endpoint 
x Objective response ‚Äì best response  determined from the sequence 
of the objective statuses described in Section 10.0  ‚ÄòResponse 
Criteria.‚Äô 
9.3.1.2 Secondary Endpoints 
x Time to treatment failure (Event-free survival, EFS) ‚Äì the time 
from study enrollment to tumor progression, tumor recurrence, death from any cause, or occurrence of a second malignant neoplasm. 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 43 
 
 
x Time to death (Overall survival, OS) ‚Äì the time from study 
enrollment to death from any cause. 
 
9.4 Analysis of Efficacy 
A total of 74 eligible patients will be enro lled on this trial. Patients will be randomly 
assigned to either the low dose (Regimen A) or the high dose arm (Regimen B).  Each 
patient will be classified according to their ‚Äòb est response‚Äô for the purposes of analysis of 
treatment effect. Best response is determined from the sequence of the objective statuses 
described in Section 10.0  ‚ÄòResponse Criteria.‚Äô A responder is defined as a patient who 
achieves a best overall response of CR or PR at  any time on the study. If a patient achieves 
a PR or CR and later has progressive disease or relapse, then the patient will be counted as 
a responder. The response rate will be calculat ed as the ratio of the number of patients who 
demonstrate response (CR or PR) divided by th e number of patients evaluable for response. 
The 95% confidence bounds for response rate  are shown in the table below for several 
different outcomes. The computation is based  on the binomial distribution, assuming the 
availability of 30 evaluable patients (7 inevalua ble patients) for response in each arm (each 
dose level). All patients eligible for study who receive any study dr ug will be considered 
evaluable for response. Any patient who goe s off protocol therapy for any reason 
(patient/parent/physician choice,  adverse event profile, etc.) prior to the first response 
evaluation will be considered a non-responder. Fo r example, an observed response rate of 
33% (10/30) will be consistent with the view that 17% or more patients will respond to the 
treatment. 
 
Outcome (#Response/#Patients) 95% Exact Confidence Bound on 
Response Rate 
20/30 (0.47, 0.83) 
15/30 (0.31, 0.69) 
10/30 (0.17, 0.53) 
5/30 (0.06, 0.35) 
 
There would be modest power to compare the response rates for the 2 dose cohorts.  With 
74 patients, we would have 80% power to detect a response rate difference of 35% vs. 15%, at the 1-sided 20% significance level.  
Disease progression will be based on the results of institutional review. Standard survival 
methods will be used for analysis of EFS a nd OS. Analyses include log rank tests and the 
product-limit (Kaplan-Meier) estimate fo r estimation of EFS and OS probability. 
Comparison of EFS between the two dose levels will primarily be exploratory.  With 74 
patients, we will have only approximately 69%  power to detect a 15% increase in long-
term EFS (30% to 45%) with 50% patients rece iving high dose vs. 50% receiving low dose, 
based on a one-sided logrank test with 20% Type I error rate. 
 
 
9.5 Monitoring for Efficacy 
Patients will be randomly assigned to either  the low dose or the high dose treatment.  Of 
the 37 patients on each treatment, we will closel y monitor the first 20 patients enrolled. For 
each regimen, the early stopping criterion an d the decision regarding ultimate further 
interest in this agent will be based on th e number of objective responses and disease 
progressions in the first 6 months of treatmen t. If the early stopping rule is met for one 
treatment, that particular arm will be closed and the other arm will continue as planned. 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 44 
 
 
A true response rate of 5% and a true early (6-month) progression rate of 40% are 
considered inadequate, whereas a true respon se rate of 20% and a true early (6-month) 
progression rate of 25% would be sufficient  for further interest in this agent. 
 The study will be a 2-stage design, with 20 evaluable patients in the first stage and 17 
evaluable patients in the second stage (37 patients total per treatment regimen), with 
decisions made as follows:   
 
Number of Evaluable 
Patients Enrolled Results Decision 
Stage I: 20 evaluable 
patients Zero or one responders or 10 
or more with early 
progression Terminate enrollment with the 
conclusion the regimen does 
not demonstrate sufficient disease control 
All other configurations of response or early progression Continue to the next stage and 
enroll 17 more patients 
Stage II:  17 additional evaluable patients (Total of 37: 20 from Stage I and 17 from Stage II) Cumulatively 3 or fewer 
responders or 15 or more with early progression Conclude the regimen does not 
demonstrate sufficient disease control 
All other configurations of response or early progression Conclude the regimen 
demonstrates sufficient disease control for further investigation 
  
A summary of the operating characteristics  of this design are provided below: 
 
Response 
Probability Early 
Progression 
Probability Probability of 
Stopping at 
First Stage Probability 
Accept 
Regimen 
0.05 0.40 0.78 0.05 
0.10 0.40 0.51 0.24 
0.20 0.30 0.11 0.81 
0.15 0.25 0.18 0.73 
0.20 0.25 0.08 0.88 
 
9.6 Monitoring for Toxicity  
‚ÄúToxic events‚Äù will be defined as one in which a patient has two dose reductions and then 
experiences another significant toxicity as defined in Section 5.0 , irrespective of 
attribution. A two-stage stopping rule will be  used to monitor for an excessive number of 
these toxic events. All patients described below must be evaluable for toxicity.  All patients 
who receive at least one dose of lenalidomide wi ll be evaluable for toxicity.  A review of 
treatment feasibility and patient safety will be  undertaken if we observe at least 5/18 or 
8/36 toxic events.  The rule will be met about 4%  of the time if the true incidence of toxic 
event is 10%, and 90% of the time if the true incidence is 30%. 
 
9.7 Interim Monitoring of Toxic Death 
Toxic death is death predominantly attributable  to treatment-related causes. The occurrence 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 45 
 
 
of toxic death at any time will be a primary endpoint for safety monitoring. Any toxic death 
on study will be reviewed with CTEP and th e DMSC prior to continuing enrollment on 
study.  The study will be stopped if there are two toxic deaths on study.  
 
9.8 Analysis of Toxicity 
Estimates will be obtained using life-table meth ods, with an event defined as the first 
occurrence of a primary toxicity. Time scale us ed in the time to first occurrence of a key 
acute and subacute toxicity is time in days since the start of therapy.  Patients who have 
progression or recurrence of disease will be censored in these analyses. The rates of 
individual toxicities in each course of treatmen t, the number of patients who require a dose 
reduction and number of patients who come off protocol therapy due to toxicity will be 
summarized using standard descri ptive statistical methods. To evaluate hematologic 
toxicity of long term le nalidomide administration  adverse event data will be collected 
using CTCAE version 4 toxicity coding. Grade 3 or greater hematologic toxicities will be 
recorded per reporting period and comp ared between 2 lenalidomide doses  
 
9.9 Analysis of Lenalidomide Pharmacokinetic Parameters 
Correlation of lenalidomide concentration obtai ned from the steady-state sample and the 
number of cycles received prior to the occurr ence of disease progression will be performed 
using Pearson‚Äôs correlation coefficient. Cox regr ession analysis will be used to assess the 
association between outcome and steady state levels at a particular cycle. 
 
9.10 Analysis of Standard MR Sequences 
To compare the methods of MRI sequence, th e response categories (complete response, 
partial response, stable disease, and progress ion) will be determined from the following 
three standard MR sequences, T2-weighted, FLAIR, T1-weighted post-contrast.  Percent 
agreement between the sequences will be estim ated as the number of  follow-up scans in 
which the corresponding sequence agreed divided by the total number of follow-up scans.  
Standard error will be estimated by use of the bootstrap method28 to account for the 
correlated dependent response data, and these values will be used to estimate the 95% 
confidence intervals.  The event- free survival distributions will  be compared across the MR 
sequences, with a proportional hazards model developed for dependent  survival data by 
Wei et al (1989).29 
 
9.11 Effect of the Stratification on Response Rate 
At enrollment, the number of prior therapies, classified as 2 or fewer versus more than 2 
will be required to complete the treatment assi gnment process.  The efficacy rule described 
in Section 9.5  will be executed as written regardless of the number of prior therapies that a 
patient has received.  The risk for EFS-event an d death associated with receiving more than 
2 prior regimens will be assessed using the st ratified 1-sided log-rank test, with randomized 
regimen as the stratification factor.  Only patients enrolled after approval of the proposed 
amendment will be considered in the analysis.  If the resulting p-value is not significant at 
the 0.10 level or less, the EFS and OS r esults will be presented without regard to 
stratification factor. 
 
The following logistic regression model will be utilized: 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 46 
 
 
'
'
1
2
3ePr | ;
1e
:1
10i
ix
ix
i
i
iCR or PR x
where x is
x is the randomtreatment assignmentx is if the patient received three or more prior regimens and otherwiseE
E 

 
 
The value and p-value associated with the HVWLPDWHRI»ï 3 will be used to infer whether there 
evidence of an association between respons e rate and number of prior regimens 
 
9.12 Gender and Minority Accrual Estimates  
Both males and females of all races and ethnic groups are eligible for this study. The gender 
and minority distribution of the st udy population is expected to be: 
 
Accrual Targets 
Ethnic Category  Sex/Gender  
Females  Males  Total  
Hispanic or Latino 2 1 3 
Not Hispanic or Latino 37 40 77 
Ethnic Category: Total of all subjects 39 41 80 
Racial Category  
American Indian or Alaskan Native 1 0 1 
Asian 1 1 2 
Black or African American 4 3 7 
Native Hawaiian or other Pacific Islander 1 1 2 
White 32 36 68 
Racial Category: Total of all subjects  39 41 80 
 
This distribution was deri ved from CCG 9891/POG 9130. 
  
10.0 EVALUATION CRITERIA 
10.1 Common Terminology Criteria for Adverse Events (CTCAE) 
This study will utilize version 4.0 of the CTCA E of the National Cancer Institute (NCI) for 
toxicity and performance repor ting. A copy of the CTCAE version 4.0 can be downloaded 
from the CTEP website (http://ctep.cancer.gov/protocolDevelopm ent/electronic_applications/ctc.htm ).  
 
Please note: ‚ÄòCTCAE v4.0‚Äô is understood to represent the most current version of CTCAE 
v4.0 as referenced on the CTEP website (ie, v4. 02 and all subsequent iterations prior to 
version 5.0). 
 
10.2 Methodology to Determine Tumor Measurement  
Tumor dimensions are determined by measurem ent of the longest tumor dimension and its 
perpendicular for each target lesion. Regard ing MRI imaging, the radiologist at each 
institution may select whatever sequence be st highlights the tumor (T1 enhanced or T2 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 47 
 
 
weighted or FLAIR images) and the same sequence should be used for serial measurements. Response determination will be based on a comparison of an area (W x T ‚Äì see below) between 
the baseline assessment and the study date design ated in the follow-up Report Form.  Reports 
for the follow-up exams should reiterate the meas urements obtained at baseline for each target 
lesion.  Non-target lesions or newly occurring lesions should also be  enumerated in these 
reports, and changes in non-target lesions should be described. 
 Tumor response criteria are determined by  changes in size usin g the longest tumor 
dimension, and its perpendicular. Either T1 or  T2 weighted images are used - which ever 
gives the best estimate of tumor size. The fo llowing section describes the methodology. 
(See Figure 10.1 below for illustration)  1. For MRI imaging (preferred), the longest di ameter can be measured from the axial 
plane or the plane in which th e tumor is best seen or meas ured, provided the same plane 
is used in follow ups. This longest measurem ent of the tumor is referred to as the width 
(W). Longest diameter of target lesion(s) should be selected in the axial plane only for 
CT. 
2. The perpendicular measurements  should be determined - tr ansverse (T) measurement, 
perpendicular to the width in the selected plane.  
3. The cystic or necrotic components of  a tumor are not considered in tumor 
measurements. Therefore only the solid com ponent of cystic/necrotic tumors should 
be measured. If cysts/necrosis composes th e majority of the lesion, the lesion may not 
be ‚Äúmeasurable‚Äù.   
Options:  
- if the cyst/necrosis is eccentric, the W and T of the solid portion should be 
measured, the cyst/necrosis excluded from measurement 
- if the cyst/necrosis is central but repr esents a small portion of the tumor (< 
25%), disregard and measure the whole lesion 
- if the cyst/necrosis is central but re presents a large portion of the tumor, 
identify a solid aspect of the mass that can be reproducibly measured 
4. Leptomeningeal tumor spread is usually not  a target lesion, and usually cannot be 
measured accurately. Presence and location of  leptomeningeal tumor spread should be 
noted and change in extent/thickness assessed on follow up studies.  
 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 48 
 
 
Figure 10.1: COG Guidelines fo r Measurement of Tumor Size 
 
5. Overall Response Assessment 
The overall response assessment takes into account response in both the target and non-
target lesion, and the appearance of new le sions, where applicable, according to the 
criteria described in the table below.  The ov erall response assessment is shown in the 
last column, and depends on the assessments of target, non-target, and new lesions in 
the preceding columns. 
 
 
Target Lesions  
Non-target Lesions  
New Lesions  
Overall Response 
CR CR No CR 
CR IR/SD No PR  
PR  CR, IR/SD No PR 
SD   CR, IR/SD No SD  
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
 
 
CR ‚Äì Complete Response   
PR ‚Äì Partial Response   
SD ‚Äì Stable Disease 
PD ‚Äì Progressive Disease 
IR ‚Äì Incomplete Response 
 
The sections that follow discuss the selec tion and evaluation of each of these types 
of lesions. 
 
 Z
AXISWTA
B
C
D
ECOG GUIDELINE: TUMOR SIZE
MEASUREMENT BASED ON
CROSS-SECTIONAL IMAGING
‚Ä¢ A, B, C, D, & E are contiguous
parallel slices in the X-Y plane
(usually axial) showing the tumor
‚Ä¢ W and T are the maximalperpendicular diameters on the slice
(C in this example) showing the
largest surface area
‚Ä¢ Tumor length in the Z-axis (L)
(perpendicular to X-Y plane) can be
obtained either by the [a] (difference
in table position of the first and last
slices showing the tumor + one slice
thickness), or [b] the product of (slice
thickness + gap) and the number ofslices showing the tumorX-Y
PLANE
L
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 49 
 
 
10.3 Selection of Target and Non-Target Lesions 
1. For most CNS tumors, only one lesion/mass is present and therefore is considered 
a ‚Äútarget‚Äù for measurement/follow up to assess for tumor progression/response.  
2. If multiple measurable lesions are present, up to 3 should be selected as ‚Äútarget‚Äù 
lesions. Target lesions should be selected  on the basis of size and suitability for 
accurate repeated measurements.  All othe r lesions will be followed as non-target 
lesions (including CSF positive for tumor cells).   
3. The lower size limit of the target lesion(s) should be at least twice the thickness of 
the slices showing the tumor to decrease the partial volume effect (e.g. 8 mm lesion 
for a 4 mm slice). 
4. Any change in size of non-target lesions should be noted, though does not need to 
be measured. 
 
10.4 Response Criteria for Target Lesions 
1. Response criteria are assessed in 2 dimensions ‚Äì the product of W x T.  
2. To assess response/progression, the ratio is calculated: 
   W x T (current scan)  
   W x T (reference scan) 
 
3. Development of new disease or progre ssion in any established lesions is 
considered progressive disease, regardless of response in other lesions ‚Äì e.g. when 
multiple lesions show opposite respon ses, the progressive disease takes 
precedence. 
 
4. For purposes of this study, response  criteria for target lesions are: 
 
Complete Response (CR):  Complete disappearance of all known disease for at least 4 
weeks. Complete response is dated from the time all lesions have disappeared.  
 
Partial response (PR):  A reduction of at least 50% in th e size of all measurable tumor as 
quantitated by the sum of the products of the largest diameters of me asurable lesions and 
maintained for at least 4 weeks. Partial response is dated from the time of first observation. 
In addition, there can be no appearance of new lesions or progression of any lesion. 
 
Stable Disease (SD):  A decrease of <50% or an increase of <25% in the sum of the 
products of the largest diameters of measurab le lesions and no evidence of new lesions. 
 Progressive Disease (PD):  ¬ïLQFUHDVHLQWKH sum of the products of the largest 
diameters of the measurable lesions or the ap pearance of one or more new lesions. Two-
dimensional measurements (using WHO criteria)  of an existing tumor will be compared to 
the study baseline or best response scan (whi chever is smaller) compared side-by-side. 
 
Local progression is defined as progression of known residual tumor or the appearance of 
tumor at known prior sites of disease that were  at some point without evidence of disease. 
Distant progression is defined as the appearan ce of tumor at sites other than known prior 
sites of disease. Distant progression most of ten occurs in the subarachnoid space and may 
occur at any point within the neuraxis. Alt hough rare, extra-CNS metastasis represents 
distant failure. Combined local and distant pr ogression is defined when evaluation of the 
entire neuraxis reveals local and distant progression. 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 50 
 
 
10.5 Response Criteria for Non-target Lesions 
 
Complete Response (CR):  Disappearance of all non-target lesions.  
 
Incomplete Response/Stable Disease (IR/SD):   The persistence of one or more non-target 
lesions.  
 
Progressive Disease (PD):  The appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions.  
 
10.6 Retrospective Response Review 
MRI imaging for all patients on study will underg o retrospective central review following 
the completion of treatment. See Section 14.4  for imaging central review requirements. 
 
 
11.0 ADVERSE EVENT REPORTING REQUIREMENTS  
11.1 Purpose 
Adverse event (AE) data collection and repor ting, which are required as part of every 
clinical trial, are done to ensure the safety of  patients enrolled in the studies as well as those 
who will enroll in future studies using simila r agents. Certain adverse events must be 
reported in an expedited manner to allow for tim elier monitoring of patient safety and care. 
The following sections provide information about expedited reporting. 
 
11.2 Expedited Reporting Requirements ‚Äì Serious Adverse Events (SAEs) 
To ensure compliance with these regulatio ns/this guidance, as IND/IDE sponsor, NCI 
requires that AEs be submitted according to the timeframes in the AE reporting table 
assigned to the protocol, using the NCI‚Äôs Adverse Event Expedi ted Reporting System 
(CTEP-AERS). 
 
Any AE that is serious qualifies for expedited reporting . An AE is defined as any 
untoward medical occurrence associated with th e use of a drug in humans, whether or not 
considered drug related. A Serious Adver se Event (SAE) is any adverse drug event 
(experience) occurring at any dose that re sults in ANY of the following outcomes: 
 
1) Death. 
2) A life-threatening adverse drug experience. 
3) An adverse event resulting in inpatient  hospitalization or prolongation of existing 
KRVSLWDOL]DWLRQIRU¬ï  24 hours). This does not incl ude hospitalizations which are 
part of routine medical practice. 
4) A persistent or significant incapacity or  substantial disruption of the ability to 
conduct normal life functions. 
5) A congenital anomaly/birth defect. 
6) Important Medical Events (IME) that may not result in death, be life threatening, 
or require hospitalization may be consid ered a serious adverse drug experience 
when, based upon medical judgment, they may jeopardize the patient or subject 
and may require medical or surgical inte rvention to prevent one of the outcomes 
listed in this definition. 
7)  Pregnancy (See Section 11.9 ) 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 51 
 
 
11.3 Specific Examples for Expedited Reporting  
11.3.1 SAEs Occurring More than 30 Da ys After Last Dose of Study Drug 
Any Serious Adverse Event that occurs more than 30 days after the last 
administration of the investigational agent/intervention and has an attribution of a 
possible, probable, or definite relationshi p to the study therapy must be reported 
according to the CTEP-AERS reporting table in this protocol.  
 
11.3.2 Persistent or Significant Disabilities/Incapacities 
Any AE that results in persistent or signific ant incapacity or substantial disrubtion of 
the ability to conduct normal life functions (formerly referred to as disabilities), 
congenital anomalies or birth defects, must be reported via CTEP-AERS if it occurs at 
any time following treatment with an ag ent under a NCI IND/IDE since these are 
considered serious AEs. 
 
11.3.3 Death 
Reportable Categories of Death  
 
x Death attributable to a CTCAE term.  
x Death Neonatal: A disorder characterized by cessation of life 
during the first 28 days of life.  
x Sudden Death NOS: A sudden (defin ed as instant or within one 
hour of the onset of symptoms) or an unobserved cessation of life that cannot be attributed to a CT CAE term associated with Grade 
5.  
x Death NOS: A cessation of life that cannot be attributed to a 
CTCAE term associated with Grade 5.  
x Death due to progressive disease should be reported as Grade 5 ‚ÄúDisease 
progression‚Äù in the system organ class (SOC)  ‚ÄúGeneral disorders and 
administration site conditions .‚Äù Evidence that the death was a 
manifestation of underlying disease ( e.g., radiological changes suggesting 
tumor growth or progression: clinical deterioration associated with a disease process) should be submitted.  
 
Any death occurring within 30 days of the last dose, regardless of attribution to 
the investigational agent/intervention requi res expedited reporting within 24 hours.  
Any death occurring greater than 30 days after the last dose of the investigational 
agent/intervention requires expedi ted reporting within 24 hours only if it is 
possibly, probably, or definitely related to the investigational agent/intervention. 
 
11.3.4 Secondary Malignancy 
A secondary malignancy is a cancer caused by treatment for a previous 
malignancy (eg, treatment with investig ational agent/intervention, radiation or 
chemotherapy). A metastasis of the initia l neoplasm is not considered a secondary 
malignancy.  
The NCI requires all secondary malignancie s that occur following treatment with 
an agent under an NCI IND/IDE be repor ted via CTEP-AERS. Three options are 
available to describe the event:  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 52 
 
 
x Leukemia secondary to oncology chemotherapy  
x Myelodysplastic syndrome  
x Treatment related secondary malignancy  
Any malignancy possibly related to can cer treatment (including AML/MDS) 
must also be reported via the routine reporting mechanisms outlined in this 
protocol. 
 
11.3.4 Second Malignancy 
A second malignancy  is one unrelated to the treatme nt of a prior malignancy (and 
is NOT a metastasis from the initial malign ancy). Second malignancies require 
ONLY routine reporting via CDUS unless otherwise specified. 
 
11.3.5  Pregnancy, Pregnancy Lo ss, and Death Neonatal  
NOTE: When submitting CTEP-AERS reports for ‚ÄúPregnancy‚Äù, ‚ÄúPregnancy loss‚Äù, 
or ‚ÄúNeonatal loss‚Äù, the Pregnancy Information Form, available at: 
http://ctep.cancer.gov/protocolDevelopmen t/electronic_applications/docs/Pregna
ncyReportForm.pdf , needs to be completed and fa xed along with any additional 
medical information to (301) 230-0159.  The potential risk of exposure of the fetus 
to the investigational agent(s) or chem otherapy agent(s) shoul d be documented in 
the ‚ÄúDescription of Event‚Äù sec tion of the CTEP-AERS report. 
 
11.3.5.1 Pregnancy  
Patients who become pregnant on study risk intrauterine exposure of the 
fetus to agents that may be teratoge nic. For this reason, pregnancy needs 
to be reported in an exped ited manner via CTEP-AERS as  
Grade 3 ‚Äú Pregnancy, puerperium an d perinatal conditions - Other 
(pregnancy )‚Äù under the ‚ÄúPregnancy, puerperium and perinatal 
conditions‚Äù SOC. 
 Pregnancy needs to be followed until the outcome is known . If the baby 
is born with a birth defect or anomaly, then a second CTEP-AERS report 
is required. 
 
11.3.5.2 Pregnancy Loss (Fetal Death)  
Pregnancy loss is defined in CTCAE as ‚Äú Death in utero. ‚Äù Any 
Pregnancy loss should be re ported expeditiously, as Grade 4 
‚ÄúPregnancy loss ‚Äù under the ‚ÄúPregnancy, puerperium and perinatal 
conditions‚Äù  SOC . Do NOT report a pregnancy loss as a Grade 5 event 
since CTEP-AERS recognizes any Grade 5 event as a patient death.  
11.3.5.3 Death Neonatal  
Neonatal death, defined in CTCAE as ‚ÄúNewborn death occurring 
during the first 28 days of birth ‚Äù, should be reported expeditiously, as 
Grade 4 ‚Äú Death neonatal ‚Äù under the ‚ÄúGeneral disorders and 
administration‚Äù  SOC when the death is the result of a patient 
pregnancy or pregnancy in partners of men on study . Do NOT report 
a neonatal death resulting from a pa tient pregnancy or pregnancy in 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 53 
 
 
partners of men on study as a Grade 5 event since CTEP-AERS recognizes any Grade 5 event as a patient death.  
 
11.4 Reporting Requirements for Specialized AEs  
11.4.1 Baseline AEs 
Although a pertinent positive finding identi fied on baseline assessment is not an 
AE, when possible it is to be documented as ‚ÄúCourse Zero‚Äù using CTCAE 
terminology and grade. An expedited AE report is not required if a patient is 
entered on a protocol with a pre-existing condition (eg, elevated laboratory value, 
diarrhea). The baseline AE must be re -assessed throughout the study and reported 
if it fulfills expedited AE reporting guidelines. 
a. If the pre-existing condition worsens in severity, the investigator must 
reassess the event to determine if an expedited report is required. 
b. If the AE resolves and then recurs, the investigator must  re-assess the event 
to determine if an expedited report is required. 
c. No modification in grading is to be made to account for abnormalities 
existing at baseline. 
 
11.4.2 Persistent AEs 
A persistent AE is one that extends continuously, without resolution between 
treatment cycles/courses.  ROUTINE reporting: The AE must be reported only once unless the grade 
becomes more severe in a subsequent co urse. If the grade becomes more severe 
the AE must be reported again with the new grade. EXPEDITED reporting: The AE must be reported only once unless the grade becomes more severe in the same or a subsequent course. 
 
11.4.3 Recurrent AEs 
A recurrent AE is one that occurs and re solves during a cycle/course of therapy 
and then reoccurs in a later cycle/course. ROUTINE reporting: An AE that resolves  and then recurs during a subsequent 
cycle/course must be reported by the routine procedures. EXPEDITED reporting: An AE that resolves and then recurs during a subsequent 
cycle/course does not requ ire CTEP-AERS reporting unless: 
1) The grade increases OR 2) Hospitalization is associated with the recurring AE. 
 
11.5 Exceptions to Expedited Reporting 
11.5.1 Specific Protocol Exceptions to Expedited Reporting (SPEER) 
SPEER: Is a subset of AEs within th e Comprehensive Adverse Events and 
Potential Risks (CAEPR) that contains a list of events that are considered expected 
for CTEP-AERS reporting purposes. (Formerly referred to as th e Agent Specific 
Adverse Event List (ASAEL).)  
 
AEs listed on the SPEER should be reported  expeditiously by investigators to the 
NCI via CTEP-AERS ONLY if they exce ed the grade of the event listed in 
parentheses after the event. If the CAEPR is part of a combination IND using 
multiple investigational agents and has an  SAE listed on different SPEERs, use the 
lower of the grades to determine if  expedited reporting is required. 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 54 
 
 
11.5.2 Special Situations as Exceptions to Expedited Reporting 
An expedited report may not be required for a specific protocol where an AE is 
listed as expected. The exception or ac ceptable reporting procedures will be 
specified in the protocol. The protocol  specific guideline s supersede the NCI 
Adverse Event Reporting Guidelines. These sp ecial situations are listed under the 
CTEP-AERS reporting table for this protocol. 
 
11.6 Reporting Requirements - Investigator Responsibility 
Clinical investigators in the treating institu tions and ultimately the Study Chair have the 
primary responsibility for AE identification,  documentation, grading, and assignment of 
attribution to the investigational agent/interven tion. It is the responsibility of the treating 
physician to supply the medical documentation needed to suppor t the expedited AE reports 
in a timely manner.  
 
Note: All expedited AEs (reported via CTEP-A ERS) must also be reported via routine 
reporting. Routine reporting is accomplished via the Adverse Event (AE) Case Report 
Form (CRF) within the study database.   
 
11.7 General Instructions for Expedited Reporting via CTEP-AERS  
The descriptions and grading scales found in  the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting. All 
appropriate treatment areas should have acces s to a copy of the CTCAE version 5.0. A 
copy of the CTCAE version 5.0 can be do wnloaded from the CTEP website at:  
http://ctep.cancer.gov/protocolDevelopmen t/electronic_applications/ctc.htm.  
 An expedited AE report for all studies utiliz ing agents under an NCI IND/IDE must be 
submitted electronically to NCI vi a CTEP-AERS at: https://eapps-
ctep.nci.nih.gov/ctepaers 
 
In the rare situation where Internet connectivity  is disrupted, the 24-h our notification is to 
be made to the NCI for agents supplied under a CTEP IND by telephone call to 301-897-
7497.  
 In addition, once Internet connectivity is restored, a 24-hour notification that was phoned in must be entered into the electronic CTEP-A ERS system by the original submitter of the 
report at the site.   
 
x Expedited AE reporting timelines are defined as: 
o 24-Hour; 5 Calendar Days -  The AE must initially be reported via CTEP-
AERS within 24 hours of learning of the event, followed by a complete expedited report within 5 calendar da ys of the initial 24-hour report. 
o 7 Calendar Days -  A complete expedited report on the AE must be 
submitted within 7 calendar days of the investigator learning of the event.  
 
x Any event that results in a persistent or significant incapacity/substantial disruption 
of the ability to conduct normal life functi ons, or a congenital anomaly/birth defect, 
or is an IME, which based upon the me dical judgment of the investigator may 
jeopardize the patient and require interven tion to prevent a serious AE, must be 
reported via CTEP-AERS if the event occurs following investigational agent 
administration.  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 55 
 
 
 
x Any death occurring within 30 days of the l ast dose, regardless of attribution to an 
agent/intervention under an NCI IND/ IDE requires expedited reporting within 24 
hours .  
x Any death occurring greater than 30 days of the last dose with an attribution of 
possible, probable, or definite to an  agent/intervention under an NCI IND/IDE 
requires expedited reporting within 24 hours .  
 
CTEP-AERS Medical Reporting includes the followi ng requirements as part of the report: 
1) whether the patient has received at least on e dose of an investigational agent on this 
study; 2) the characteristics of  the adverse event including the grade  (severity), the 
relationship to the study therapy  (attribution), and the prior experience  (expectedness) of 
the adverse event; 3) the Phase (1, 2, or 3) of the trial; and 4) whether or not hospitalization 
or prolongation of hospitalization w as associated with  the event.  
 Any medical documentation supporting an expedited report (eg, H & P, admission 
and/or notes, consultations, ECG results, etc.) MUST be faxed within 48-72 hours to 
the NCI. NOTE: English is strongly reco mmended for supporting documentation 
submitted to the numbers listed below in order for the NCI to meet the regulatory 
reporting timelines.   Fax supporting documentation for AEs related to investigational agents supplied under 
a CTEP IND to: 301-230-0159 (back-up: 301-897-7404).  
 Also: Fax or email supporting documentation to COG for all IND studies (Fax# 626-303-
1768; email: COGAERS@child rensoncologygroup.org; Attention: COG AERS 
Coordinator).  
 
x ALWAYS include the ticket number on all faxed documents.  
 
x Use the NCI protocol number and the protocol-specific patient ID 
provided during trial registration on all reports.  
 
11.8 Reporting Table for Late Phase 2 and Phase 3 Studies 
Expedited Reporting Requirements for Adve rse Events that Occur on Studies under an 
IND/IDE within 30 Days of the Last Administration of the Investigational Agent/Intervention 
1 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 56 
 
 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
NOTE: Investigators MUST immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or 
not they are considered related to the investig ational agent(s)/intervention (21 CFR 312.64)  
An adverse event is considered serious if it results in ANY of the following outcomes:  
1) Death.  2) A life-threatening adverse event.  
3) $Q\$(WKDWUHVXOWVLQLQSDWLHQWKRVSLWDOL]DWLRQRUSURORQJDWLR QRIH[LVWLQJKRVSLWDOL]DWLRQIRU¬ï  24 hours. This 
 does not include hospitalizations which are part of routine medical practice. 4) A persistent or significant incapacity or substantial di sruption of the ability to conduct normal life functions.  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in  death, be life threatening, or require hospitalization 
may be considered serious when, based upon medical judg ment, they may jeopardize the patient or subject and 
may require medical or surgical intervention to prevent on e of the outcomes listed in this definition. (FDA, 21 
CFR 312.32; ICH E2A and ICH E6.)  
 
ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the NCI via 
CTEP-AERS within the timeframes detailed in the table below.    
Hospitalization Grade 1 
Timeframes  Grade 2 
Timeframes  Grade 3 
Timeframes  Grade 4 & 5 
Timeframes  
Resulting in 
Hospitalization 
¬ïKUV   
7 Calendar Days  
 
24-Hour Notification 
5 Calendar Days  Not resulting in 
Hospitalization 
¬ïKUV   
Not Required   
7 Calendar Days  
NOTE: Protocol specific exceptions to expedited reporting of  serious adverse events are found in the Specific 
Protocol Exceptions to Expedited Reporting (SPEER) por tion of the CAEPR. Additional Special Situations as 
Exceptions to Expedited Reporting are listed below (see Section 11.10 ).  
 
Expedited AE reporting timelines are defined as:  
‚Äú24-Hour; 5 Calendar Days‚Äù - The AE must initially be re ported via CTEP-AERS within  24 hours of learning of 
the AE, followed by a complete expedited report within  5 calendar days of the in itial 24-hour notification. 
‚Äú7 Calendar Days‚Äù - A complete expedited report on the AE must be submitted within 7 calendar days of 
learning of the AE.  
 
1SAEs that occur more than 30 days after the last admini stration of investigational ag ent/intervention and have an 
attribution of possible, probable, or de finite require reporting as follows:  
Expedited 24-hour notification followed by complete report wi thin 5 calendar days for:  
x All Grade 4, and Grade 5 AEs  
Expedited 7 calendar day reports for:  
x Grade 2 adverse events resulting in hospitalization or prolongation of hospitalization  
x Grade 3 adverse events  
 
 
11.9 Protocol Specific Additional Instructions and Reporting Exceptions 
x Grades 1 4 myelosuppression do not require expedited reporting unless 
unexpected.   
x Grades 13 of the following do not require e xpedited reporting: nausea, diarrhea, 
constipation, headache, rash and muscle cramps. 
x Expedited reporting guidelines for occurre nce of pregnancy or suspected pregnancy 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 57 
 
 
Pregnancy Females of Childbearing Potential: 
 
x Pregnancies and suspected pregnanc ies (including a positive pregnancy 
test regardless of age or disease state) of a female subject or the partner of a male subject occurring while the subj ect is on lenalidomide or within 28 
days after the subject‚Äôs last dose, are considered immediately reportable events. Lenalidomide must be discont inued immediately. The pregnancy, 
suspected pregnancy, or positive pregnancy test must be reported via 
CTEP-AERS as a grade 4  event under: SOC pregnancy, puerperium and 
perinatal conditions; adverse event: pregnancy, puerperium and 
perinatal conditions-other, fetal exposure.  
o The female subject should be referred to an obstetrician-
gynecologist, preferably one experienced in reproductive toxicity 
for further evaluation and counseling. 
x The Investigator will follow the fe male subject until completion of the 
pregnancy, and must make an amendm ent to the initial pregnancy report 
immediately regarding the outcome of the pregnancy and neonatal status 
(either normal or abnormal outcome). 
x If the outcome of the pregnancy wa s abnormal (including spontaneous or 
therapeutic abortion, fetal demise and congenital abnormalities), the 
Investigator should report the abnormal outcome as an amendment to the initial pregnancy report as soon as the as the Investigator has knowledge of the outcome.  
x All neonatal deaths and neonatal comp lications that occur within 28 days 
of birth should be reported, without regard to causality, as an amendment 
to the initial pregnancy report. In add ition, any infant death after 28 days 
that the Investigator suspects is related to the in utero  exposure to the 
lenalidomide should also be reported as  an amendment within 24 hours of 
the Investigator‚Äôs knowledge of the event. 
 
Male Subjects 
x If a female partner of a male s ubject taking investigational product 
becomes pregnant, the male subject ta king lenalidomide should notify the 
Investigator, and the pregnant female partner should be advised to call her 
healthcare provider immediately. 
 
11.10  Routine Reporting of Adverse Events 
Note: The guidelines below are for routine repor ting of study specific adverse events on 
the COG case report forms and do not affect  the requirements for CTEP-AERS reporting. 
 
Routine reporting is accomplished via the Adve rse Event (AE) Case Report Form (CRF) 
within the study database. For this study, routine reporting will include all CTEP-AERS 
reportable events and Grade 3 and higher Adverse Events. 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 58 
 
 
12.0 STUDY REPORTING AND MONITORING  
The Case Report Forms and the submission schedule  are posted on the COG web site with each 
protocol under ‚Äú Data Collection/Specimens ‚Äù. A submission schedule is included. 
 
12.1 CDUS 
This study will be monitored by the Clini cal Data Update System (CDUS). Cumulative 
CDUS data will be submitted quarterly to CTEP by electronic means. Reports are due 
January 31, April 30, July 31 an d October 31. This is not a responsibility of institutions 
participating in this trial. 
 
12.2 Data and Safety Monitoring Committee 
To protect the interests of patients and the scien tific integrity for all clinical trial research 
by the Children‚Äôs Oncology Group, the COG Data and Safety Monitoring Committee 
(DSMC) reviews reports of interim analyses  of study toxicity and outcomes prepared by 
the study statistician, in conjunction with  the study chair‚Äôs report. The DSMC may 
recommend the study be modified or terminated based on these analyses.  
 
Toxicity monitoring is also the responsib ility of the study committee and any unexpected 
frequency of serious events on the trial are to be brought to the attention of the DSMC. The 
study statistician is responsible for the monitoring  of the interim results and is expected to 
request DSMC review of any protocol issues  s/he feels require special review. Any COG 
member may bring specific study concerns to the attention of the DSMC.   The DSMC approves major study modifications proposed by the study committee prior to 
implementation (eg, termination,  dropping an arm based on toxici ty results or other trials 
reported, increasing target sample size, etc.).  The DSMC determines whether and to whom 
outcome results may be released prior to the release of study results at the time specified 
in the protocol document. 
 
12.3 CRADA/CTA 
NCI/ DCTD Standard Language to Be Inco rporated into All Protocols Involving 
Agent(s) Covered by a Clinical Trials Ag reement (CTA), a Cooperative Research and 
Development Agreement (CRADA) or a Clinical Supply Agreement, hereinafter referred to as Collaborative Agreement:  
The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to the 
NCI under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical 
Company(ies) (hereinafter referred to as ‚ÄúCo llaborator(s)‚Äù) and the NCI Division of Cancer 
Treatment and Diagnosis. Therefore, the fo llowing obligations/guidelines, in addition to 
the provisions in the ‚ÄúIntellectual Property Option to Collaborator‚Äù 
(http://ctep.cancer.gov/industryCollaborations 2/intellectual_property.htm) contained 
within the terms of award, apply to th e use of the Agent(s) in this study: 
 1. Agent(s) may not be used for any purpo se outside the scope of this protocol, nor 
can Agent(s) be transferred or licensed to any party not participating in the clinical 
study. Collaborator(s) data for Agent(s)  are confidential and proprietary to 
Collaborator(s) and shall be maintained as such by the investigators. The protocol 
documents for studies utilizing Agents c ontain confidential information and should 
not be shared or distributed without the permission of the NCI. If a copy of this 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 59 
 
 
protocol is requested by a patient or patie nt‚Äôs family member participating on the 
study, the individual should sign a conf identiality agreement. A suitable model 
agreement can be downloaded from: http://ctep.cancer.gov. 
 2. For a clinical protocol where there is an  investigational Agent used in combination 
with (an)other Agent(s), each the subject of different collaborative agreements, the 
access to and use of data by each Collaborato r shall be as follows (data pertaining 
to such combination use shall hereinafter be referred to as "Multi-Party Data‚Äù): 
 
a. NCI will provide all Collaborators with prior written notice regarding the 
existence and nature of any agreemen ts governing their collaboration with 
NCI, the design of the proposed comb ination protocol, and the existence 
of any obligations that would tend to  restrict NCI's participation in the 
proposed combination protocol. 
 
b. Each Collaborator shall agree to permit use of the Multi-Party Data from 
the clinical trial by any other Collabo rator solely to the extent necessary 
to allow said other Collaborator to develop, obtain regulatory approval or 
commercialize its own Agent. 
 
c. Any Collaborator having the right to use the Multi-Party Data from these 
trials must agree in writing prior to th e commencement of the trials that it 
will use the Multi-Party Data solely fo r development, regulatory approval, 
and commercialization of its own Agent. 
 
3. Clinical Trial Data and Results and Raw Data developed under a Collaborative 
Agreement will be made available to Colla borator(s), the NCI, and the FDA, as 
appropriate and unless additional disclosu re is required by law or court order as 
described in the IP Option to Collaborator 
(http://ctep.cancer.gov/industryCollabora tions2/intellectual_property.htm). 
Additionally, all Clinical Data and Results  and Raw Data will be collected , used 
and disclosed consistent with all applicable  federal statutes and regulations for the 
protection of human subjects, including, if applicable, the  Standards for Privacy 
of Individually Identifiable Health Information  set forth in 45 C.F.R. Part 164. 
 
4. When a Collaborator wishes to initiate a data request, the request should first be 
sent to the NCI, who will then notify the appropriate investigators (Group Chair for Cooperative Group studies, or PI for other studies) of Collaborator's wish to contact them. 
 
5. Any data provided to Collaborator(s) fo r Phase 3 studies must be in accordance 
with the guidelines and policies of th e responsible Data Monitoring Committee 
(DMC), if there is a DMC for this clinical trial. 
 6. Any manuscripts reporting the results of this clinical trial must be provided to 
CTEP by the Group office for Cooperative Group studies or by the principal 
investigator for non-Cooperative Gr oup studies for immediate delivery to 
Collaborator(s) for advisory review and comment prior to submission for 
publication. Collaborator(s) will have 30 days  from the date of receipt for review. 
Collaborator shall have the right to request that publication be delayed for up to an 
additional 30 days in order to ensure  that Collaborator‚Äôs confidential and 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 60 
 
 
proprietary data, in addition to Collabo rator(s)‚Äôs intellectual property rights, are 
protected. Copies of abstracts must be provided to CTEP for forwarding to 
Collaborator(s) for courtesy review as soon  as possible and preferably at least three 
(3) days prior to submission,  but in any case, prior to presentation at the meeting 
or publication in the proceedings. Press releases and other media presentations 
must also be forwarded to CTEP prior to release. Copies of any manuscript, abstract and/or press release/ media presentation should be sent to: 
 
Email: ncicteppubs@mail.nih.gov 
 The Regulatory Affairs Branch will then distri bute them to Collaborator(s). No publication, 
manuscript or other form of public disclosure shall contain any of Collaborator‚Äôs 
confidential/proprietary information. 
 
 
13.0 SPECIAL STUDIES SPECIMEN REQUIREMENTS  
13.1 Steady State Pharmacokinetic Study 
Participation in the pharmacokinetic study is required.  Peripheral blood will be 
collected from all patients, for correlation of steady state pharmacokinetic levels of 
lenalidomide with best response and EFS at the patient dose.  
 Serum samples will be assayed for lenalidom ide by a validated high performance liquid 
chromatography assay with MS detection th at has been developed for the quantitative 
determination of lenalidom ide in biological matrices
30. 
 
13.1.1 Sampling Schedule 
Plasma samples will be obtained prior to drug administration at the following three 
time-points: 
x any day between Days 5-21 on Cycle 1, 
x any day between Days 5-21 on the cycle following a first dose 
reduction 
x any day between Days 5-21 on the cycle following a second dose 
reduction. 
 Patients do not need to be NPO for the samples. Whenever possible, institutions 
are encouraged to collect samples at the same time other labs are collected (eg, 
weekly CBC).  
 
13.1.2 Sample Collection and Processing Instructions 
Draw 2 mL of blood into a green top (s odium heparin) tube  for pharmacokinetic 
evaluation, and immediately place on wet ice. Centrifuge whole blood at room 
temperature within 30 minutes to 1 hour at 2000G X 5 minutes. Transfer serum to individually labeled tubes and store at -70¬∞ C to -80¬∞ C.  
 
Label all serum specimens and the accom panying paperwork with the patient‚Äôs 
COG ID number, patient‚Äôs BPC number, the specimen collection date and time, 
the designated time point that the sample represents (eg, Cycle 1, Day X) and the 
COG study number (ACNS1022).  
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 61 
 
 
13.1.3 Sample Handling and Shipping Instructions  
Sample kits and shipping containers are not provided. 
Sample shipments should be made Monday through Thursday only, for delivery 
Tuesday through Friday. Weekend deliveries should be avoided. Sites should call 
Dr. Brigitte Widemann‚Äôs Laboratory (details below) to notify her of the shipment 
and provide the courier and tracking number . Ship all serum specimens on dry ice, 
with a completed ACNS1022 Pharmacokine tic Sample Collection Form for each 
sample shipment (see Appendix VII ) to: 
 
Widemann Laboratory Pediatric Oncology Branch, NCI, CCR 10 Center Dr. 10-CRC, Rm 1-5750 MSC 1101 Bethesda, MD 20892-1928   
Phone: 301-496-7387 
   
 
14.0 IMAGING STUDIES REQUIRED AND GUIDELINES FOR OBTAINING  
Timing of protocol therapy administration, response assessment studies, and su rgical interventions are 
based on schedules derived from the experimental de sign or on established standards of care. Minor 
unavoidable departures (up to 72 hours) from protocol directed therapy and/or disease evaluations (and 
up to 1 week for surgery) for valid clinical, patient and family logistical, or facility, procedure and/or 
anesthesia scheduling issues are acceptable per C OG administrative Policy 5.14  (except where explicitly 
prohibited within the protocol). 
 
14.1 Timing of MRIs 
To document the degree of residual tumor, st andard whole brain MRI with and without 
contrast (gadolinium) and spine MRI with a nd without contrast (gadolinium) must be 
performed at the following time points: 
x within 1 week preceding enrollment into the study 
x at the following timepoints during protocol therapy: 
o within 1 week prior to each odd-numbe red treatment cycle (ie, prior to 
cycles 3, 5, 7, 9, 11, 13) for the first 13 cycles,   
o within 1 week prior to every third trea tment cycle (ie, prior to 16, 19, 22, 
25) for cycles 14-26. 
x when patient is removed from protocol th erapy (upon completion of therapy or at 
progression)  
 
In addition, for patients who have undergone surgical tumo r debulking prior to protocol 
therapy, pre-operative and post-operative imagi ng must be obtained preferably within 48 
hours of surgery.  
 
14.2 MRI Guidelines for Brain/Spine Tumors 
Juvenile pilocytic astrocytomas and optic path ways gliomas are generally measured on the 
sequence that best demonstrates tumor (usua lly FLAIR or T2), although this sometimes 
varies. For the purposes of this study, tumors  will be measured two-dimensionally using 
the sequence that best demonstrates tu mor as determined by the institutional 
neuroradiologist. No additional measurements  will be required from the institution.   
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 62 
 
 
For recommended brain/spine imaging, requi red and optional sequences and technical 
details, see the COG CNS Imaging Guidelines  posted on the COG member website at: 
https://members.childrensoncologygroup.or g/_files/reference/RefMaterial/COGCNSImag
ingGuidelines6_4_10.pdf. 
 
14.3 Tumor Response Assessment 
For the response assessments, MRI scans ob tained at the time-points during protocol 
therapy (see Section 14.1) will be compared to the baseline MRI scan.  Exception:  In cases 
of progressive disease, the reference scan sh ould be the MRI with the smallest product 
observed since the start of treatment). 
 
14.4 Retrospective Central Review 
A retrospective central review of imaging wi ll be performed for all patients enrolled on 
ACNS1022 for determination of best response. Results of the retrospective review will not be returned to the site. Submit the followin g studies with their co rresponding reports for 
central review at the completion of treatment or when the patient is removed from protocol 
therapy:  
 
- Initial (pre-operative) scan 
- Post operative scan (if applicable) 
- Recurrence scan (baseline scan) 
- Removal from protocol therapy 
- Best response (if different from end of treatment scan) (Subsequent evaluations do 
not need to be submitted if no change from earliest best response) 
 For each study sent to IROC RI (QARC), all im aging sequences obtain ed (e.g. Precontrast 
T1, FLAIR, T2, diffusion, post contrast T1, etc.) must be submitted. 
 
14.4.1 Address Information 
Submission of Diagnostic Imaging data in di gital format is required. Digital files 
must be in DICOM format. These files ca n be submitted via sFTP. Information for 
obtaining a sFTP account and submissi on instructions can be found at 
www.QARC.org. Follow the link labeled digital data. Alternatively, if sFTP is not 
feasible, the imaging may be burned to a CD and mailed to IROC RI (QARC) at 
the address below. Multiple studies for th e same patient may be submitted on one 
CD; however, please submit only one pati ent per CD. Sites using Dicommunicator 
may submit imaging via that application. Contact IROC RI (QARC) with questions 
or for additional information. 
Copies of scans of the required studies for central review should be forwarded to: 
 
IROC RI (QARC) 640 George Washington Highway 
Buildig B, Suite 201 
Lincoln, RI 02865-4207 
Phone: (401) 753-7600 Fax: (401) 753-7601 
 
 
Imaging will then be uploaded by IROC RI (QARC) for review by the National 
Cancer Institute (Drs Warren and Patron as). Measurements on T2, FLAIR and T1 
post gadolinium will be ta ken to determine correlat ion between sequences and 
patient outcome. 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 63 
 
 
APPENDIX I:  SITE COUNSELOR IDENTIFICATION FORM 
x Please identify at least two (2) counselors There must be two persons at your institution trained. Previous 
trainings for lenalidomide counseling ARE NOT accepted in lieu of the current training. 
x  Please fax the request for training form to Celgene at  888-314-2392 
x Use one form per counselor. 
x Identified counselors must be licensed healthcare professional s (e.g. RN, PA, RPh, PhD, LPN, CNP, or 
MD) and must not be the principal investigator. 
x You may list all the protocols and sites that you are requesting training for on the bottom of the form. 
Please add the NCI protocol number(s). 
x You will receive e-mail instructions on accessin g and completing the tr aining from Celgene. 
x Please note: There may be a delay if the handwriting is unclear. Celgene will contact the counselor at the 
phone numbe provided if this is the case. 
x Please allow adequate time for Celgene to proces s your request (3-5 business days) most forms are 
processed withinthe week they are received. If trai ning instructions are no  received within this 
timeframs, please e-mail coop_ma@celgene.com  to inquire. 
x After taking the training, print and fax the Certificat e of Completion and your training request form to 
the CTAU at 1-888-691-8039 to ensure the training is applied appropriately to all studies and sites you 
are covering. The CTSU ONLY needs the Certificate of Completion and does no need the additional 
‚Äúrisk minimization plan‚Äù certificates. 
x For questions on the training content and scheduling of trainings contact Celgene at 
coop_ma@celgene.com  and someone will respond within 24 to 48 hours. 
x For questions on study status and CTSU processing  of the form contact the CTSU Help Desk at 
ctsucontact@westat.com  or 1-888-823-5923. 
 
General Information 
Principal Investigator: ____________________________ Institution Name: _____________________________ Celgene 
Corporation  Celgene Pregnancy Prevention & Counseling Program 
Site Counselor Identification Form 
NCI Protocol #: _______________________________ 
 
Counselor Information  
 
CTEP person ID:  ______________________________  CTEP site ID:  ____________________________________ 
 First Name: __________________________   Middle Initial:_____   Last Name: ____________________________ 
 
License Type: (circle one)    MD        PhD        PA        CNP        RN        LPN       RPh      Other:_________________  
Email Address:________________________________________________________________________________ 
 Phone: ___________________________________         Fax:___________________________________________ 
 
Institution Street Address: _______________________________________________________________________ 
 
City: ____________________________________   State/Region: ______________________________________ 
 
Zip/Post Code: _______________________    Country: ______________________________________________ 
 
Which training will you require?  ¬Ö Adult     ¬Ö Pediatric  
 
Were you previously appr oved as a Counselor? 
¬Ö No ¬Ö Yes (Previous training) ¬Ö Adult     ¬Ö Pediatric  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 64 
 
 
 
If no, please list all the protocols #(s), correspond ing CTEPsiteID(s) and institution names(s) that you plan to provide  
counseling for: 
 If yes, please list the protocols #(s), corresp onding CTEPsiteID(s) and institution names(s) for protocols Celgene has 
already associated you with : 
 
Protocol#: CTEPsiteID  Institution 
   
   
   
   
   
 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 65 
 
 
APPENDIX II: LENALIDOMIDE RISKS OF FETAL EXPOSURE, PREGNANCY TESTING GUIDELINES AND ACCEPTABLE BIRTH CONTROL METHODS 
 
Risks Associated with Pregnancy  Lenalidomide was teratogenic in both rats and rabbits when administered during the period of 
organogenesis. Thalidomide is a known human teratoge n that causes severe life-threatening human birth 
defects.  If Lenalidomide is taken during pregnancy, it may cause birth de fects or death to an unborn baby. 
 
 
Definition of female children of childbearing potential (FCCBP)  
 
A FCCBP is a female child who:  
 
‚Ä¢ Has achieved menarche and/or breast development in Tanner stage 2 or greater  
x Onset of fertility typically occurs within 3- 12 months after menarche. Menarche varies 
considerably from person to pe rson, and thus no age cut off can be attributed. One of the 
primary tools used to follow a girl‚Äôs progress through puberty is the Tanner staging 
system which describes the pattern of devel opment of the secondary sex characteristics. 
Tanner stage 2 corresponds to the beginning of  breast development, which is the first 
visible sign of puberty in girls. Breast development is estrogen stimulated, and since 
ovulation cannot occur without estrogen, Tanner stage 2 will be a reliable marker for the 
definition of fertility.   
‚Ä¢ Has not undergone a hysterectomy or bilateral oophorectomy.   
Note: Amenorrhea following cancer therapy does not rule out childbearing potential    
 
Definition of Female Children NOT of Childbearing Potential (FCNCBP)   
 
A FCNCBP is a female child who:  
‚Ä¢ has not yet experienced menarche or breast develo pment has not reached Tanner stage 2 or  
‚Ä¢ has undergone a hysterectomy or  bilateral oophorectomy.  
 
Counseling  
 
Female Children of Childbearing Potential (FCCBP) 
 For a, FCCBP lenalidomide is contraindicated unless a ll of the following are met (i.e., all female children 
of childbearing potential must be counseled concerni ng the following risks and requirements prior to the 
start of lenalidomide):   
‚Ä¢ She understands the potential teratogenic risk to the unborn child  
‚Ä¢ She understands the need to co mmence the study treatment as soon as lenalidomide is dispensed 
following a negative pregnancy test  
‚Ä¢ She understands and accepts the need to unde rgo pregnancy testing based on the frequency 
outlined in this protocol and in the Informed Consent.  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 66 
 
 
For FCCBP who do not commit to complete abstinence or  plan not to commit to complete abstinence, the 
following are required prior to the start of lenalidomide:  
x She understands the need for effective contracepti on, without interruption, 28 days (4 weeks) 
before starting lenalidomide, throughout the en tire duration of lena lidomide, during dose 
interruptions and at least 28 days after the last dose of lenalidomide 
x She understands and agrees to inform the Invest igator if a change or stop of method of 
contraception is needed 
x She must be capable of complying with  effective contraceptive measures   
x She is informed and understands the potential cons equences of pregnancy and the need to notify 
her study doctor immediately if there is a risk of pregnancy  
x She acknowledges that she understa nds the hazards lenalidomide can  cause to an unborn fetus and 
the necessary precautions associated  with the use of lenalidomide. 
 
The investigator must ensure that:  
‚Ä¢ A FCCBP complies with the conditions of the PPP, including confirmation that she has an 
adequate level of understanding  
‚Ä¢ A FCCBP and/or her parent/guardian acknow ledge the aforementioned requirements  
Female Children Not of Childbearing Potential 
 For a FCNCBP, lenalidomide is contraindicated unless all of the following are met (i.e., all FCNCBP must 
be counseled concerning the following risks and requi rements prior to the start of lenalidomide):  
  
‚Ä¢ She and/or her parent/guardian acknowledge an  understanding of the hazards lenalidomide can 
cause to an unborn fetus and necessary precautions  associated with the use of lenalidomide  
‚Ä¢ She and/or her parent/guardian will inform site staff as soon as possible regarding new onset of 
menarche  
Male Children 
The effect of lenalidomide on sperm development is not known and has not been studied. The risk to an 
unborn baby in females of child bearing potential whos e male partner is receiv ing lenalidomide is unknown 
at this time. Male subjects taking lenalidomide (and/ or his parent/guardian) must meet the following 
conditions (ie, all males must be counseled concerni ng the following risks and requirements prior to the 
start of lenalidomide): 
x Understand the potential teratogenic risk if enga ged in sexual activity with a pregnant female 
or a female of childbearing potential 
x Understand the need for the use of a condom ev en if he has had a vasectomy, if engaged in 
sexual activity with a pregnant female or a female of childbearing potential. 
x Understand the potential teratogenic risk if the subject donates semen or sperm. 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 67 
 
 
Contraception  
Females of childbearing potential (FCB P) enrolled in this protocol must agree to use two reliable forms of 
contraception simultaneously or to practice complete abs tinence (true abstinence is acceptable when this is 
in line with the preferred and usual lifestyle of the subject. Periodic abstinence [eg calendar, ovulation, 
symptothermal or post-ovulation methods] and withdraw al are not acceptable methods of contraception.) 
from heterosexual contact during the following time periods re lated to this study:   1) for at least 28  days 
(4 weeks) before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at 
least 28 days after study treatment discontinuation.    
The two methods of reliable contraception must in clude one highly effectiv e method and one additional 
effective (barrier) method. If the below contraception methods are not appropriate for the FCCBP, she must 
be referred to a qualified provide r of contraception methods to de termine the medically effective 
contraception method appropriate to the subject. The following are examples of highly effective and 
additional effective methods of contraception:    
x Highly effective methods:  
x Intrauterine device (IUD)  
¬É Hormonal (birth control pills, injections, implants)  
¬É Tubal ligation  
¬É Partner‚Äôs vasectomy  
x Additional effective methods:  
¬É Male condom  
¬É Diaphragm  
¬É Cervical Cap  
 
Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection 
at the time of insertion and irregular vaginal bleed ing. Prophylactic antibiotics should be considered 
particularly in patients with neutropenia.    
Male children must practice complete abstinence (true abstinence  is acceptable when this is in line with the 
preferred and usual lifestyle of the subject. Periodic abstinence [eg calendar, ovulation, symptothermal or 
post-ovulation methods] and withdrawal are not accepta ble methods of contraception.) or agree to use a 
condom during sexual contact with a pregnant female or a female of childbearing potential while taking 
lenalidomide, during dose interruptions and for at least 28 days after the last dose of lenalidomide, even if 
he has undergone a successful vasectomy. 
 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 68 
 
 
Pregnancy testing  
 
Medically supervised pregnancy tests with a minimu m sensitivity of 25 mIU/mL must be performed for 
FCCBP.  Before starting study drug   Female Patients: 
 
FCCBP must have two negative pregnancy tests (sens itivity of at least 25 mIU/mL) prior to starting 
lenalidomide.  The first pregnancy test must be pe rformed within 10-14 days prior to the start of 
lenalidomide and the second pregnanc y test must be performed within 24 hours prior to the start of 
lenalidomide.  The patient may not receive study drug unt il the Investigator has veri fied that the results of 
these pregnancy tests are negative.  
 
Female children of childbearing potential with regular  or no menstrual cycles must agree to have pregnancy 
tests weekly for the first 28 days of study participa tion and then every 28 days while taking lenalidomide, 
at study discontinuation, and at Day 28 following the last dose of lenalidomide. 
Female children of childbearing potential with irregu lar menstrual cycles must agree to have pregnancy 
tests weekly for the first 28 days of study participa tion and then every 14 days while taking lenalidomide, 
at study discontinuation, and at Days 14 and 28 following the last dose of lenalidomide. 
 
Male Patients: Must practice complete abstinence or  agree to use a condom during sexual  contact with a pregnant female 
or a female of childbearing potential while participati ng in the study, during dose interruptions and for at 
least 28 days following study drug discontinuation, ev en if he has undergone a successful vasectomy. 
 During study participation and for at least 28 days following study drug discontinuation   Female Patients: 
 
x FCCBP with regular or no menstrual cycles must ag ree to have pregnancy tests weekly for the first 
28 days of study participation and then every 28 days while on study, at study discontinuation, and 
at day 28 following study drug discontinuation.  
 
x Female children of childbearing potential with  irregular menstrual cycles , must agree to have 
pregnancy tests weekly for the first 28 days a nd then every 14 days while on study, at study 
discontinuation, and at days 14 and 28 fo llowing study drug discontinuation.  
 
x At each visit the Investigator must confirm with  the FCCBP that she is continuing to use two 
reliable methods of birth control   
x Counseling about pregnancy precautions and the poten tial risks of fetal exposure must be conducted 
at a minimum of every 28 days (once per cycle).   
 
x If a FCCBP considers the need to change or to stop a method of contraception, the Investigator 
must be notified immediately. 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 69 
 
 
 
x If pregnancy or a positive pregnancy test does  occur in a study patient, lenalidomide must be 
immediately discontinued.  
 
x Pregnancy testing and counseling must be performed if a patient  misses her period or if her 
pregnancy test or her me nstrual bleeding is abnor mal.  Study drug treatment  must be discontinued 
during this evaluation.  
 
x Female children must agree to abstain from breastfeed ing during study participation and for at least 
28 days after study drug discontinuation.  
 Male Patients:  
‚Ä¢ Must practice complete abstinence (Tru e abstinence is acceptabl e when this is in line with the preferred 
and usual lifestyle of the subject. Periodic abstin ence [eg calendar, ovulation, symptothermal or 
post-ovulation methods] and withdrawal are not accepta ble methods of contraception.) or use a condom 
during sexual contact with a preg nant female or a female of childbearing potential while receiving 
lenalidomide, during dose interruptions and for at least 28 days after the last dose of lenalidomide, even 
if he has undergone a successful vasectomy. 
x Must not donate semen or sperm while receiving lenalidomide, during dose interruptions and for 
at least 28 days after the last dose of lenalidomide. 
 
x Counseling about pregnancy precautions and the poten tial risks of fetal exposure must be conducted 
at a minimum of every 28 days (once per cycle).   
 
x If pregnancy or a positive pregnancy test does occu r in the partner of a male study patient during 
study participation, the investigator must be notified immediately.  
 
Additional precautions  
 
Patients should be instructed never to  give lenalidomide to another person and to return any unused capsules 
to the Investigator at the end of treatment.   
Patients should not donate blood duri ng therapy and for at least 28 da ys following discontinuation of 
lenalidomide.   Only enough lenalidomide for one cycle of therapy ma y be dispensed with each cycle of lenalidomide.  
 
 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 70 
 
 
APPENDIX III A: LENALIDOMIDE EDUCATION AND COUNSELING GUIDANCE 
DOCUMENT FOR FEMALE SUBJECTS 
 
To be completed prior to each dispensing of lenalidomide.   Protocol Number: ACNS1022   COG Patient ID#: __________________ DOB: _____/_____/_____ (mm/dd/yyyy)  
 
(Check the appropriate box to indicate risk category) 
¬Ö FCCBP (Female children of childbearing potenti al): female child who: 1) has achieved 
menarche or breast development in Tanner St age 2 or greater, and 2) has not undergone a 
hysterectomy or bilateral oophorectomy. 
Note: Amenorrhea following cancer therapy does not rule out childbearing potential 
¬Ö FCNCBP (Female Children Not of Childbeari ng Potential): female child who: 1) has not 
experienced menarche or breast development has not reached Tanner Stage 2 or 2) has 
undergone a hysterectomy or bilateral oophorectomy.  
 
Female Child of Childbearing Potential and/or Parent/Guardian:   
1. I have verified and counseled the subject and/ or parent/guardian regarding the following: 
¬Ö Potential risk of fetal exposure to lenalidom ide: A teratogenic potential of lenalidomide in 
humans cannot be ruled out. If lenalidomide is  taken during pregnancy, it may cause birth 
defects or death to any unborn baby. Females are advised to avoid pregnancy while taking 
lenalidomide. Female children of childbearing potential must agree not to become pregnant 
while taking lenalidomide.  
¬Ö That the required pregnancy tests performed are negative. 
¬Ö The subject confirmed that she is using TWO reliable methods of birth control at the same 
time, or complete abstinence (T rue abstinence is acceptable wh en this is in line with the 
preferred and usual lifestyle of the subject. Periodic abstinence [eg calendar, ovulation, 
symptothermal or post-ovulation methods] and withdrawal are not acceptable methods of 
contraception.) from heterosexual contact (at le ast 28 days prior to receiving lenalidomide, 
while receiving lenalidomide, during dose interruptio ns and for at least 28 days after the last 
dose of lenalidomide).  
One highly effective method and one additional meth od of birth control must be used AT THE 
SAME TIME. The following are examples of high ly effective and additional effective methods 
of contraception: 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 71 
 
 
Examples of highly effective methods: 
o Intrauterine device (IUD) 
o Hormonal (birth control pills, injec tions, implants, levonorgestrel-releasing 
intrauterine system [IUS], medroxyprogeste rone acetate depot injections, ovulation 
inhibitory progesterone-only pills [e.g. desogestrel]) 
o Tubal ligation 
o Partner‚Äôs vasectomy 
Examples of additional effective methods: 
o Male condom 
o Diaphragm 
o Cervical Cap 
¬Ö The subject confirmed that even if she ha s amenorrhea she must co mply with advice on 
contraception. 
¬Ö Pregnancy tests before, during administrati on of lenalidomide and at the last dose of 
lenalidomide, even if the subject agrees not to have reproductive heterosexual contact. 
¬Ö Frequency of pregnancy tests to be done: 
Two pregnancy tests will be performed prior to receiving lenalidomide, one within 10 to 14 
days, and a second within 24 hour s of the start of lenalidomide. 
Every week during the first 28 days of this st udy and a pregnancy test every 28 days while the 
subject is taking lenalidomide if menstrual cycles are regular.  
Every week during the first 28 days of this st udy and a pregnancy test every 14 days while the 
subject is taking lenalidomide if menstrual cycles are irregular. 
If the subject missed a period or has unusual menstrual bleeding.   When the subject is discontinued from the study and at Day 28 after the last dose of 
lenalidomide if menstrual cycles are regular. If  menstrual cycles are irregular, pregnancy 
tests will be done at discontinuation from the study and at Days 14 and 28 after the last 
dose of lenalidomide. 
¬Ö The subject confirmed that she will stop taki ng lenalidomide immediately in the event of 
becoming pregnant and to call her study doctor as soon as possible.  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 72 
 
 
¬Ö The subject confirmed that she has not and will not breastfeed a baby while taking lenalidomide 
and for at least 28 days after the last dose of lenalidomide. 
¬Ö The subject has not and will never share lenalidomide with anyone else. 
¬Ö The subject has not and will not donate bl ood while taking lenali domide, during dose 
interruptions and for at least 28 days after the last dose of lenalidomide. 
¬Ö The subject has not and will not break, chew, or open lenalidomide capsules at any point. 
¬Ö The subject confirmed that she will return un used lenalidomide capsul es to the study doctor. 
2. I have provided the Lenalidomide Information Sheet to the subject. 
 
Female Child Not of Childbearing Potential: 
1. I have verified and counseled the female ch ild NOT of childbearing potential and/or her 
parent/guardian regarding the following: 
¬Ö The need to be aware of signs of menarche an d inform site staff as soon as possible regarding 
onset, if it occurs. 
¬Ö Potential risk of fetal exposure to lenalidom ide: A teratogenic potential of lenalidomide in 
humans cannot be ruled out. If lenalidomide is  taken during pregnancy, it may cause birth 
defects or death to any unborn baby. 
¬Ö The subject has not and will never share lenalidomide with anyone else. 
¬Ö The subject has not and will not donate bl ood while taking lenali domide, during dose 
interruptions and for at least 28 days after the last dose of lenalidomide. 
¬Ö The subject has not and will not break, chew , or open lenalidomide capsules at any point. 
¬Ö The subject confirmed that she will return unu sed lenalidomide capsules to the study doctor. 
2. I have provided the Lenalidomide Information Sheet to the subject. 
Do Not Dispense Lenalidomide if: 
x The subject is pregnant. 
x No pregnancy tests were conducted for a FCCBP. 
x The subject states she did not use TWO reliable methods of birth control (unless 
practicing complete abstinence from heterose xual contact) at least 28 days prior to 
receiving lenalidomide, while receiving le nalidomide and during dose interruptions. 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 73 
 
 
x The subject stated that she has or does no t want to adhere to pregnancy precautions 
outlined within this PPP. 
 
Counselor Name (Print): _________________________   
Counselor Signature: _____________________________Date:_____/_____/_____  
 **Maintain a copy of the Education and Counseling Guidance Document in the patient records. **  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 74 
 
 
APPENDIX III B: LENALIDOMIDE EDUCATION AND COUNSELING GUIDANCE 
DOCUMENT FOR MALE SUBJECTS 
 
To be completed prior to each dispensing of lenalidomide.   Protocol Number: ACNS1022   COG Patient ID#: __________________ DOB: _____/_____/_____ (mm/dd/yyyy) \ 
 
1. I have verified and counseled the male subject a nd/or his parent/guardian regarding the following: 
¬Ö Potential risks of fetal exposure to lenalidom ide: A teratogenic potential of lenalidomide in 
humans cannot be ruled out. If lenalidomide is  taken during pregnancy, it may cause birth 
defects or death to any unborn baby. 
¬Ö The subject confirmed that he has practiced comp lete abstinence (True ab stinence is acceptable 
when this is in line with the preferred and usua l lifestyle of the subject. Periodic abstinence 
[eg calendar, ovulation, symptothermal or pos t-ovulation methods] and withdrawal are not 
acceptable methods of contraception.) or used  a condom when engagi ng in sexual contact 
(including those who have had a vasectomy) with a pregnant female or a female of 
childbearing potential, while taking lenalidomide,  during dose interruptions and for at least 
28 days after the last dose of lenalidomide.  
¬Ö The subject confirmed that he has not impre gnated his female partner while in the study. 
¬Ö The subject confirmed that he will notify hi s study doctor if his female partner becomes 
pregnant and the female partner of a male subj ect taking lenalidomide confirmed that she will 
call her healthcare provider immediately if she becomes pregnant. 
¬Ö The subject has not and will never share lenalidomide with anyone else. 
¬Ö The subject confirmed that he has not donated a nd will not donate semen or sperm while taking 
lenalidomide or during dose interruptions and th at he will not donate semen or sperm for at 
least 28 days after the last dose of lenalidomide. 
¬Ö The subject has not and will not donate bl ood while taking lenali domide, during dose 
interruptions and for at least 28 days  after the last dose of lenalidomide. 
¬Ö The subject has not and will not break, chew, or open lenalidomide capsules at any point. 
¬Ö The subject confirmed that he will return un used lenalidomide capsules to the study doctor. 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 75 
 
 
2. I have provided the Lenalidomide Information Sheet to the subject. 
Do Not Dispense Lenalidomide if: 
x The subject stated that he has or does no t want to adhere to pregnancy precautions 
outlined within this PPP. 
 
Counselor Name (Print): _______________________   Counselor Signature: __________________ ________Date: _____/_____/_____(dd/mmm/yyyy) 
 
**Maintain a copy of the Education and Counseling Gu idance Document in the subject‚Äôs records. ** 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 76 
 
 
APPENDIX IV: LENALIDOMIDE PATIENT CARD FOR PEDIATRIC PATIENTS 
 
Protocol Number: ACNS1022  
 
Subject COG ID#: __________________ DOB: _____/_____/_____ (mm/dd/yyyy)  
Investigator to complete each section.   1. Status of Patient (check one)   
Female Children NOT of childbearing potential*           
(*no monitoring of pregnancy tests requi red. Retain card in records)  
 Male   
Female children of child bearing potential              
   2. Counseling regarding the potential  teratogenicity of lenalidomide 
and the need to avoid pregnancy has been provided before first dose 
dispensed.      
3. For Female Children of Childbearing potential ‚Äì If all fields have 
been used below, print additional Le nalidomide Patient Cards as needed to collect and document results.  
   Investigator‚Äôs Signature  
Date  
Date of 
Visit  Date of NEGATIVE 
pregnancy test  Confirmed no risk 
of pregnancy  Date lenalidomide 
prescribed  Investigator‚Äôs signature  
     
     
     
     
     
     
     
     
     
     
     
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 77 
 
 
APPENDIX V:   LENALIDOMIDE INFORMATION SHEET  
 
FOR PATIENTS ENROLLED IN CLINICAL RESEARCH STUDIES 
 Please read this Lenalidomide Information Sheet be fore you start taking lenalidomide and each time you 
get a new supply, since there may be new information.  This Lenalidomide Information Sheet does not take 
the place of an informed consent to  participate in clinical research or talking to your study doctor or 
healthcare provider about your medical condition or your treatment.    
 
What is the most important informatio n I should know about lenalidomide?  
 Lenalidomide may cause birth defects (deforme d babies) or death of an unborn baby. Lenalidomide 
is similar to the medicine thalidom ide. It is known that thalidomide causes life-threatening birth defects. 
Lenalidomide has not been tested in pregnant women but may also cause birth defects. Lenalidomide was 
found to cause birth defects when tested in pregnant rabbits.  If you are a female who is able to become pregnant:   
x Do not take lenalidomide if you are preg nant or plan to become pregnant  
x You must either not have any sexual relations with a man or use two reliable, 
separate forms of effective birth control at the same time: 
o for 28 days before starting lenalidomide  
o while taking lenalidomide   
o during dose interruptions of lenalidomide   
o for 28 days after stopping lenalidomide   
x You must have pregnancy testing done at the following times:  
o within 10 ‚Äì 14 days and again 24 hours pr ior to the first dose of lenalidomide   
o weekly for the first 28 days  
o every 28 days after the first month or  every 14 days if you have irregular 
menstrual periods  
o if you miss your period or ha ve unusual menstrual bleeding  
o 28 days after the last dose of lenalidomid e (14 and 28 days after the last dose if 
menstrual periods are irregular)  
x Stop taking lenalidomide if you become pregnant during lenalidomide treatment  
o If you suspect you are pregnant at any time during the study, you must stop 
lenalidomide immediately and immediately inform your study doctor. The 
study doctor will report all cases of pregnancy to the NCI. 
x Do not breastfeed while taking lenalidomid e and for at least 28 days after thee last 
dose of lenalidomide  
o The study doctor will be able to advise you where to get additional advice on 
contraception 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 78 
 
 
If you are a female child not able to become pregnant:   
In order to ensure that an unborn baby is not exposed to lenalidomide, your study doctor will confirm that 
you are not able to become pregnant. Any awareness of me nstrual periods must be reported to site staff.  
 If you are a male:   The effect of lenalidomide on sperm development is not known and has not been studies. The rsik to an 
unborn baby in females whose male partneris r eceiving lenalidomide is unknown at this time. 
 
 
1. Male children, (including those who have had a vasectomy), must either not have any sexual 
relations with a pregnant female or a female who can become pregnant, or must use a condom 
during sexual contact with a pregnant female or a female who that can become pregnant: 
o While you are taking lenalidomide   
o During dose interruptions of lenalidomide   
o For 28 days after you stop taking lenalidomide    
2. Male children should not donate sperm or semen  while taking lenalidomide and for 28 days 
after stopping lenalidomide.  
3. If you suspect that your partner is pregnant any time during the study, you must immediately 
inform your study doctor. The study doctor will re port all cases of pregnancy to the National 
Cancer Institute. Your partner should call her healthcare provider immediately if she gets 
pregnant. 
All subjects: 
 
x Do not share lenalidomide with other people. It must be kept out of the reach of 
children and should never be given to any other person.  
x Do not give blood  while you take lenalidomide and for 28 days after stopping 
lenalidomide.   
x Do not break, chew, or open lenalidomide capsules.  
x You will get no more than a 28-day supp ly of lenalidomide at one time.  
x Return unused lenalidomide capsules to your study doctor.  
Additional information is provided in the informed consent form and you can ask your study doctor for 
more information.  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 79 
 
 
APPENDIX VI: PATIENT DIARY FOR LENALIDOMIDE CAPSULE ADMINISTRATION 
Date: From _____________ To _______________ (4 weeks)  Cycle _______________ 
 
COG Patient ID _________________________ ACC#: _________ Institution: ____________________    
Please do not write patient name on this form. 
 
My daily dose of lenalidomide is:_______ mg, (____ 2.5 mg capsule, _____ 5 mg capsule, ______ 25 mg capsule)  
once a day for 21 days.  
1 Take/give lenalidomide dose  by mouth with a full glass of water. The lenalidomide capsules should not be 
opened, broken or chewed. 
2 Take/give the medication at a convenient time approximately the same time each day for 21 days (THREE 
weeks). You should take/give the medication without food. If nausea occurs after taking the dose, try 
taking/giving it with food as administration with food may decrease nausea. 
3 Write down date, number of capsule(s) you gave/ took. Wash your hands if you touch the pills. 
4 If you forget to take/give the dose on time and you remember that a dose is missed within 8 hours, take the 
missed dose. If more than 8 hours have passed then skip that dose. Notify the clinic that a dose was taken 
late or skipped at the next visit. 
5 If you vomit within 10 minutes of taking the dose and you can see the capsules, take another dose and notify 
the clinic. You may need to obtain additional supply of drug to finish the cycle. 
6 Write down any side effects (like diarrhea, constipation, nausea) in the comments column. 
7 Bring your capsule bottle and this form to your doctor when you return to your next appointment.  
Date Day # Capsules 
(list strength 
and quantity) Comments (example: 
diarrhea, constipation, 
nausea) Date Day # Capsules 
(list 
strength 
and 
quantity) Comments 
(example: diarrhea, 
constipation, 
nausea) 
 1    15   
 2    16   
 3    17   
 4    18   
 5    19   
 6    20   
 7    21   
 8    22 Rest period 
of 7 days  
 9    23  
 10    24  
 11    25  
 12    26  
 13    27  
 14    28  
Patient‚Äôs/Caregiver Signature: __________________________  Date: _________________________ 
Physician‚Äôs Office will complete this section: 
1.   Date patient started protocol treatment  _________   Date patient was removed from study _______________ 
2.   Patient‚Äôs planned daily dose ______________________     
 
Physician/Nurse/Data Manager‚Äôs Signature ______________________________________________ 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 80 
 
 
APPENDIX VII: ACNS1022 PHARMACOKINETIC STUDY FORM: STEADY STATE SAMPLES 
 
COG Pt ID #  _______________ ACC #  _______________ 
 
Please do not write patient name s on this form or on samples.  
 
Cycle ____, Day______ Date:  |__/__|__/__|__/__|  
 
Body Surface Area: |__|¬∞|__|__| m2  Total Dose: |__| |__| |__|¬∞|__| |__| mg 
 
Blood samples (2 mL) will be drawn peripherally in green top (sodium heparin) tubes. Please see protocol 
Section 13.1 for detailed Sample Collection, Handling, and Processing instructions . Record the exact time that 
the sample is drawn along with the exact time that th e drug was administered after sample collection. 
 
 
 
 Date Sample 
Collected Time Sample 
Collected Administration of 
Lenalidomide 
Blood 
Sample 
No. Collection Time (prior to drug 
administration)   Date Time 
1 Cycle 1,  
Between Days 5-21  Date: _______ Time: _____ Date: ___ Time: ____ 
2 Cycle following a first dose 
reduction, 
Any day between Days 5-21 Date: _______ 
 Time: _____ Date: ___ Time: ____ 
3 Cycle following a second dose 
reduction, 
Any day between Days 5-21 Date: _______ 
 Time: _____ Date: ___ Time: ____ 
 
Each tube must be labeled with ‚ÄúACNS1022‚Äù, the patient‚Äôs COG number, the date and time the sample was 
drawn, and the designated time point that the sample represents (eg, ‚ÄúCycle 1, Day X‚Äù). Data should be recorded 
on this Pharmacokinetic Study Form, which must accompany the sample(s). 
 
Please see Section 13.1 for detailed sample shipping inst ructions. Prior to shipping, please contact Dr. Brigitte 
Widemann (301-496-7387) for notification of sample shipment. DO NOT SHIP SAMPLES ON A FRIDAY 
OR WEEKEND.  Refer to the following link for information regarding Federal Express Account information to 
use for shipping pk samples: https://members.childrensoncol ogygroup.org/prot/biology.asp .  Ship samples 
to: 
Widemann Laboratory 
Pediatric Oncology Branch, NCI, CCR 10 Center Dr. 10-CRC, Rm 1-5750 MSC 1101 
Bethesda, MD 20892-1928   
Phone: 301-496-7387 
 
If this form will be used as  a source document, the site personnel who collected the samples must sign and date 
this form below: Signature: __________________________________________  Date: ____________________ 
 (site personnel who collected samples) 
 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 81 
 
 
APPENDIX VIII:  YOUTH INFORMATION SHEETS 
INFORMATION SHEET REGARDING RESEARCH STUDY ‚Äì ACNS1022 
(for children from 7 through 12 years of age) 
 
A Study of An Experimental Drug in Children and Teens with Brain Tumors 
That are Hard to Treat or Have Come Back after Treatment 
 
1. We have been talking with you ab out your brain tumor. Your brain tumor has either come back or 
not gone away with the treatments you already received. 
 
2. We are asking you to take  part in a research study because ot her treatments did not get rid of your 
tumor. A research study is when doctors work toge ther to try out new ways to help people who are 
sick. In this study, we are trying to find out if an experimental anti-cancer medicine can make your 
tumor get smaller or go away.  
 
3. Children who are part of this study will be tr eated with the anti-cancer medicine called 
lenalidomide. This medicine has been used to treat children with different kinds of cancers, 
including brain cancer. In this study, we want to treat more children with brain cancers so we can 
get more information about how we ll lenalidomide works.  This study will look at two doses of the 
anti-cancer medicine. Half of the children in this  study will get a lower dose of the anti-cancer 
medicine and half will get a highe r dose. Which dose you get will get is decided on by chance. This 
is like flipping a coin and saying, ‚ÄúHeads means I get the lower dose treatment, but tails means I 
get the higher-dose treatment.‚Äù A computer decide s which treatment you will get, not you or your 
doctor. 
 
4. Sometimes good things can happen to people when th ey are in a research study.  These good things 
are called ‚Äúbenefits.‚Äù  We hope that a benefit to you of being part of this study is that the new anti-
cancer medicine will make your tumor get smaller or  go away for as long as possible.  But, we do 
not know for sure if there is any be nefit of being part of this study. 
 
5. Sometimes bad things can happen to people when th ey are in a research study.  These bad things 
are called ‚Äúrisks.‚Äù  One risk to you from this study is  that the study treatment may not work as well 
as other treatments to make your tumor get smaller or go away for as long as possible. Other things 
may happen to you that we don‚Äôt yet know about. 
 
6. Your family can choose to be part of this study or  not.  Your family can also decide to stop being 
in this study at any time once you start.  There may be other treatments for your illness that your 
doctor can tell you about.  Make sure to ask your doctors any questions that you have. 
 
7. We are asking your ‚Äúokay‚Äù to collect extra blood.  We  want to see if there are ways to tell how the 
tumor will react to treatment. We would like to co llect about ¬Ω teaspoon of blood at up to 3 times 
during your treatment. We will try to collect the ex tra blood at the same ti me other standard blood 
tests are being done. If we can‚Äôt do this, you mi ght have up to two extra needle sticks.   
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 82 
 
 
INFORMATION SHEET REGARDING RESEARCH STUDY ‚Äì ACNS1022 
(for teens from 13 through 17 years of age) 
 
A Study of An Experimental Drug in Children and Teens with Brain Tumors 
That are Difficult to Treat or Have Come Back after Treatment 
 
1. We have been talking with you about your low grad e glioma. Low grade glioma s are types of cancer 
that grow in the brain . Your tumor has either come back or no t gone away with previous treatments.  
 
2. We are asking you to take part in a research stud y because other treatments did not get rid of your 
low grade glioma. A research study is when doctors  work together to try out new ways to help 
people who are sick.  In this study, doctors want to  try an experimental anti-cancer drug to see if 
this drug will work well to make your tumor get smaller or go away. 
 
3. All children and teens who are part of this study will be treated with the anti-cancer drug called 
lenalidomide. This drug has been used to treat children and teens with di fferent types of cancer, 
including some children and teens with brain cancer. In this study, doctors would like to treat a 
larger group of children and teens with brain can cers so they can get more  information about how 
well lenalidomide works.  This st udy will look at two doses of the anti-cancer drug. Half of the 
children in this study will get a lower dose of the anti-cancer drug and half will get a higher dose. 
Which dose you get will get is decided on by chance. Th is is like flipping a coin and saying, ‚ÄúHeads 
means I get the lower dose treatment, but tails me ans I get the higher-dose treatment.‚Äù A computer 
decides which treatment you will get, not you or your doctor. 
 
4. Sometimes good things can happen to people when th ey are in a research study.  These good things 
are called ‚Äúbenefits.‚Äù  We hope that a benefit to  you of being part of this study is that the 
lenalidomide will make your tumor get smaller or  go away for as long as possible, but we don‚Äôt 
know for sure if there is any benefit of being part of this study. 
 
5. Sometimes bad things can happen to people when th ey are in a research study.  These bad things 
are called ‚Äúrisks.‚Äù  One risk to you from this st udy is that the treatment you get may not work as 
well as other treatments to get rid of the tumor for as long as possible.  Another risk is that you may 
have more side effects from the drug if you get th e higher dose. If you get the lower dose, there is 
a risk is that you may get a treatment that does not work as well as the higher dose. Other things 
may happen to you that we don‚Äôt yet know about. 
 
6. Your family can choose to be part of this study or  not.  Your family can also decide to stop being 
in this study at any time once you start.  There may be other treatments for your illness that your 
doctor can tell you about. Make sure to ask your  doctors any questions that you have.  
 
7. We are asking your permission to collect additional bl ood.  We want to see if there are ways to tell 
how the cancer will respond to treatment. We woul d like to collect about ¬Ω teaspoon of blood at 
up to 3 times during your treatment. We will try to  collect the extra blood at the same time other 
standard blood tests are being performed. If we ca n‚Äôt do this, you might have up to two extra needle 
sticks.  
 
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 83 
 
 
 APPENDIX IX:  REGIMEN A LENALIDOMIDE DOSING TABLES  
 
 
  
 
 
   
 15 mg/m2, 
Dose Level -1 
BSA (m2) Daily Dose 
(mg) 
0.44 ‚Äì 0.56 7.5 
0.57 ‚Äì 0.75 10 
0.76 ‚Äì 0.91 12.5 
0.92 ‚Äì 1.08 15 
1.09 ‚Äì 1.25 17.5 
1.26 ‚Äì 1.42 20 
1.43 ‚Äì 1.58 22.5 
1.59 ‚Äì 1.76 25 
1.77 ‚Äì 1.91 27.5 
1.92 ‚Äì 2.08 30 
2.09 ‚Äì 2.20 32.5 
¬ï  Round to 
nearest 2.5 
mg 10 mg/m2, 
Dose Level -2 
BSA (m2) Daily Dose 
(mg) 
0.44 ‚Äì 0.62 5 
0.63 ‚Äì 0.82 7.5 
0.83 ‚Äì 1.12 10 
1.13 ‚Äì 1.37 12.5 
1.38 ‚Äì 1.62 15 
1.63 ‚Äì 1.87 17.5 
1.88 ‚Äì 2.12 20 
2.13 ‚Äì 2.20 22.5 
¬ï  Round to 
nearest 2.5 mg 20 mg/m2, 
Dose Level 1 
BSA (m2) Daily Dose 
(mg) 
0.44 ‚Äì 0.56 10 
0.57 ‚Äì 0.69 12.5 
0.70 ‚Äì 0.81 15 
0.82 ‚Äì 0.93 17.5 
0.94 ‚Äì 1.06 20 
1.07 ‚Äì 1.18 22.5 
1.19 ‚Äì 1.31 25 
1.32 ‚Äì 1.43 27.5 
1.44 ‚Äì 1.56 30 
1.57 ‚Äì 1.69 32.5 
1.70 ‚Äì 1.82 35 
1.83 ‚Äì 1.94 37.5 
1.95 ‚Äì 2.06 40 
2.07 ‚Äì 2.19 42.5 
¬ï  Round to 
nearest 2.5 
mg 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 84 
 
 
APPENDIX X:  CTEP AND CTSU REGISTRATION PROCEDURES 
CTEP INVESTIGATOR REGISTRATION PROCEDURES 
 
Food and Drug Administration (FDA) regulations  and National Cancer Institute (NCI) policy 
require all investigators participating in any NCI-sp onsored clinical trial to register and to renew 
their registration annually. 
 Registration requires the submission of: 
 
x a completed Statement of Investigator Form  (FDA Form 1572) with an original signature 
x a current Curriculum Vitae (CV) 
x a completed and signed Supplemental Investigator Data Form  (IDF) 
x a completed Financial Disclosure Form  (FDF) with an original signature 
 Fillable PDF forms and additional informa tion can be found on the CTEP website at 
<http://ctep.cancer.gov/investigatorRe sources/investigator_registratio n.htm>. For questions, please 
contact the CTEP Investigator Registration Help Desk  by email at 
<pmbregpend@ctep.nci.nih.gov>.  
CTEP Associate Registration Procedures / CTEP-IAM Account  
 
The Cancer Therapy Evaluation Program (C TEP) Identity and Acce ss Management (IAM) 
application is a web-based application intended fo r use by both Investigators (i.e., all physicians 
involved in the conduct of NCI-sponsored clinical trials) and Associates (i.e., all staff involved in the conduct of NCI-sponsored clinical trials).  Associates will use the CTEP-IAM application to re gister (both initial registration and annual re-
registration) with CTEP and to obtain a user account. 
 Investigators will use the CTEP-IAM application to obtain a user account only. (See CTEP Investigator Registration Procedures above for in formation on registering with CTEP as an 
Investigator, which must be completed befo re a CTEP-IAM account can be requested.) 
 
An active CTEP-IAM user account will be needed to access all CTEP and CTSU (Cancer Trials 
Support Unit) websites and applications, including the CTSU members‚Äô website. 
 Additional information can be found on the CTEP website at 
<http://ctep.cancer.gov/branches/pmb/associate_regi stration.htm>. For questions, please contact 
the CTEP Associate Registration Help Desk  by email at <ctepre ghelp@ctep.nci.nih.gov>. 
  
CTSU REGISTRATION PROCEDURES 
 
This study is supported by the NCI Ca ncer Trials Support Unit (CTSU).  
 
Requirements for ACNS1022 Site Registration:  
 ‚Ä¢ CTSU IRB Certification (for sites not participating via the CIRB) ‚Ä¢ CTSU IRB/Regulatory Approval Transmittal Sh eet (for sites not participating via the NCI 
CIRB)  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 85 
 
 
 
Submitting Regulatory Documents: 
 
Submit completed forms along with a copy of your IRB Approval to the CTSU Regulatory Office, 
where they will be entered an d tracked in the CTSU RSS.  
CTSU Regulatory Office 1818 Market Street, Suite 1100 Philadelphia, PA 19103 
Phone: 1-866-651-2878 
Fax: 215-569-0206 
E-mail: CTSURegulatory@ctsu.coccg.org (f or regulatory document submission only) 
 
Checking Your Site‚Äôs Registration Status: 
 
Check the status of your site‚Äôs registration packets by querying the RSS site registration status page 
of the members‚Äô section of the CTSU website. (Not e: Sites will not receive formal notification of 
regulatory approval from the CTSU Regulatory Office.) 
¬É Go to https://www.ctsu.org and log in to  the members‚Äô area using your CTEP-IAM 
username and password 
¬É Click on the Regulatory tab at the top of your screen 
¬É Click on the Site Registration tab 
¬É Enter your 5-character CTEP Ins titution Code and click on Go 
  
  
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 86 
 
 
REFERENCES 
1. Rekate HL, Rakfal SM: Low-grade astrocytom as of childhood. Neurol Clin 9:423-40, 1991 
2. Fisher PG, Tihan T, Goldthwaite PT, et al: Ou tcome analysis of childhood low-grade astrocytomas. 
Pediatr Blood Cancer 51:245-50, 2008 
3. Shaw EG, Wisoff JH: Prospective clinical trials  of intracranial low-grade glioma in adults and 
children. Neuro Oncol 5:153-60, 2003 
4. Prayson RA, Agamanolis DP, Cohen ML, et al: Interobserver reproducibility among 
neuropathologists and surgical pathologists in fi brillary astrocytoma grading. J Neurol Sci 175:33-
9, 2000 
5. Gilles FH, Tavare CJ, Becker LE, et al: Patholog ist interobserver variability of histologic features 
in childhood brain tumors: results from the CCG- 945 study. Pediatr Dev Pathol 11:108-17, 2008 
6. Packer RJ, Lange B, Ater J, et al: Carboplatin  and vincristine for recurrent and newly diagnosed 
low-grade gliomas of childhood. J Clin Oncol 11:850-6, 1993 
7. Prados MD, Edwards MS, Rabbitt J, et al: Tr eatment of pediatric low-grade gliomas with a 
nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 32:235-41, 1997 
8. Packer RJ, Ater J, Allen J, et al: Carboplatin and vincristine chemotherapy for children with newly 
diagnosed progressive low-grade g liomas. J Neurosurg 86:747-54, 1997 
9. Nicholson HS, Kretschmar CS, Krailo M, et a l: Phase 2 study of temozolomide in children and 
adolescents with recurrent central nervous system  tumors: a report from the Children's Oncology 
Group. Cancer 110:1542-50, 2007 
10. Gururangan S, Fisher MJ, Allen JC, et al: Temo zolomide in children with progressive low-grade 
glioma. Neuro Oncol 9:161-8, 2007 
11. Bouffet E, Jakacki R, Goldman S, et al: Phase II study of weekly vinblastine in recurrent/refractory 
pediatric low grade gliomas. J Clin Oncol 26, 2008 
12. CBTRUS (2008). Supplement Report: Primary Brai n Tumors in the United States, 2004. Published 
by the Central Brain Tumor Registry of the United States, Hinsdale, IL.  
13. Maxwell M, Naber SP, Wolfe HJ, et al: Expression  of angiogenic growth factor genes in primary 
human astrocytomas may contribute to their grow th and progression. Canc er Res 51:1345-51, 1991 
14. Takahashi JA, Mori H, Fukumoto M, et al: Gene  expression of fibroblast growth factors in human 
gliomas and meningiomas: demonstr ation of cellular source of basic fibroblast growth factor 
mRNA and peptide in tumor tissues. Proc  Natl Acad Sci U S A 87:5710-4, 1990 
15. Huang H, Held-Feindt J, Buhl R, et al: Expre ssion of VEGF and its receptors in different brain 
tumors. Neurol Res 27:371-7, 2005 
16. Auguste P, Gursel DB, Lemiere S, et al: Inhib ition of fibroblast growth factor/fibroblast growth 
factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and 
-independent mechanisms. Cancer Res 61:1717-26, 2001 
17. Nabors LB, Suswam E, Huang Y, et al: Tumor necrosis factor alph a induces angiogenic factor up-
regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res 63:4181-
7, 2003 
18. Jain RK, di Tomaso E, Duda DG, et al: Angiog enesis in brain tumours. Nat Rev Neurosci 8:610-
22, 2007 
19. Haslett PA, Corral LG, Albert M, et al: Thalid omide costimulates primary human T lymphocytes, 
preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ 
subset. J Exp Med 187:1885-92, 1998 
20. Fine HA, Figg WD, Jaeckle K, et al: Phase II trial of the antiangiogenic agent thalidomide in 
patients with recurrent high-grade gliomas. J Clin Oncol 18:708-15, 2000 
21. Short SC, Traish D, Dowe A, et al: Thalidomide as an anti-angiogenic agent in relapsed gliomas. J 
Neurooncol 51:41-5, 2001 
 THIS PROTOCOL IS FOR RESEARCH PURPOSES ONLY , SEE PAGE 1 FOR USAGE POLICY  ACNS1022 
Version Date: 6/1/2018  Page 87 
 
 
22. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013 overcomes 
drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-
7, 2002 
23. Liu Y, Tohnya TM, Figg WD, et al: Phase I st udy of CC-5013 (Revimid), a thalidomide derivative 
in patients with refractory metastatic ca ncer Proc Am Soc Clin Oncol 22, 2003 
24. Sharma RA, Marriott JB, Clarke I, et al: Tolera bility of the novel oral thalidomide analog CC-5013 
demonstrating extensive immune activation and cl inical response. Proc Am Soc Clin Oncol 22, 
2003 
25. Warren KE, Goldman S, Pollack IF, et al: Phase I trial of lenalidomide in pediatric patients with 
recurrent, refractory, or progressive primary CN S tumors: Pediatric Brain Tumor Consortium study 
PBTC-018. J Clin Oncol 29(3):324-9, 2011 
26. Adams SA, Subramanian V: The angiogenins: an em erging family of ribonuclease related proteins 
with diverse cellular functions. Angiogenesis 3:189-99, 1999 
27. Osteonecrosis of the jaw has been seen with increased frequency when lenalidomide is used in 
combination with bevacizumab,  docetaxel (Taxotere¬Æ), prednisone, and zolendronic acid 
(Zometa¬Æ).  
28. Xiong X, Tan M, Boyett J: A sequential procedure for monitoring clinical trials against historical 
controls. Stat Med 26:1497-511, 2007 
29. Wei, L. J., D. Y. Lin, et al: Regression analys is of multivariate incomplete failure time data by 
modeling  marginal distributions. . Journal of th e American Statistical Association 84:1065‚Äì1073, 
1989 
30. Corral LG, Haslett PA, Muller GW, et al: Diffe rential cytokine modulation and T cell activation 
by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380-6, 1999 
 
  